"","StudyId","Title","Authors","PublicationName","AlternateName","Abstract","Url","AuthorAddress","Year","Doi","ReferenceType","Keywords","PdfRelativePath","CustomId","DateTimeStudyAdded","SystematicSearchId","SystematicSearchName","Reconciled","InvestigatorId","InvestigatorName","What is the experimental unit?","Method of allocation of experimental units to groups?","(RoB) was the allocation sequence adequately generated and applied?","(RoB) Were groups similar at baseline or adjusted for confounders in analysis?","(RoB) Was the allocation adequately concealed?","(RoB) Were the animals randomly housed during the experiment?","Were caregivers/investigator blinded to which intervention each animal received?","(RoB) Were animals selected at random for outcome assessment?","(RoB) Was the outcome assessor blinded?","(RoB) Were incomplete outcome data adequately addressed?","(RoB) Are reports of the study free of selective outcome reporting?","(RoB) Was the study free of other problems that could result in high RoB?","(ARRIVE) Are all experimental and control groups clearly defined?","(ARRIVE) Is the experimental unit (animal, cage, litter) clearly identified?","(ARRIVE) Is the exact number of EUs in each group at start of study provided?","(ARRIVE) Is the method by which the sample size was chosen explained?","(ARRIVE) Are criteria for including&excluding animals/EUs/data points provided?","(ARRIVE) Are any exclusions of animals/EUs/data points reported?","(ARRIVE) Is it clear whether randomised allocation to group for any experiments?","(ARRIVE) Clear whether researchers were aware of/blinded to group allocation?","ARRIVE) For all outcomes, are details provided of exactly what was measured?","(ARRIVE) Is the statistical approach used to analyse each outcome detailed?","(ARRIVE) Description of methods to assess if data met statistical assumptions?","(ARRIVE) Are ALL species of animal used specified?","(ARRIVE) Is the sex of the animals specified?","(ARRIVE) Is at least one of age, weight or dev stage of the animals specified?","(ARRIVE) Are both timing & frequency with which procedures took place specified?","(ARRIVE) Details of acclimatisation periods to experimental locations provided?","(ARRIVE) Are desc stats for each exp group provided with measure of variability?","(ARRIVE) Is the effect size and confidence interval provided?","(ARRIVE) Provide name ethics review committee/equivalent + license/protocol ID?","(ARRIVE) if ethical approval was not sought/granted, is justification provided?","(ARRIVE) Declare potential conflicts of interest or declare that none exist?","(ARRIVE) Do they list all funding sources (including grant identifier)?","Is any role of the funder in the design/analysis/reporting of study described?","Should this have been excluded?","Is this a reconciliation?","Type of depression/anhedonia model","Type of control for disease model","Type of disease model induction","Timing of disease model induction","Method of pro-dopaminergic action:...62","Name of Intervention","Method of pro-dopaminergic action:...64","Dose of treatment used:","Measurement unit for treatment dose:","Timing of treatment administration:","Duration of treatment:","Unit of measurement for treatment duration:","Type of control used:","Treatment administration route:","Treatment dosing regime:","How long before/after treatment was disease model induction?","Unit of measurement for time separating model induction and treatment:","Type of outcome:","Time elapsed since intervention administration?","Unit of measurement?","Type of numerical data:","Type of measurement:","Type of outcome data:","Greater value = worse outcome","Sex of animals?","Genetic background of animals?","Species of animals?","Animal strain?","Is the n number exact or the lower bound of a range?","n allocated to group at experiment start?","Age of animals at intervention? (mean)","Age of animals at intervention? (SD)","Age of animals at intervention? (range lower bound)","Age of animals at intervention? (range upper bound)","Unit of measurement (age)","At which point was weight measured/reported?","Weight of animals? (mean)","Weight of animals? (SD)","Weight of animals? (range lower limit)","Weight of animals? (range upper limit)","Unit of measurement for weight","did all animals randomised to cohorts in expt contribute to outcome reported?","DateTimeDataEntered","ExperimentID","ExperimentLabel","OutcomeLabel","OutcomeId","CohortId","CohortLabel","NumberOfAnimals","IsDiseaseModelControl","ModelID","DiseaseModelLabel(s)","IsTreatmentControl","InterventionID","InterventionLabel","GreaterIsWorse","TimeInMinute","OutcomeResult","OutcomeAverageType","OutcomeUnit","OutcomeError","ErrorType"
"1","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Kd","0ac6404a-1a88-4154-964f-44f2831b6d40","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.25,"Mean","nM",0.007,"SEM"
"2","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Bmax binding","2042c21c-a498-4cb7-a4f7-dba194c6917f","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,5.85,"Mean","pmol/g",0.15,"SEM"
"3","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Bmax binding","47f7267d-1f61-4471-8bef-91bcf3572438","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,18.66,"Mean","pmol/g",0.6,"SEM"
"4","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Bmax binding","7c403ffb-4116-41a0-acee-84823e2ecb42","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,49.83,"Mean","pmol/g",0.5,"SEM"
"5","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Kd","d5dc2479-7e63-44a2-821d-ff1fbc6068e4","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.16,"Mean","nM",0.008,"SEM"
"6","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Kd","d68ddacc-5964-4fb9-a68b-9c77665fa5df","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.25,"Mean","nM",0.033,"SEM"
"7","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Kd","d8939e1e-d318-4b1c-a358-f66e4a77f6da","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.17,"Mean","nM",0.014,"SEM"
"8","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,14.15,"Mean","g",0.19,"SEM"
"9","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,1,10.74,"Mean","g",0.23,"SEM"
"10","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,2,13.88,"Mean","g",0.19,"SEM"
"11","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,3,13.25,"Mean","g",0.23,"SEM"
"12","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,4,13.57,"Mean","g",0.3,"SEM"
"13","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,5,13.95,"Mean","g",0.23,"SEM"
"14","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Bmax binding","f2b3db75-327f-4773-9380-aa57ba80531b","74299974-0ca9-4362-a37f-fcc4f0522003","Control + imipramine",10,NA,NA,NA,"False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,16.96,"Mean","pmol/g",0.3,"SEM"
"15","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Kd","0ac6404a-1a88-4154-964f-44f2831b6d40","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.25,"Mean","nM",0.006,"SEM"
"16","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Bmax binding","2042c21c-a498-4cb7-a4f7-dba194c6917f","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,3.5,"Mean","pmol/g",0.2,"SEM"
"17","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Bmax binding","47f7267d-1f61-4471-8bef-91bcf3572438","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,20.66,"Mean","pmol/g",0.4,"SEM"
"18","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Bmax binding","7c403ffb-4116-41a0-acee-84823e2ecb42","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,63.23,"Mean","pmol/g",0.7,"SEM"
"19","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Kd","d5dc2479-7e63-44a2-821d-ff1fbc6068e4","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.16,"Mean","nM",0.006,"SEM"
"20","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Kd","d68ddacc-5964-4fb9-a68b-9c77665fa5df","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.26,"Mean","nM",0.025,"SEM"
"21","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Kd","d8939e1e-d318-4b1c-a358-f66e4a77f6da","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.16,"Mean","nM",0.009,"SEM"
"22","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,8.1,"Mean","g",0.27,"SEM"
"23","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,1,7.67,"Mean","g",0.2,"SEM"
"24","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,2,7.25,"Mean","g",0.19,"SEM"
"25","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,3,7.09,"Mean","g",0.26,"SEM"
"26","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,4,7.44,"Mean","g",0.23,"SEM"
"27","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,5,7.32,"Mean","g",0.19,"SEM"
"28","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Bmax binding","f2b3db75-327f-4773-9380-aa57ba80531b","9555855d-b2ee-4b28-97e2-94e31e28786b","CMS + vehicle",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,20.15,"Mean","pmol/g",0.32,"SEM"
"29","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Kd","0ac6404a-1a88-4154-964f-44f2831b6d40","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.27,"Mean","nM",0.015,"SEM"
"30","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Bmax binding","2042c21c-a498-4cb7-a4f7-dba194c6917f","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,6.2,"Mean","pmol/g",0.2,"SEM"
"31","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Bmax binding","47f7267d-1f61-4471-8bef-91bcf3572438","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,20.02,"Mean","pmol/g",0.34,"SEM"
"32","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Bmax binding","7c403ffb-4116-41a0-acee-84823e2ecb42","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,58.34,"Mean","pmol/g",0.3,"SEM"
"33","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Kd","d5dc2479-7e63-44a2-821d-ff1fbc6068e4","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.17,"Mean","nM",0.009,"SEM"
"34","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Kd","d68ddacc-5964-4fb9-a68b-9c77665fa5df","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.27,"Mean","nM",0.03,"SEM"
"35","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Kd","d8939e1e-d318-4b1c-a358-f66e4a77f6da","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,0.14,"Mean","nM",0.012,"SEM"
"36","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,14.23,"Mean","g",0.23,"SEM"
"37","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,1,11.5,"Mean","g",0.2,"SEM"
"38","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,2,15.35,"Mean","g",0.23,"SEM"
"39","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,3,13.41,"Mean","g",0.23,"SEM"
"40","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,4,13.57,"Mean","g",0.22,"SEM"
"41","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,5,13.95,"Mean","g",0.15,"SEM"
"42","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Bmax binding","f2b3db75-327f-4773-9380-aa57ba80531b","e418f847-e672-44b5-81e7-b5324ba89949","Control + vehicle",10,NA,NA,NA,"True","07a38ad0-7733-4f7a-b0ca-91b61de73626","Vehicle",FALSE,0,21.73,"Mean","pmol/g",0.4,"SEM"
"43","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Kd","0ac6404a-1a88-4154-964f-44f2831b6d40","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.25,"Mean","nM",0.003,"SEM"
"44","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Bmax binding","2042c21c-a498-4cb7-a4f7-dba194c6917f","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,4.8,"Mean","pmol/g",0.2,"SEM"
"45","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Bmax binding","47f7267d-1f61-4471-8bef-91bcf3572438","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,19.6,"Mean","pmol/g",1,"SEM"
"46","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors striatum Bmax binding","7c403ffb-4116-41a0-acee-84823e2ecb42","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,62.53,"Mean","pmol/g",1,"SEM"
"47","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors striatum Kd","d5dc2479-7e63-44a2-821d-ff1fbc6068e4","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.16,"Mean","nM",0.009,"SEM"
"48","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Kd","d68ddacc-5964-4fb9-a68b-9c77665fa5df","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.25,"Mean","nM",0.033,"SEM"
"49","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D2 receptors limbic forebrain Kd","d8939e1e-d318-4b1c-a358-f66e4a77f6da","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,0.15,"Mean","nM",0.008,"SEM"
"50","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,8.06,"Mean","g",0.27,"SEM"
"51","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,1,8.49,"Mean","g",0.16,"SEM"
"52","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,2,9.46,"Mean","g",0.19,"SEM"
"53","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,3,11.05,"Mean","g",0.19,"SEM"
"54","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,4,12.55,"Mean","g",0.2,"SEM"
"55","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","Sucrose intake","e25210e9-08df-42d1-a56e-61a7620d0365","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,5,13.02,"Mean","g",0.19,"SEM"
"56","08e83c8f-49d3-49dd-a895-20dbd253f719","PARALLEL CHANGES IN DOPAMINE-D-2 RECEPTOR-BINDING IN LIMBIC FOREBRAIN ASSOCIATED WITH CHRONIC MILD STRESS-INDUCED ANHEDONIA AND ITS REVERSAL BY IMIPRAMINE","PAPP, M and KLIMEK, V and WILLNER, P","PSYCHOPHARMACOLOGY",NA,"Chronic sequential exposure to a variety of mild stressors has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions, associated with abnormalities of dopaminergic neurotransmission in the nucleus accumbens. In the present study, 5 weeks of treatment with imipramine (10 mg/kg b.i.d.) reversed the decreased sucrose intake of rats exposed to chronic mild stress. Stress also caused a decrease in D-2-receptor binding in the limbic forebrain (but not the striatum), which was completely reversed by imipramine. In nonstressed animals, imipramine decreased D-1-receptor binding in both regions. However, in stressed animals, imipramine did not significantly alter D-1-receptor binding in either area. Stress alone slightly increased D-1-receptor binding, in striatum only. Scatchard analysis showed that all changes in receptor binding resulted from changes in receptor number (B-max) rather than receptor affinity (K-D). The results support the hypothesis that changes in D-2-receptor function in the nucleus accumbens are responsible for chronic mild stress-induced anhedonia and its reversal by antidepressant drugs. They do not support the hypothesis that the sensitization of D-2-receptors seen following chronic antidepressant treatment is caused by a down-regulation of D-1-receptors.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1994","10.1007/BF02245566","JOUR","CHRONIC MILD STRESS and IMIPRAMINE and ANIMAL MODEL OF DEPRESSION and DOPAMINE and D-1-RECEPTORS and D-2-RECEPTORS and RAT and ANIMAL-MODEL and NUCLEUS ACCUMBENS and MESOLIMBIC DOPAMINE and LOCOMOTOR RESPONSE and D-AMPHETAMINE and ANTIDEPRESSANTS and DEPRESSION and ATTENUATION and PREFERENCE and RATS",NA,"WOS:A1994PB61000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Matched-pairs randomisation","Yes","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","IMIPRAMINE","Other","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-3","Weeks","Dopamine-related non behavioural outcome",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",10,999,999,999,999,"Days","At recruitment to study",360,9,999,999,"Grams (g)","Yes",2024-01-26 16:14:46,"cf0ace21-67d4-4aa1-a077-09b8657cc3de","sucrose intake and dopamine outcomes","D1 receptors limbic forebrain Bmax binding","f2b3db75-327f-4773-9380-aa57ba80531b","e48f9fa8-6621-4292-9af4-3dca370daa08","CMS + imipramine",10,"False","a6e55082-22cb-4921-9aa9-277efc9d6879","CMS","False","8b5e0030-18e6-4c11-bea1-b07fbcc7a0ef","Imipramine",FALSE,0,18.32,"Mean","pmol/g",0.25,"SEM"
"57","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50Hz NAC","0b1008f2-7688-4c38-9cfe-39322f20ca3b","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,7,"Mean","uM",1,"SEM"
"58","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100Hz NAC","136a1830-7ed9-43c2-9421-bd8391e18978","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,3.15,"Mean","uM",0.53,"SEM"
"59","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,50,0.65,"Mean","uM",0,"SEM"
"60","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,100,3.14,"Mean","uM",0,"SEM"
"61","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,150,2.23,"Mean","uM",0,"SEM"
"62","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,200,1.66,"Mean","uM",0,"SEM"
"63","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100 Hz CPu","45d919fd-0128-4449-809d-48de3a7e982b","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,3,"Mean","uM",0.6,"SEM"
"64","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,50,0.65,"Mean","uM",0,"SEM"
"65","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,100,3,"Mean","uM",0,"SEM"
"66","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,150,2,"Mean","uM",0,"SEM"
"67","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,200,1.5,"Mean","uM",0,"SEM"
"68","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo NAc","8660af7b-5e83-413c-97b1-6d5c1fafbffb","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,0.81,"Mean","uM",0.12,"SEM"
"69","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50 Hz CPu","df93d547-9967-4ad3-8930-86aef6a3c0bc","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,8.8,"Mean","uM",1,"SEM"
"70","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo CPu","e71a1abf-6f1a-4c07-9554-78cc578dd6c9","218ecb33-e595-4e8f-832f-e1aa5d9eab14","stress + imi exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,1.12,"Mean","uM",0.14,"SEM"
"71","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50Hz NAC","0b1008f2-7688-4c38-9cfe-39322f20ca3b","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,6.28,"Mean","uM",0.27,"SEM"
"72","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100Hz NAC","136a1830-7ed9-43c2-9421-bd8391e18978","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,3,"Mean","uM",0.17,"SEM"
"73","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,50,0.65,"Mean","uM",0,"SEM"
"74","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,100,3.14,"Mean","uM",0,"SEM"
"75","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,150,2.23,"Mean","uM",0,"SEM"
"76","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,200,1.66,"Mean","uM",0,"SEM"
"77","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100 Hz CPu","45d919fd-0128-4449-809d-48de3a7e982b","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,3.8,"Mean","uM",0.8,"SEM"
"78","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,50,0.66,"Mean","uM",0,"SEM"
"79","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,100,4.1,"Mean","uM",0,"SEM"
"80","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,150,2.77,"Mean","uM",0,"SEM"
"81","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,200,2,"Mean","uM",0,"SEM"
"82","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo NAc","8660af7b-5e83-413c-97b1-6d5c1fafbffb","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,0.79,"Mean","uM",0.11,"SEM"
"83","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50 Hz CPu","df93d547-9967-4ad3-8930-86aef6a3c0bc","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,9.5,"Mean","uM",1.2,"SEM"
"84","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo CPu","e71a1abf-6f1a-4c07-9554-78cc578dd6c9","28f4bf41-83d0-4c86-853f-154f5f0f3e43","stress exp 2",6,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,1.43,"Mean","uM",0.12,"SEM"
"85","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50Hz NAC","0b1008f2-7688-4c38-9cfe-39322f20ca3b","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,6.7,"Mean","uM",0.6,"SEM"
"86","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100Hz NAC","136a1830-7ed9-43c2-9421-bd8391e18978","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,3.18,"Mean","uM",0.38,"SEM"
"87","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,50,0.8,"Mean","uM",0,"SEM"
"88","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,100,3,"Mean","uM",0,"SEM"
"89","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,150,2.2,"Mean","uM",0,"SEM"
"90","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,200,1.66,"Mean","uM",0,"SEM"
"91","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100 Hz CPu","45d919fd-0128-4449-809d-48de3a7e982b","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,4.1,"Mean","uM",0.7,"SEM"
"92","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,50,0.72,"Mean","uM",0,"SEM"
"93","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,100,3.8,"Mean","uM",0,"SEM"
"94","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,150,2.44,"Mean","uM",0,"SEM"
"95","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,200,1.65,"Mean","uM",0,"SEM"
"96","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo NAc","8660af7b-5e83-413c-97b1-6d5c1fafbffb","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,0.69,"Mean","uM",0.1,"SEM"
"97","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50 Hz CPu","df93d547-9967-4ad3-8930-86aef6a3c0bc","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,9.5,"Mean","uM",0.9,"SEM"
"98","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo CPu","e71a1abf-6f1a-4c07-9554-78cc578dd6c9","4beb87b2-c3da-4686-acb4-d36d5d2d4bca","control + imi exp 2",6,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,1.09,"Mean","uM",0.11,"SEM"
"99","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50Hz NAC","0b1008f2-7688-4c38-9cfe-39322f20ca3b","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,4.24,"Mean","uM",0.68,"SEM"
"100","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100Hz NAC","136a1830-7ed9-43c2-9421-bd8391e18978","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,2,"Mean","uM",0.3,"SEM"
"101","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,50,0.6,"Mean","uM",0,"SEM"
"102","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,100,1.95,"Mean","uM",0,"SEM"
"103","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,150,1.53,"Mean","uM",0,"SEM"
"104","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release NAc fig 4","1b457caa-6852-4ddf-8627-2c7ef4e2489f","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,200,1.11,"Mean","uM",0,"SEM"
"105","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 100 Hz CPu","45d919fd-0128-4449-809d-48de3a7e982b","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,3.6,"Mean","uM",1,"SEM"
"106","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,50,0.72,"Mean","uM",0,"SEM"
"107","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,100,3.65,"Mean","uM",0,"SEM"
"108","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,150,2.64,"Mean","uM",0,"SEM"
"109","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release CPu fig 4","4d36a53a-8233-420f-952d-dc2c3e8589f8","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,200,1.75,"Mean","uM",0,"SEM"
"110","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo NAc","8660af7b-5e83-413c-97b1-6d5c1fafbffb","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,0.54,"Mean","uM",0.09,"SEM"
"111","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine release 50 Hz CPu","df93d547-9967-4ad3-8930-86aef6a3c0bc","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,8.3,"Mean","uM",0.7,"SEM"
"112","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Hours","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"18442071-8599-4f48-aeb1-8dd6c3813a0a","exp 2","dopamine uptake in vivo CPu","e71a1abf-6f1a-4c07-9554-78cc578dd6c9","fbc4c20b-7d6b-4a0b-868d-63864d457c9c","control exp 2",6,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,1.11,"Mean","uM",0.13,"SEM"
"113","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","02354be6-17c4-46d8-bf4f-16104c958668","control IMI",9,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,10.5,"Mean","g",0.5,"SEM"
"114","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","02354be6-17c4-46d8-bf4f-16104c958668","control IMI",9,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,3,7.66,"Mean","g",0.34,"SEM"
"115","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","02354be6-17c4-46d8-bf4f-16104c958668","control IMI",9,NA,NA,NA,"False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,8,5.9,"Mean","g",0.38,"SEM"
"116","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","50a595c4-f39c-4f71-8e12-10e4dbda00cc","stress",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,9.8,"Mean","g",0.8,"SEM"
"117","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","50a595c4-f39c-4f71-8e12-10e4dbda00cc","stress",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,3,10,"Mean","g",0.6,"SEM"
"118","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","50a595c4-f39c-4f71-8e12-10e4dbda00cc","stress",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,8,9.7,"Mean","g",0.5,"SEM"
"119","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","6a659338-1609-4538-8a6c-1eada46c69ec","control",9,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,0,10.2,"Mean","g",0.6,"SEM"
"120","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","6a659338-1609-4538-8a6c-1eada46c69ec","control",9,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,3,9.8,"Mean","g",0.4,"SEM"
"121","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","6a659338-1609-4538-8a6c-1eada46c69ec","control",9,NA,NA,NA,"True","6339193d-9fa9-4878-8e34-41e43aad1e25","vehicle",FALSE,8,9.3,"Mean","g",0.34,"SEM"
"122","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","b99dbb3f-3d00-429d-b4d7-4119c1002906","stress  IMI",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,0,9.9,"Mean","g",0.3,"SEM"
"123","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","b99dbb3f-3d00-429d-b4d7-4119c1002906","stress  IMI",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,3,6.7,"Mean","g",0.4,"SEM"
"124","2fb947ef-b55f-406f-b61a-c62f229f6ed0","Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine","Stamford, Jonathan A and Muscat, Richard and O'Connor, John J and Patel, Jyoti and Trout, Stephen J and Wieczorek, Walter J and Kruk, Zygmunt L and Willner, Paul","Psychopharmacology",NA,"Chronic exposure to mild unpredictable stress caused a decrease in male rats' consumption of a palatable weak sucrose solution, which was reversed by chronic (5 wks) administration of imipramine. Dopamine (DA) release in the nucleus accumbens (NAc) and caudate putamen was measured in vivo, following electrical stimulation of the medial forebrain bundle. Experiments were performed under chloral hydrate anesthesia 48 hrs after the termination of stress and the final imipramine injection. DA release was increased in the NAc of both stressed and imipramine-treated Ss: imipramine did not normalize the increased DA release in stressed Ss. Brain slices from stressed Ss tended to be subsensitive to the inhibition of DA release in the NAc by quinpirole. Data are discussed in relation to stress-induced anhedonia. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND and UNIV LONDON, QUEEN MARY & WESTFIELD COLL, DEPT PHARMACOL, LONDON E1 4NS, ENGLAND","1991","https://dx.doi.org/10.1007/BF02244322","JOUR","*Dopamine and *Imipramine and *Neurochemistry and *Reinforcement and *Stress and Electrical Brain Stimulation and Forebrain and Sugars",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","Yes","Yes","No","No","Yes","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","imipramine","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",48,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Lower bound of range (put range in comments)",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2023-12-19 15:42:36,"f72fec2b-4e42-4057-b0d6-16bc200087aa","sucrose intake","sucrose intake","a0610e14-5e84-467c-a7c7-3ad30431efa5","b99dbb3f-3d00-429d-b4d7-4119c1002906","stress  IMI",9,"False","edc5b8f4-84b2-4107-ba16-f0911345ed71","CUMS","False","18993436-30ab-488a-a8c7-9123181f233e","imipramine",FALSE,8,8.4,"Mean","g",0.4,"SEM"
"125","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","2","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","4262e354-b2b3-4a43-b961-1a35ac684a73","MPH 2mg/kg  male",10,NA,NA,NA,"False","af4ae166-9d69-4f1a-8f8a-b5b173e47a55","Methylphenidate 2mg/kg",FALSE,0,15,"Mean","g",1.7,"SEM"
"126","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","2","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","4262e354-b2b3-4a43-b961-1a35ac684a73","MPH 2mg/kg  male",10,NA,NA,NA,"False","af4ae166-9d69-4f1a-8f8a-b5b173e47a55","Methylphenidate 2mg/kg",FALSE,0,70.7,"Mean","%",7.2,"SEM"
"127","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","2","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","4f11489d-ae6f-4eac-9478-02d610f5ebab","MPH 2mg/kg  female",10,NA,NA,NA,"False","af4ae166-9d69-4f1a-8f8a-b5b173e47a55","Methylphenidate 2mg/kg",FALSE,0,7.4,"Mean","g",1.5,"SEM"
"128","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","2","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","4f11489d-ae6f-4eac-9478-02d610f5ebab","MPH 2mg/kg  female",10,NA,NA,NA,"False","af4ae166-9d69-4f1a-8f8a-b5b173e47a55","Methylphenidate 2mg/kg",FALSE,0,46.6,"Mean","%",6.9,"SEM"
"129","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","87cd0547-4cc9-4e9a-a29b-fb8c4b693e50","Vehicle  female",10,NA,NA,NA,"True","18e4eab2-5dd7-4f61-906b-3ad375b5e679","Vehicle",FALSE,0,8.7,"Mean","g",1.5,"SEM"
"130","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","87cd0547-4cc9-4e9a-a29b-fb8c4b693e50","Vehicle  female",10,NA,NA,NA,"True","18e4eab2-5dd7-4f61-906b-3ad375b5e679","Vehicle",FALSE,0,64.1,"Mean","%",11.2,"SEM"
"131","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","5","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",47.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","a256802f-cc18-4f77-81fe-9fce84d97022","MPH 5mg/kg  male",10,NA,NA,NA,"False","50146e59-5406-4319-bcc4-66d34721e084","Methylphenidate 5mg/kg",FALSE,0,13.7,"Mean","g",1.8,"SEM"
"132","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","5","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",47.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","a256802f-cc18-4f77-81fe-9fce84d97022","MPH 5mg/kg  male",10,NA,NA,NA,"False","50146e59-5406-4319-bcc4-66d34721e084","Methylphenidate 5mg/kg",FALSE,0,65.4,"Mean","%",8.4,"SEM"
"133","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","5","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",47.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","c39f68bb-cd77-4775-b81b-0ae70323e740","MPH 5mg/kg  female",10,NA,NA,NA,"False","50146e59-5406-4319-bcc4-66d34721e084","Methylphenidate 5mg/kg",FALSE,0,8.9,"Mean","g",1,"SEM"
"134","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"METHYLPHENIDATE","DAT inhibitor (Methylphenidate, Bupropion)","5","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Female","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",47.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","c39f68bb-cd77-4775-b81b-0ae70323e740","MPH 5mg/kg  female",10,NA,NA,NA,"False","50146e59-5406-4319-bcc4-66d34721e084","Methylphenidate 5mg/kg",FALSE,0,60.5,"Mean","%",7,"SEM"
"135","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose consumption","0878eddd-06c2-4705-a7b6-db23f25f8ef6","fc67ff23-9881-49af-98fe-109f083039fc","Vehicle  male",10,NA,NA,NA,"True","18e4eab2-5dd7-4f61-906b-3ad375b5e679","Vehicle",FALSE,0,14,"Mean","g",2.6,"SEM"
"136","37aa1ce5-ac5e-4f63-ad8a-87832c45d3e4","Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period","Crawford, Cynthia A and Der-Ghazarian, Taleen and Britt, Cynthia E and Varela, Fausto A and Kozanian, Olga O","Behavioural Brain Research",NA,"Early treatment with methylphenidate has a persistent effect on the affective (i.e., anxiety- and depressive-like) behaviors of adult rats and mice. Interestingly, age at methylphenidate exposure appears to be a critical determinant influencing the expression of affective behaviors. In the present study, we exposed rats to methylphenidate during the preweanling period (i.e., PD 11-PD 20) because this ontogenetic period is analogous to early childhood in humans (an age associated with increasing methylphenidate usage). Rats were injected with methylphenidate (0, 2, or 5 mg/kg) from PD 11 to PD 20 and reactivity to rewarding and aversive stimuli were measured in early adulthood. Specifically, novelty-induced CPP, sucrose preference, and elevated plus maze behavior were assessed on PD 60. Early treatment with 2 or 5 mg/kg methylphenidate increased total time spent in the white compartment of the CPP chamber. This methylphenidate-induced effect occurred regardless of exposure condition. Performance on the elevated plus maze was also impacted by early methylphenidate exposure, because rats treated with 5 mg/kg methylphenidate spent more time in the closed compartment of the elevated plus maze than vehicle controls. Early methylphenidate exposure did not alter sucrose preference. These data indicate that exposing rats to methylphenidate during the preweanling period differentially affects anxiety-like behavior depending on the type of anxiety-provoking stimulus. Specifically, early methylphenidate exposure decreased aversion to a bright white room when measured on a novelty-induced CPP task, whereas methylphenidate caused a long-term increase in anxiety when measured on the elevated plus maze. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Crawford, Cynthia A.: Department of Psychology, California State University, San Bernardino, CA, US, 92407, ccrawfor@csusb.edu and Crawford, Cynthia A.: ccrawfor@csusb.edu","2013","https://dx.doi.org/10.1016/j.bbr.2013.02.031","JOUR","*Glucose and *Methylphenidate and *Place Conditioning and *Preferences and *Sensation Seeking and Animal Models and Development and Emotional States and Rats",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",50,"Days","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Lower bound of range (put range in comments)",999,11,0,11,11,"Days","At treatment",49.9,2.53,999,999,"Grams (g)","No",2024-01-24 12:01:38,"a6a4691f-9d31-45b8-a092-85d5adcd140c","sucrose","Sucrose preference","adc4c632-378a-43ab-93a1-a1b6348af006","fc67ff23-9881-49af-98fe-109f083039fc","Vehicle  male",10,NA,NA,NA,"True","18e4eab2-5dd7-4f61-906b-3ad375b5e679","Vehicle",FALSE,0,66.6,"Mean","%",6.8,"SEM"
"137","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,72.77,"Mean","%",1.35,"SD"
"138","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,73.45,"Mean","%",1.58,"SD"
"139","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,72.54,"Mean","%",1.81,"SD"
"140","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,74.12,"Mean","%",1.36,"SD"
"141","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.125,2.36,"Mean","ng/mg",0.16,"SD"
"142","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.25,2.39,"Mean","ng/mg",0.16,"SD"
"143","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.5,2.34,"Mean","ng/mg",0.37,"SD"
"144","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,1,2.39,"Mean","ng/mg",0.25,"SD"
"145","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,2.27,"Mean","ng/mg",0.25,"SD"
"146","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,2.29,"Mean","ng/mg",0.23,"SD"
"147","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,2.71,"Mean","ng/mg",0.37,"SD"
"148","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,2.34,"Mean","ng/mg",0.3,"SD"
"149","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.125,1.36,"Mean","ng/mg",0.1,"SD"
"150","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.25,1.43,"Mean","ng/mg",0.18,"SD"
"151","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.5,1.36,"Mean","ng/mg",0.22,"SD"
"152","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,1,0.13,"Mean","ng/mg",0.18,"SD"
"153","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,1.34,"Mean","ng/mg",0.29,"SD"
"154","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,1.39,"Mean","ng/mg",0.27,"SD"
"155","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,1.36,"Mean","ng/mg",0.17,"SD"
"156","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","20cc30a6-22d7-45e0-aad0-7225dffd3b26","control: vehicle",8,NA,NA,NA,"True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,1.41,"Mean","ng/mg",0.36,"SD"
"157","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,3,51.53,"Mean","%",1.14,"SD"
"158","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,7,53.11,"Mean","%",1.58,"SD"
"159","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,14,60.34,"Mean","%",1.56,"SD"
"160","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,28,72.54,"Mean","%",0.91,"SD"
"161","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.125,3.05,"Mean","ng/mg",0.24,"SD"
"162","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.25,1.15,"Mean","ng/mg",0.16,"SD"
"163","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.5,1.06,"Mean","ng/mg",0.09,"SD"
"164","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,1,0.67,"Mean","ng/mg",0.05,"SD"
"165","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,3,1.06,"Mean","ng/mg",0.18,"SD"
"166","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,7,2.2,"Mean","ng/mg",0.23,"SD"
"167","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,14,2.74,"Mean","ng/mg",0.32,"SD"
"168","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,28,3.03,"Mean","ng/mg",0.3,"SD"
"169","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.125,2.15,"Mean","ng/mg",0.26,"SD"
"170","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.25,0.83,"Mean","ng/mg",0.07,"SD"
"171","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,0.5,0.85,"Mean","ng/mg",0.09,"SD"
"172","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,1,0.89,"Mean","ng/mg",0.06,"SD"
"173","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,3,0.51,"Mean","ng/mg",0.07,"SD"
"174","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,7,1.45,"Mean","ng/mg",0.24,"SD"
"175","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,14,2.73,"Mean","ng/mg",0.2,"SD"
"176","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","135","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","59a76796-41fe-48f3-ba25-d672e09f18df","TBI: Amantadine (135mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","f46e8a82-89b1-4201-8c6d-08b0c967734d","Amantadine (135mg/kg)",FALSE,28,1.94,"Mean","ng/mg",0.31,"SD"
"177","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,52.43,"Mean","%",0.9,"SD"
"178","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,48.36,"Mean","%",1.58,"SD"
"179","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,54.69,"Mean","%",2.49,"SD"
"180","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,63.05,"Mean","%",1.13,"SD"
"181","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.125,3.05,"Mean","ng/mg",0.14,"SD"
"182","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.25,1.15,"Mean","ng/mg",0.22,"SD"
"183","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.5,0.93,"Mean","ng/mg",0.11,"SD"
"184","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,1,0.6,"Mean","ng/mg",0.12,"SD"
"185","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,0.805,"Mean","ng/mg",0.05,"SD"
"186","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,1.49,"Mean","ng/mg",0.09,"SD"
"187","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,2.7,"Mean","ng/mg",0.38,"SD"
"188","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,2.25,"Mean","ng/mg",0.23,"SD"
"189","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.125,2.15,"Mean","ng/mg",0.2,"SD"
"190","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.25,0.81,"Mean","ng/mg",0.07,"SD"
"191","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,0.5,0.8,"Mean","ng/mg",0.09,"SD"
"192","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,1,0.78,"Mean","ng/mg",0.08,"SD"
"193","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,3,0.45,"Mean","ng/mg",0.05,"SD"
"194","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,7,0.12,"Mean","ng/mg",0.27,"SD"
"195","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,14,2.57,"Mean","ng/mg",0.15,"SD"
"196","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","5baa7d40-4457-4f58-baf7-9e22b78c6a2a","TBI: vehicle",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","True","0c14bd0c-dc05-487e-a17f-d6a6d3cc027c","vehicle",FALSE,28,0.81,"Mean","ng/mg",0.04,"SD"
"197","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,3,52.13,"Mean","%",1.96,"SD"
"198","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,7,49.94,"Mean","%",0.67,"SD"
"199","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,14,56.72,"Mean","%",0.9,"SD"
"200","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","sucrose preference","6ffffd79-b9d4-4ace-92bd-1466539be9f7","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,28,67.35,"Mean","%",1.8,"SD"
"201","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.125,2.96,"Mean","ng/mg",0.16,"SD"
"202","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.25,1.15,"Mean","ng/mg",0.22,"SD"
"203","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.5,1.08,"Mean","ng/mg",0.16,"SD"
"204","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,1,0.64,"Mean","ng/mg",0.14,"SD"
"205","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,3,0.94,"Mean","ng/mg",0.18,"SD"
"206","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,7,1.75,"Mean","ng/mg",0.29,"SD"
"207","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,14,2.68,"Mean","ng/mg",0.3,"SD"
"208","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","Dopamine concentration (striatum)","f17acd55-1797-4b0e-bf46-dbfeb17ca270","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,28,2.83,"Mean","ng/mg",0.32,"SD"
"209","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.125,2.15,"Mean","ng/mg",0.13,"SD"
"210","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.25,0.83,"Mean","ng/mg",0.06,"SD"
"211","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,0.5,0.82,"Mean","ng/mg",0.09,"SD"
"212","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,1,0.83,"Mean","ng/mg",0.12,"SD"
"213","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,3,0.49,"Mean","ng/mg",0.04,"SD"
"214","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,7,1.29,"Mean","ng/mg",0.02,"SD"
"215","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,14,2.39,"Mean","ng/mg",0.2,"SD"
"216","42693d44-0a22-45bd-ad4a-f6d60b276b82","Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats","Tan, Liang and Ge, Hongfei and Tang, Jun and Fu, Chuhua and Duanmu, Wangsheng and Chen, Yujie and Hu, Rong and Sui, Jianfeng and Liu, Xin and Feng, Hua","Behavioural Brain Research",NA,"Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Feng, Hua: Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Chongqing, China, 400038, fenghua8888@aliyun.com.cn and Tan, Liang: tracy200712@hotmail.com, Ge, Hongfei: mudan13868@126.com, Tang, Jun: juntang881025@sina.com, Fu, Chuhua: 87848946@qq.com, Duanmu, Wangsheng: 510149003@qq.com, Chen, Yujie: yujiechen6886@foxmail.com, Hu, Rong: huchrong@aliyun.com, Sui, Jianfeng: jfsui2003@163.com, Liu, Xin: shenwai@tmmu.edu.cn, Feng, Hua: fenghua8888@aliyun.com.cn","2015","https://dx.doi.org/10.1016/j.bbr.2014.10.037","JOUR","*Amantadine and *Dopamine and *Traumatic Brain Injury and *Neuroprotection and Animal Models and Rats and Stimulus Attenuation and Substantia Nigra",NA,"PsychINFO-0166-4328-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy)",NA,"Single acute stressor","Post-weaning","Other","AMANTADINE","Other","45","miligrams (mg) per kg","After disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,999,250,280,"Grams (g)","No",2023-12-18 16:49:25,"55311fda-0722-4fbb-905a-5d547ce6fdee","Fig 2 + 5 (SPT and dopamine conc)","DOPAC concentration (striatum)","f675d119-33c0-4d25-8906-c12d18d655ca","de354851-1eb0-4d42-a1ca-4abc3d5d587c","TBI: Amantadine (45mg/kg)",7,"False","0034b9a1-8559-4785-b1f9-43b56990ff72","TBI","False","0b3b2e77-0d0c-4ea2-bf56-0adfafbc7408","Amantadine (45mg/kg)",FALSE,28,1.67,"Mean","ng/mg",0.41,"SD"
"217","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","2","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-1","Weeks","Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",25.26,1.81,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","7e13c7f6-a3f3-4883-8b91-f23b2d66b5e5","PSD + aripiprazole",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","False","921323dc-4a73-4d65-afd7-d652eb2aaa63","Aripiprazole",FALSE,7,60.62,"Mean","%",4.76,"SEM"
"218","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","2","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-1","Weeks","Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",25.26,1.81,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","7e13c7f6-a3f3-4883-8b91-f23b2d66b5e5","PSD + aripiprazole",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","False","921323dc-4a73-4d65-afd7-d652eb2aaa63","Aripiprazole",FALSE,9,67.65,"Mean","%",3.81,"SEM"
"219","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","2","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-1","Weeks","Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",25.26,1.81,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","7e13c7f6-a3f3-4883-8b91-f23b2d66b5e5","PSD + aripiprazole",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","False","921323dc-4a73-4d65-afd7-d652eb2aaa63","Aripiprazole",FALSE,11,76.5,"Mean","%",1.75,"SEM"
"220","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",26,1.32,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","9aa8dcf1-ed3a-4a9e-a9e5-31ceae50e0be","PSD",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,7,29.78,"Mean","%",4.65,"SEM"
"221","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",26,1.32,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","9aa8dcf1-ed3a-4a9e-a9e5-31ceae50e0be","PSD",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,9,33,"Mean","%",5.9,"SEM"
"222","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Surgical models (e.g. olfactory bulbectomy);Chronic unpredictable mild stress (CMS) or restraint stress",";","Single acute stressor;Multiple acute stressors","Post-weaning;Post-weaning","Other;Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",26,1.32,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","9aa8dcf1-ed3a-4a9e-a9e5-31ceae50e0be","PSD",6,"False;False","f90b9ff9-9864-47af-af77-ed55d93e2a84;e6b5efec-d69d-4202-850a-86ae09257fb4","MCAO;Spatial restraint stress","True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,11,43.35,"Mean","%",7.6,"SEM"
"223","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",30.7,6.12,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","d9197e12-dbf2-4e43-a13c-51ff4f75958d","Control",6,NA,NA,NA,"True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,7,65.6,"Mean","%",3.03,"SEM"
"224","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",30.7,6.12,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","d9197e12-dbf2-4e43-a13c-51ff4f75958d","Control",6,NA,NA,NA,"True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,9,67.65,"Mean","%",3.69,"SEM"
"225","42797051-fac6-4cf4-9faa-1c1a0f3a351e","Indoleamine 2,3-Dioxygenase-Dependent Neurotoxic Kynurenine Metabolism Contributes to Poststroke Depression Induced in Mice by Ischemic Stroke along with Spatial Restraint Stress.","Koo YS and Kim H and Park JH and Kim MJ and Shin YI and Choi BT and Lee SY and Shin HK","Oxidative medicine and cellular longevity",NA,"AIM: Poststroke depression (PSD), which occurs in approximately one-third of stroke survivors, is clinically important because of its association with slow functional recovery and increased mortality. In addition, the underlying pathophysiological mechanisms are still poorly understood. METHODS: We used a mouse model of PSD to examine the neurobiological mechanisms of PSD and the beneficial effects of aripiprazole, an atypical antipsychotic drug. PSD was induced in mice by combining middle cerebral artery occlusion (MCAO) with spatial restraint stress. The body weight, sucrose preference, and forced swim tests were performed at 5, 7, and 9 weeks and the Morris water maze test at 10 weeks after completing MCAO and spatial restraint stress. RESULTS: Mice subjected to MCAO and spatial restraint stress showed significant depressive-like behavior in the sucrose preference test and forced swim test as well as cognitive impairment in the Morris water maze test. The PSD-like phenotype was accompanied by an indoleamine 2,3-dioxygenase 1 (IDO1) expression increase in the nucleus accumbens, hippocampus, and hypothalamus, but not in the striatum. Furthermore, the increased IDO1 levels were localized in Iba-1(+) cells but not in NeuN(+) or GFAP(+) cells, indicating that microglia-induced IDO1 expression was prominent in the PSD mouse brain. Moreover, 3-hydroxyanthranilate 3,4-dioxygenase (HAAO), quinolinic acid (QUIN), and reactive oxygen species (ROS) were significantly increased in the nucleus accumbens, hippocampus, and hypothalamus of PSD mice. Importantly, a 2-week aripiprazole (1mg/kg, per os) regimen, which was initiated 1 day after MCAO, ameliorated depressive-like behavior and impairment of cognitive functions in PSD mice that was accompanied by downregulation of IDO1, HAAO, QUIN, and ROS. CONCLUSIONS: Our results suggest that the IDO1-dependent neurotoxic kynurenine metabolism induced by microglia functions in PSD pathogenesis. The beneficial effect of aripiprazole on depressive-like behavior and cognitive impairment may be mediated by inhibition of IDO1, HAAO, QUIN, and ROS.",NA,"Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Rehabilitation Medicine, School of Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Research Institute for Convergence of Biomedical Science and Technology, Pusan and National University Yangsan Hospital, Yangsan, Gyeongnam 50612, Republic of and Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Department of Korean Medical Science, School of Korean Medicine, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Korean Medical Science Research Center for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea. and Graduate Training Program of Korean Medicine for Healthy-Aging, Pusan National and University, Yangsan, Gyeongnam 50612, Republic of Korea.","2018","10.1155/2018/2413841","Journal Article","QUINOLINIC ACID and COGNITIVE FUNCTIONS and OXIDATIVE STRESS and SOCIAL-ISOLATION and ARIPIPRAZOLE and BEHAVIOR and MODEL and ANTIDEPRESSANT and 3-HYDROXYKYNURENINE and INFLAMMATION",NA,"pubmed-30693061",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",7,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Lower bound of range (put range in comments)",999,8,999,999,999,"Weeks","After treatment",30.7,6.12,999,999,"Grams (g)","No",2024-01-24 14:31:18,"8742e669-eb1e-4cba-8e67-ea11336fd91a","SPT","Sucrose preference test","5a71b776-947f-4384-b280-2f72882a27b3","d9197e12-dbf2-4e43-a13c-51ff4f75958d","Control",6,NA,NA,NA,"True","31f029ba-3357-4870-86c5-66a69acc7efb","Vehicle",FALSE,11,81.3,"Mean","%",3.58,"SEM"
"226","50d146a3-fc24-450a-be1f-c7b1c9fc322f","Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.","Wei SZ and Yao XY and Wang CT and Dong AQ and Li D and Zhang YT and Ren C and Zhang JB and Mao CJ and Wang F and Liu CF","Brain research bulletin",NA,"Depression is one of the strongest predictors of quality of life in patients with Parkinson's disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2(-/-) mice but not in DRD3(-/-) mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future.",NA,"Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of and Neuroscience, Soochow University, Suzhou, China. and Department of Neurology, Suqian First Hospital, Suqian, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. Electronic address: wangfen_1982@126.com. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China: Department of Neurology, Suqian First Hospital, and Suqian, China: Department of Neurology, The Second Affiliated Hospital of and Xinjiang Medical University, Urumqi, China. Electronic address: and liuchunfeng@suda.edu.cn.","2021","10.1016/j.brainresbull.2021.10.015","Journal Article and Research Support, Non-U.S. Gov't","Depression-like behavior and Dopamine D2 receptor and Dopamine D3 receptor and Parkinson<e2><80><99>s disease and Pramipexole",NA,"pubmed-34699917",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Unclear/not specified","Complete randomisation","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress;Other",";","Multiple acute stressors;Other (specify in comments)","Post-weaning;Prenatal/gestational","Not specified/unclear;Other","Pramipexole","Dopamine agonist (e.g. apomorphine, rotigotine)","999","Other (enter in comments box)","After disease model induction","2","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","6","Weeks","Sucrose/saccharin intake or preference test",2,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","DRD2-/-","Mouse","C57BL/6J (mouse)","Exact number",6,999,999,4,6,"Months","At recruitment to study",999,999,23,25,"Grams (g)","Yes",2024-01-23 10:39:42,"d95e0573-2b36-480d-bd8d-b9d5c4c19622","SPT","Sucrose preference test","39822f3e-b5e4-4469-9e84-3eba83d31455","20c38490-ce3a-40a2-b262-91652c67ea03","CUMS + pramiprexole",6,"False;False","dfd9dd7d-4807-419f-9822-a7c59f44773a;36ab56b6-e0fa-4d6d-ad88-c0a2c5cf1bda","CMS;D2R KO","False","31c815b8-67d8-48c9-85db-d690f769404a","Pramipexole",FALSE,0,62.64,"Mean","%",7.22,"SEM"
"227","50d146a3-fc24-450a-be1f-c7b1c9fc322f","Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.","Wei SZ and Yao XY and Wang CT and Dong AQ and Li D and Zhang YT and Ren C and Zhang JB and Mao CJ and Wang F and Liu CF","Brain research bulletin",NA,"Depression is one of the strongest predictors of quality of life in patients with Parkinson's disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2(-/-) mice but not in DRD3(-/-) mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future.",NA,"Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of and Neuroscience, Soochow University, Suzhou, China. and Department of Neurology, Suqian First Hospital, Suqian, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. Electronic address: wangfen_1982@126.com. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China: Department of Neurology, Suqian First Hospital, and Suqian, China: Department of Neurology, The Second Affiliated Hospital of and Xinjiang Medical University, Urumqi, China. Electronic address: and liuchunfeng@suda.edu.cn.","2021","10.1016/j.brainresbull.2021.10.015","Journal Article and Research Support, Non-U.S. Gov't","Depression-like behavior and Dopamine D2 receptor and Dopamine D3 receptor and Parkinson<e2><80><99>s disease and Pramipexole",NA,"pubmed-34699917",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Unclear/not specified","Complete randomisation","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress;Other",";","Multiple acute stressors;Other (specify in comments)","Post-weaning;Prenatal/gestational","Not specified/unclear;Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",2,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","DRD2-/-","Mouse","C57BL/6J (mouse)","Exact number",6,999,999,4,6,"Months","At recruitment to study",999,999,23,25,"Grams (g)","Yes",2024-01-23 10:39:42,"d95e0573-2b36-480d-bd8d-b9d5c4c19622","SPT","Sucrose preference test","39822f3e-b5e4-4469-9e84-3eba83d31455","3b51b762-68b6-4cce-90c3-6c246bb5ba4e","CUMS + vehicle",6,"False;False","dfd9dd7d-4807-419f-9822-a7c59f44773a;36ab56b6-e0fa-4d6d-ad88-c0a2c5cf1bda","CMS;D2R KO","True","6d308f6f-cc85-4358-b114-75e15053d55d","Vehicle",FALSE,0,41.95,"Mean","%",9.45,"SEM"
"228","50d146a3-fc24-450a-be1f-c7b1c9fc322f","Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.","Wei SZ and Yao XY and Wang CT and Dong AQ and Li D and Zhang YT and Ren C and Zhang JB and Mao CJ and Wang F and Liu CF","Brain research bulletin",NA,"Depression is one of the strongest predictors of quality of life in patients with Parkinson's disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2(-/-) mice but not in DRD3(-/-) mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future.",NA,"Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of and Neuroscience, Soochow University, Suzhou, China. and Department of Neurology, Suqian First Hospital, Suqian, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China. Electronic address: wangfen_1982@126.com. and Department of Neurology and Clinical Research Center of Neurological Disease, The and Second Affiliated Hospital of Soochow University, Suzhou, China: Jiangsu Key and Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow and University, Suzhou, China: Department of Neurology, Suqian First Hospital, and Suqian, China: Department of Neurology, The Second Affiliated Hospital of and Xinjiang Medical University, Urumqi, China. Electronic address: and liuchunfeng@suda.edu.cn.","2021","10.1016/j.brainresbull.2021.10.015","Journal Article and Research Support, Non-U.S. Gov't","Depression-like behavior and Dopamine D2 receptor and Dopamine D3 receptor and Parkinson<e2><80><99>s disease and Pramipexole",NA,"pubmed-34699917",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Unclear/not specified","Complete randomisation","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",2,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","DRD2-/-","Mouse","C57BL/6J (mouse)","Exact number",6,999,999,4,6,"Months","At recruitment to study",999,999,23,25,"Grams (g)","Yes",2024-01-23 10:39:42,"d95e0573-2b36-480d-bd8d-b9d5c4c19622","SPT","Sucrose preference test","39822f3e-b5e4-4469-9e84-3eba83d31455","46ea2f8e-12a3-48a4-9fdc-7f96947d130a","Control + vehicle",6,NA,NA,NA,"True","6d308f6f-cc85-4358-b114-75e15053d55d","Vehicle",FALSE,0,57.69,"Mean","%",8.68,"SEM"
"229","56b27e0c-df42-4305-9bb5-945bfa7e7968","[Activation of hippocampal D1 dopamine receptor inhibits glutamate-mediated depression induced by chronic unpredictable mild stress in rats].","Yuan TT and Qiao H and Dong SP and An SC","Sheng li xue bao : [Acta physiologica Sinica]",NA,"The present study was to investigate the role of dopamine D1 receptors and its relationship with glutamate, N-methyl-D-aspartic acid (NMDA) receptor and -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intrahippocampal microinjections of D1 dopamine receptor agonist SKF38393, non-competitive NMDA receptor antagonist MK-801 and AMPA receptor antagonist NBQX were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of weight changes, sucrose preference test, open-field test and tail suspension test. The concentration of glutamic acid and the expression of its receptors' subunits were detected by HPLC and Western blot, respectively. The results showed that, compared with control group, CUMS rats showed depression-like behavioral changes, higher concentration of glutamic acid, lower expressions of NMDA receptor (NR1) and AMPA receptor (GluR2/3) in hippocampus. Pretreatment with injection of SKF38393 could rescue such depression effect of CUMS, decrease the concentration of glutamic acid, and increase the expressions of NMDA receptor (NR1), AMPA receptor (GluR2/3) in hippocampus. Pretreatment with MK-801 could enhance the antidepressant effect of SKF38393, while NBQX weakened. These results suggest that agonists of D1 dopamine receptor could reduce the concentration of glutamic acid in hippocampus, and its antidepressant effect may be mediated by AMPA receptor partially.",NA,"College of Life Sciences, Shaanxi Normal University, Xi'an 710062, China.","2011",NA,"English Abstract and Journal Article and Research Support, Non-U.S. Gov't",NA,NA,"pubmed-21861052",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,999,999,999,"Days","At recruitment to study",999,999,250,300,"Grams (g)","No",2024-01-29 12:37:57,"e4d302ca-1af9-4be0-be65-76ae58660f2b","SPT","Sucrose preference","e64aa7c6-e525-4086-a7bd-e986250f4a36","24e2d000-4119-4dc5-904c-8234739d27b5","Control + vehicle",8,NA,NA,NA,"True","d9c0f53f-3690-4d9f-9576-ec95ff68ccb5","Vehicle",FALSE,0,82.29,"Mean","%",0.86,"SEM"
"230","56b27e0c-df42-4305-9bb5-945bfa7e7968","[Activation of hippocampal D1 dopamine receptor inhibits glutamate-mediated depression induced by chronic unpredictable mild stress in rats].","Yuan TT and Qiao H and Dong SP and An SC","Sheng li xue bao : [Acta physiologica Sinica]",NA,"The present study was to investigate the role of dopamine D1 receptors and its relationship with glutamate, N-methyl-D-aspartic acid (NMDA) receptor and -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intrahippocampal microinjections of D1 dopamine receptor agonist SKF38393, non-competitive NMDA receptor antagonist MK-801 and AMPA receptor antagonist NBQX were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of weight changes, sucrose preference test, open-field test and tail suspension test. The concentration of glutamic acid and the expression of its receptors' subunits were detected by HPLC and Western blot, respectively. The results showed that, compared with control group, CUMS rats showed depression-like behavioral changes, higher concentration of glutamic acid, lower expressions of NMDA receptor (NR1) and AMPA receptor (GluR2/3) in hippocampus. Pretreatment with injection of SKF38393 could rescue such depression effect of CUMS, decrease the concentration of glutamic acid, and increase the expressions of NMDA receptor (NR1), AMPA receptor (GluR2/3) in hippocampus. Pretreatment with MK-801 could enhance the antidepressant effect of SKF38393, while NBQX weakened. These results suggest that agonists of D1 dopamine receptor could reduce the concentration of glutamic acid in hippocampus, and its antidepressant effect may be mediated by AMPA receptor partially.",NA,"College of Life Sciences, Shaanxi Normal University, Xi'an 710062, China.","2011",NA,"English Abstract and Journal Article and Research Support, Non-U.S. Gov't",NA,NA,"pubmed-21861052",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,999,999,999,"Days","At recruitment to study",999,999,250,300,"Grams (g)","No",2024-01-29 12:37:57,"e4d302ca-1af9-4be0-be65-76ae58660f2b","SPT","Sucrose preference","e64aa7c6-e525-4086-a7bd-e986250f4a36","31930a8d-1425-4238-992f-92796c84c425","CMS + vehicle",9,"False","d3321a64-ae04-4988-8266-9f96195f2eca","CUMS","True","d9c0f53f-3690-4d9f-9576-ec95ff68ccb5","Vehicle",FALSE,0,60.75,"Mean","%",2.15,"SEM"
"231","56b27e0c-df42-4305-9bb5-945bfa7e7968","[Activation of hippocampal D1 dopamine receptor inhibits glutamate-mediated depression induced by chronic unpredictable mild stress in rats].","Yuan TT and Qiao H and Dong SP and An SC","Sheng li xue bao : [Acta physiologica Sinica]",NA,"The present study was to investigate the role of dopamine D1 receptors and its relationship with glutamate, N-methyl-D-aspartic acid (NMDA) receptor and -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intrahippocampal microinjections of D1 dopamine receptor agonist SKF38393, non-competitive NMDA receptor antagonist MK-801 and AMPA receptor antagonist NBQX were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of weight changes, sucrose preference test, open-field test and tail suspension test. The concentration of glutamic acid and the expression of its receptors' subunits were detected by HPLC and Western blot, respectively. The results showed that, compared with control group, CUMS rats showed depression-like behavioral changes, higher concentration of glutamic acid, lower expressions of NMDA receptor (NR1) and AMPA receptor (GluR2/3) in hippocampus. Pretreatment with injection of SKF38393 could rescue such depression effect of CUMS, decrease the concentration of glutamic acid, and increase the expressions of NMDA receptor (NR1), AMPA receptor (GluR2/3) in hippocampus. Pretreatment with MK-801 could enhance the antidepressant effect of SKF38393, while NBQX weakened. These results suggest that agonists of D1 dopamine receptor could reduce the concentration of glutamic acid in hippocampus, and its antidepressant effect may be mediated by AMPA receptor partially.",NA,"College of Life Sciences, Shaanxi Normal University, Xi'an 710062, China.","2011",NA,"English Abstract and Journal Article and Research Support, Non-U.S. Gov't",NA,NA,"pubmed-21861052",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Unclear","Unclear","Yes","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SKF-38393","Dopamine agonist (e.g. apomorphine, rotigotine)","1.12","micrograms (ug) per kg","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,999,999,999,"Days","At recruitment to study",999,999,250,300,"Grams (g)","No",2024-01-29 12:37:57,"e4d302ca-1af9-4be0-be65-76ae58660f2b","SPT","Sucrose preference","e64aa7c6-e525-4086-a7bd-e986250f4a36","679c11c1-b6e1-4fa6-b0c9-297def874eac","CMS + SKF-38393",7,"False","d3321a64-ae04-4988-8266-9f96195f2eca","CUMS","False","351401f2-404e-4171-8edd-1dee6e5f7d4b","SKF-38393",FALSE,0,80.5,"Mean","%",4.1,"SEM"
"232","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","378cc5eb-20c4-48ec-a79e-b281c040c360","Control + vehicle",6,NA,NA,NA,"True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,1,83.25,"Mean","%",3.34,"SEM"
"233","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","378cc5eb-20c4-48ec-a79e-b281c040c360","Control + vehicle",6,NA,NA,NA,"True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,7,79.09,"Mean","%",2.58,"SEM"
"234","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","378cc5eb-20c4-48ec-a79e-b281c040c360","Control + vehicle",6,NA,NA,NA,"True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,14,80,"Mean","%",3.22,"SEM"
"235","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","378cc5eb-20c4-48ec-a79e-b281c040c360","Control + vehicle",6,NA,NA,NA,"True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,21,81.54,"Mean","%",3.17,"SEM"
"236","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","6963cb9c-0bd7-4bb1-83c4-17cb217e7298","Control + amantadine",6,NA,NA,NA,"False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,1,83.25,"Mean","%",3.24,"SEM"
"237","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","6963cb9c-0bd7-4bb1-83c4-17cb217e7298","Control + amantadine",6,NA,NA,NA,"False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,7,85.94,"Mean","%",2.21,"SEM"
"238","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","6963cb9c-0bd7-4bb1-83c4-17cb217e7298","Control + amantadine",6,NA,NA,NA,"False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,14,87.8,"Mean","%",2.15,"SEM"
"239","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","6963cb9c-0bd7-4bb1-83c4-17cb217e7298","Control + amantadine",6,NA,NA,NA,"False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,21,85.32,"Mean","%",3.48,"SEM"
"240","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","7578a6b3-1758-49e7-80ea-5602bc302f52","CUS + vehicle",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,1,83.2,"Mean","%",3.2,"SEM"
"241","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","7578a6b3-1758-49e7-80ea-5602bc302f52","CUS + vehicle",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,7,71.74,"Mean","%",2.89,"SEM"
"242","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","7578a6b3-1758-49e7-80ea-5602bc302f52","CUS + vehicle",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,14,69.52,"Mean","%",3.38,"SEM"
"243","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","7578a6b3-1758-49e7-80ea-5602bc302f52","CUS + vehicle",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","True","281c1ef0-c9ca-412f-99c1-c4ef821adafe","Vehicle",FALSE,21,53.27,"Mean","%",3.48,"SEM"
"244","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","a10acad7-bd13-4342-babf-b20dccea9a6a","CUS + amantadine",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,1,83,"Mean","%",3.34,"SEM"
"245","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","a10acad7-bd13-4342-babf-b20dccea9a6a","CUS + amantadine",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,7,78.84,"Mean","%",2.44,"SEM"
"246","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","a10acad7-bd13-4342-babf-b20dccea9a6a","CUS + amantadine",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,14,78.71,"Mean","%",2.94,"SEM"
"247","57186a77-f3dd-4dbb-9911-f90ceedfed91","Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress","Yu, Mei and Zhang, Yuan and Chen, Xiaoyu and Zhang, Tao","Stress: The International Journal on the Biology of Stress",NA,"The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zhang, Tao: College of Life Sciences, Nankai University, Tianjin, China, 300071, zhangtao@nankai.edu.cn and Zhang, Tao: zhangtao@nankai.edu.cn","2016","https://dx.doi.org/10.3109/10253890.2015.1108302","JOUR","*Amantadine and *Chronic Stress and *Animal Cognition and *Synaptic Plasticity and Rats",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","AMANTADINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","25","miligrams (mg) per kg","At disease model induction","20","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","-4","Days","Sucrose/saccharin intake or preference test",999,"Days","Measured from figures","Baseline measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Weeks","At recruitment to study",999,999,220,230,"Grams (g)","No",2024-01-24 11:09:28,"83673475-ad48-4c6c-b882-2c54fda8db35","SPT","Sucrose consumption","76be99d6-18bd-4ae7-b860-b0082c46c808","a10acad7-bd13-4342-babf-b20dccea9a6a","CUS + amantadine",6,"False","189fdf21-e15f-4e44-a830-07e69913c592","CUS","False","a8b21130-1908-4764-a072-349a500a29f6","Amantadine",FALSE,21,81.64,"Mean","%",3.08,"SEM"
"248","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other","ROPINIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Days","Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (hippocampus)","4e9404f2-2ab1-4968-a73d-4580e5160e43","3344722f-e991-41fb-99c6-fd7cb81caa91","PNS: Ropinirole (10mg/kg)",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","False","149c16ae-e28a-4bc5-89aa-9a73877d634e","Ropinirole (10mg/kg)",FALSE,0,0.93,"Mean","fold of control",0.05,"SEM"
"249","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other","ROPINIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Days","Sucrose/saccharin intake or preference test",1,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","Sucrose Preference (offspring)","65aea820-bed0-4fb1-b6ee-85150cd1b6c2","3344722f-e991-41fb-99c6-fd7cb81caa91","PNS: Ropinirole (10mg/kg)",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","False","149c16ae-e28a-4bc5-89aa-9a73877d634e","Ropinirole (10mg/kg)",FALSE,0,60.7,"Mean","%",5.3,"SEM"
"250","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other","ROPINIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","1","Days","Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (PFC)","c9830664-e4d8-44b8-9b26-f50a5f3db227","3344722f-e991-41fb-99c6-fd7cb81caa91","PNS: Ropinirole (10mg/kg)",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","False","149c16ae-e28a-4bc5-89aa-9a73877d634e","Ropinirole (10mg/kg)",FALSE,0,0.87,"Mean","fold of control",0.03,"SEM"
"251","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (hippocampus)","4e9404f2-2ab1-4968-a73d-4580e5160e43","48d27b17-c9f6-42e8-8964-14572add83f1","PNS: vehicle",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,0.6,"Mean","fold of control",0.02,"SEM"
"252","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",1,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","Sucrose Preference (offspring)","65aea820-bed0-4fb1-b6ee-85150cd1b6c2","48d27b17-c9f6-42e8-8964-14572add83f1","PNS: vehicle",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,50.7,"Mean","%",2.2,"SEM"
"253","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (PFC)","c9830664-e4d8-44b8-9b26-f50a5f3db227","48d27b17-c9f6-42e8-8964-14572add83f1","PNS: vehicle",6,"False","36e978d4-5837-4643-b827-8be8d7b54c3e","PNS","True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,0.65,"Mean","fold of control",0.027,"SEM"
"254","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (hippocampus)","4e9404f2-2ab1-4968-a73d-4580e5160e43","b0b8952a-6035-4552-9269-24b40b2894ec","control: vehicle",6,NA,NA,NA,"True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,1,"Mean","fold of control",0.06,"SEM"
"255","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",1,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","Sucrose Preference (offspring)","65aea820-bed0-4fb1-b6ee-85150cd1b6c2","b0b8952a-6035-4552-9269-24b40b2894ec","control: vehicle",6,NA,NA,NA,"True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,63.8,"Mean","%",5,"SEM"
"256","5b6add08-d167-4637-a1fb-054bbb4cf02f","A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats.","Fatima M and Ahmad MH and Srivastav S and Rizvi MA and Mondal AC","Neurochemistry international",NA,"Prenatal stress (PNS) has its negative impact on both the infant hippocampal neurogenesis and pregnancy outcomes in the neonates that serves as a risk factor for postnatal depression in adult offsprings. Therefore, main objectives of the present study were to evaluate the effect of maternal chronic unpredictable mild stress (CUMS) on behavioural changes, levels of oxidative stress, changes in selective developmental signaling genes and neurogenesis in the adult brain of Wistar rats and its reversal through a selective non-ergoline D2 type dopamine receptor (D2R) agonist Ropinirole (ROPI). Effects of ROPI treatment on CUMS induced adult rats offspring were measured by assessment of behavioural tests (sucrose preference test and forced swim test), biomarkers of oxidative stress, protein expression of tyrosine hydroxylase (TH), mRNA expression of SHH, GSK-3, -catenin, Notch, brain-derived neurotrophic factor (BDNF), Dopamine receptor 2 (Drd2) and bromodeoxyuridine (BrdU) cell proliferation assay. The oxidative stress, protein and mRNA expression were determined in the hippocampus and prefrontal cortex while the BrdU cell proliferation was observed in the hippocampus of rat brain. PNS induced changes resulted in depression validated by the depression-like behaviours, increased oxidative stress, decreased TH expression, altered expression of selective developmental genes, along with the reduced hippocampal neurogenesis and BDNF expression in the brain of adult offsprings. Chronic ROPI treatment reversed those effects and was equally effective like Imipramine (IMI) treatment. So, the present study suggested that ROPI can be used as an antidepressant drug for the treatment of depressive disorders.",NA,"Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India: Department of Biosciences, and Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. and Department of Biosciences, Jamia Millia Islamia, New Delhi, 110025, India. and Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, and Jawaharlal Nehru University, New Delhi, 110067, India. Electronic address: and acmondal@mail.jnu.ac.in.","2020","10.1016/j.neuint.2020.104730","Journal Article and Research Support, Non-U.S. Gov't","Behaviour and Gene expression and Imipramine and Neurogenesis and Prenatal stress and Ropinirole",NA,"pubmed-32201282",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Litter","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",2,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,79,9999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 12:41:25,"fb3f388d-571a-4d14-b0dd-c49d4b8c19c6","sucrose preference test","DRD2 mRNA expression (PFC)","c9830664-e4d8-44b8-9b26-f50a5f3db227","b0b8952a-6035-4552-9269-24b40b2894ec","control: vehicle",6,NA,NA,NA,"True","2f4c0c2a-cad8-48d2-b5fe-a4c38ae258f6","vehicle",FALSE,0,1,"Mean","fold of control",0.05,"SEM"
"257","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in hippocampus","4df394ac-ff1f-475c-906d-66fc58c89446","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,1.54,"Mean","nmol/g",0.22,"SD"
"258","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in prefrontal cortex","57754f67-e810-4bb1-b042-e5481d67de25","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,4.8,"Mean","nmol/g",0.74,"SD"
"259","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in dorsal raphe nucleus","57ff01d5-36ed-4e15-8304-5896c8eece17","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,236.65,"Mean","nmol/g",46.58,"SD"
"260","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in hippocampus","99b32141-508d-46ad-9163-9f9705fd51a6","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,18.21,"Mean","nmol/g",1.85,"SD"
"261","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in prefrontal cortex","e631feed-a17d-4651-9eed-05a535288bba","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,31.76,"Mean","nmol/g",8.73,"SD"
"262","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in dorsal raphe nucleus","e943a667-85c7-4a95-ad63-1056877e3ee2","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,4.18,"Mean","nmol/g",0.77,"SD"
"263","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","Sucrose preference","f113c620-61c4-450e-9ad4-5b411ca2fe49","012fa8f2-ffaf-41c2-bd05-f10b434b6229","CUMS + S4 10mg/kg (low)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","727a9b89-3b9a-46c6-979e-010a365c8591","S4 10mg/kg",FALSE,0,65.33,"Mean","%",8.48,"SD"
"264","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in hippocampus","4df394ac-ff1f-475c-906d-66fc58c89446","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,1.64,"Mean","nmol/g",0.29,"SD"
"265","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in prefrontal cortex","57754f67-e810-4bb1-b042-e5481d67de25","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,4.23,"Mean","nmol/g",0.4,"SD"
"266","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in dorsal raphe nucleus","57ff01d5-36ed-4e15-8304-5896c8eece17","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,208.7,"Mean","nmol/g",16.77,"SD"
"267","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in hippocampus","99b32141-508d-46ad-9163-9f9705fd51a6","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,19.44,"Mean","nmol/g",3.24,"SD"
"268","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in prefrontal cortex","e631feed-a17d-4651-9eed-05a535288bba","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,32,"Mean","nmol/g",4,"SD"
"269","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in dorsal raphe nucleus","e943a667-85c7-4a95-ad63-1056877e3ee2","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,3.18,"Mean","nmol/g",0.54,"SD"
"270","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","Sucrose preference","f113c620-61c4-450e-9ad4-5b411ca2fe49","97302341-2b18-4fa2-8792-967821f7cf8d","CUMS + vehicle",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,51.91,"Mean","%",7.95,"SD"
"271","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in hippocampus","4df394ac-ff1f-475c-906d-66fc58c89446","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,1.54,"Mean","nmol/g",0.11,"SD"
"272","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in prefrontal cortex","57754f67-e810-4bb1-b042-e5481d67de25","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,5.03,"Mean","nmol/g",0.28,"SD"
"273","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in dorsal raphe nucleus","57ff01d5-36ed-4e15-8304-5896c8eece17","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,475.15,"Mean","nmol/g",87.58,"SD"
"274","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in hippocampus","99b32141-508d-46ad-9163-9f9705fd51a6","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,36.57,"Mean","nmol/g",3.6,"SD"
"275","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in prefrontal cortex","e631feed-a17d-4651-9eed-05a535288bba","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,51.64,"Mean","nmol/g",6.06,"SD"
"276","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in dorsal raphe nucleus","e943a667-85c7-4a95-ad63-1056877e3ee2","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,3.59,"Mean","nmol/g",0.41,"SD"
"277","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","Sucrose preference","f113c620-61c4-450e-9ad4-5b411ca2fe49","bbe4cb70-9580-453e-af1a-6358bb16c677","Control + vehicle",10,NA,NA,NA,"True","2b0273fa-75f3-4b01-b6f5-f2875fbefdec","Vehicle",FALSE,0,89.3,"Mean","%",4.63,"SD"
"278","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in hippocampus","4df394ac-ff1f-475c-906d-66fc58c89446","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,1.71,"Mean","nmol/g",0.22,"SD"
"279","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in prefrontal cortex","57754f67-e810-4bb1-b042-e5481d67de25","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,7.2,"Mean","nmol/g",0.74,"SD"
"280","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in dorsal raphe nucleus","57ff01d5-36ed-4e15-8304-5896c8eece17","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,430.43,"Mean","nmol/g",48.45,"SD"
"281","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in hippocampus","99b32141-508d-46ad-9163-9f9705fd51a6","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,31.64,"Mean","nmol/g",5.25,"SD"
"282","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in prefrontal cortex","e631feed-a17d-4651-9eed-05a535288bba","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,50.91,"Mean","nmol/g",8.97,"SD"
"283","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in dorsal raphe nucleus","e943a667-85c7-4a95-ad63-1056877e3ee2","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,4.68,"Mean","nmol/g",0.41,"SD"
"284","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","100","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","Sucrose preference","f113c620-61c4-450e-9ad4-5b411ca2fe49","bc2890e1-1fdd-44fa-bb00-42ac8eabc556","CUMS + S4 100mg/kg (high)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","90d8186a-02b3-449f-944f-f785b67a1b8a","S4 100mg/kg",FALSE,0,89.22,"Mean","%",3.53,"SD"
"285","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in hippocampus","4df394ac-ff1f-475c-906d-66fc58c89446","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,1.64,"Mean","nmol/g",0.28,"SD"
"286","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in prefrontal cortex","57754f67-e810-4bb1-b042-e5481d67de25","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,5.43,"Mean","nmol/g",0.4,"SD"
"287","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in dorsal raphe nucleus","57ff01d5-36ed-4e15-8304-5896c8eece17","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,322.36,"Mean","nmol/g",48.45,"SD"
"288","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in hippocampus","99b32141-508d-46ad-9163-9f9705fd51a6","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,20.7,"Mean","nmol/g",0.62,"SD"
"289","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA in prefrontal cortex","e631feed-a17d-4651-9eed-05a535288bba","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,31.76,"Mean","nmol/g",3.3,"SD"
"290","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Dopamine-related non behavioural outcome",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","DA/DOPC ratio in dorsal raphe nucleus","e943a667-85c7-4a95-ad63-1056877e3ee2","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,5.04,"Mean","nmol/g",1.05,"SD"
"291","604af48f-e2b7-4a0c-a425-ee934fcf0f05","Platycladus orientalis seed extract as a potential triple reuptake MAO inhibitor rescue depression phenotype through restoring monoamine neurotransmitters.","Yan L and Wang J and He X and Jin Y and Chen P and Bai Y and Li P and Su W","Journal of ethnopharmacology",NA,"ETHNOPHARMACOLOGY RELEVANCE: Platycladus orientalis seeds are recorded in traditional Chinese medicine (TCM) formulations for modulation of mood and physical activity in ""Shen Nong Ben Cao Jing"" and ""Compendium of Materia Medica"" and so on. Recently, we identified its extracting components and looked for the potentials in treatment for depression by improving the function of monoamine neurotransmitters. AIM OF THE STUDY: We investigated the mechanism of action of the seed extracts of P. orientalis (S4) to rescue depressive behavior in a chronic, unpredicted, mild stress (CUMS)-induced model in rats. MATERIALS AND METHODS: We used ultra-fast liquid chromatography coupled with triple quadrupole-time of flight tandem mass spectrometry to analyze the chemical constituents in S4. An assay platform in zebrafish and molecular docking were used to analyze if S4 regulated rest/wake behavior and predict the biological targets which correlated with monoamine neurotransmitters. Depressive-behavior tests (body weight, sucrose preference test, tail-suspension test, forced-swimming test) were carried in the CUMS model. After behavior tests and killing, rat brains were separated into the hippocampus, frontier cortex and dorsal raphe nucleus. The main monoamine neurotransmitters and their metabolite concentrations in these three brain regions were measured by rapid resolution liquid chromatography coupled with triple quadrupole tandem mass spectrometry. RESULTS: Forty-one compounds were identified in S4, including fatty acids, terpenoids, amino acids, plant sterols and flavonoids. S4 could increase the total rest time and decrease the waking activity of zebrafish. S4 showed high correlation with adrenaline agonists, 5-hydroxytryptamine (5-HT) reuptake inhibitors and dopamine agonists. CUMS-group rats, compared with controls, had significantly decreased body weight and preference for sucrose water, whereas the immobility time in the tail-suspension test and forced-swimming test was increased. S4 could significantly rescue the increased levels of 5-HT, noradrenaline and dopamine in the prefrontal cortex and dorsal raphe nucleus. CONCLUSIONS: We demonstrated that S4 was a potential inhibitor of MAO reuptake that could rescue depression in a CUMS-model rats by restoring monoamine neurotransmitters in different encephalic regions.",NA,"Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China: Formula-Pattern Research Center, School of Traditional Chinese Medicine, and Jinan University, Guangzhou, 510632, China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lipeibo@mail.sysu.edu.cn. and Guangdong Engineering & Technology Research Center for Quality and Efficacy and Reevaluation of Post-Market Traditional Chinese Medicine, State Key Laboratory of and Biocontrol and Guangdong Provincial Key Laboratory of Plant Resources, School of and Life Sciences, Sun Yat-sen University, 135 Xingang Xi Road, Guangzhou, 510275, and China. Electronic address: lsssww@mail.sysu.edu.cn.","2022","10.1016/j.jep.2022.115302","Journal Article","CUMS and Depression and MAO inhibitor and Platycladus orientalis seed Extract and Zebrafish larvae",NA,"pubmed-35489661",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","No","No","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","seed extracts of P. orientalis (S4)","MAO inhibitor (Selegiline, Rasagiline)","33","miligrams (mg) per kg","Prior to disease model induction","3","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","3","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Not reported","WT","Rat","Sprague-dawley (rat)","Exact number",10,8,999,999,999,"Weeks","At recruitment to study",220,10,999,999,"Grams (g)","Yes",2024-01-22 12:48:24,"295c9d2b-788f-4695-b28d-2a9d6ca8160c","exp","Sucrose preference","f113c620-61c4-450e-9ad4-5b411ca2fe49","d1aace95-0e8e-4462-b6db-0a31a3ddc4b2","CUMS + S4 33mg/kg (mid)",10,"False","9c57c427-890a-4983-aa87-a2eee29081a3","CUMS","False","1c763aa5-6c57-44f5-abba-e49c93bff539","S4 33mg/kg",FALSE,0,77.46,"Mean","%",5.88,"SD"
"292","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","121e4d03-68ae-485e-bdbf-193d355f0bca","CUMS: quin 200",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,5,8.7,"Mean","g",0.75,"SEM"
"293","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","121e4d03-68ae-485e-bdbf-193d355f0bca","CUMS: quin 200",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,6,7.88,"Mean","g",0.82,"SEM"
"294","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","121e4d03-68ae-485e-bdbf-193d355f0bca","CUMS: quin 200",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,7,11.6,"Mean","g",1,"SEM"
"295","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","121e4d03-68ae-485e-bdbf-193d355f0bca","CUMS: quin 200",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,8,13,"Mean","g",1.5,"SEM"
"296","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","2e8b7fd5-8147-4d3c-953c-5d90ba70eac3","control veh 1",16,NA,NA,NA,"True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,5,12.4,"Mean","g",0.68,"SEM"
"297","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","2e8b7fd5-8147-4d3c-953c-5d90ba70eac3","control veh 1",16,NA,NA,NA,"True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,6,11.35,"Mean","g",0.598,"SEM"
"298","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","2e8b7fd5-8147-4d3c-953c-5d90ba70eac3","control veh 1",16,NA,NA,NA,"True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,7,11.05,"Mean","g",0.813,"SEM"
"299","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","2e8b7fd5-8147-4d3c-953c-5d90ba70eac3","control veh 1",16,NA,NA,NA,"True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,8,12.175,"Mean","g",0.715,"SEM"
"300","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","3903743d-e24c-4311-967a-d37b37f05f47","CUMS: quin 100",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,5,7.5,"Mean","g",1.3,"SEM"
"301","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","3903743d-e24c-4311-967a-d37b37f05f47","CUMS: quin 100",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,6,7.8,"Mean","g",1,"SEM"
"302","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","3903743d-e24c-4311-967a-d37b37f05f47","CUMS: quin 100",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,7,11.7,"Mean","g",1.2,"SEM"
"303","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","3903743d-e24c-4311-967a-d37b37f05f47","CUMS: quin 100",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,8,13.7,"Mean","g",1.2,"SEM"
"304","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","495ddfde-c5e8-4684-bf4f-04fd07281ba8","control quin 200",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,5,11.6,"Mean","g",0.7,"SEM"
"305","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","495ddfde-c5e8-4684-bf4f-04fd07281ba8","control quin 200",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,6,11.8,"Mean","g",0.76,"SEM"
"306","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","495ddfde-c5e8-4684-bf4f-04fd07281ba8","control quin 200",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,7,11.9,"Mean","g",0.7,"SEM"
"307","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","495ddfde-c5e8-4684-bf4f-04fd07281ba8","control quin 200",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,8,11.8,"Mean","g",0.9,"SEM"
"308","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","6a79edc0-a0d3-40bb-ba9b-ecc9444f7419","CUMS: veh 1",16,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,5,8.24,"Mean","g",0.61,"SEM"
"309","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","6a79edc0-a0d3-40bb-ba9b-ecc9444f7419","CUMS: veh 1",16,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,6,6.7,"Mean","g",0.559,"SEM"
"310","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","6a79edc0-a0d3-40bb-ba9b-ecc9444f7419","CUMS: veh 1",16,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,7,7.55,"Mean","g",0.61,"SEM"
"311","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",16,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","6a79edc0-a0d3-40bb-ba9b-ecc9444f7419","CUMS: veh 1",16,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","True","5e0f1354-c69b-4d9c-8285-3fe1a7ae3deb","vehicle",FALSE,8,9.25,"Mean","g",0.651,"SEM"
"312","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","919be4c7-98e0-4cff-9611-83376a0afd69","control quin 400",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,5,10.8,"Mean","g",0.8,"SEM"
"313","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","919be4c7-98e0-4cff-9611-83376a0afd69","control quin 400",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,6,11.9,"Mean","g",0.8,"SEM"
"314","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","919be4c7-98e0-4cff-9611-83376a0afd69","control quin 400",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,7,11.3,"Mean","g",0.9,"SEM"
"315","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","919be4c7-98e0-4cff-9611-83376a0afd69","control quin 400",8,NA,NA,NA,"False","e429c7fc-4503-48cb-9755-a6d27bf2f19a","Quinpirole 200",FALSE,8,12.8,"Mean","g",1.2,"SEM"
"316","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","400","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e04ce4d6-64c4-4b9b-b459-dabaa9a3b3cf","CUMS: quin 400",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","bfae3a5f-3609-45ad-af97-b14e4794c12c","Quinpirole 400",FALSE,5,8.4,"Mean","g",1,"SEM"
"317","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","400","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e04ce4d6-64c4-4b9b-b459-dabaa9a3b3cf","CUMS: quin 400",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","bfae3a5f-3609-45ad-af97-b14e4794c12c","Quinpirole 400",FALSE,6,8.37,"Mean","g",0.4,"SEM"
"318","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","400","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e04ce4d6-64c4-4b9b-b459-dabaa9a3b3cf","CUMS: quin 400",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","bfae3a5f-3609-45ad-af97-b14e4794c12c","Quinpirole 400",FALSE,7,13,"Mean","g",0.55,"SEM"
"319","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","400","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e04ce4d6-64c4-4b9b-b459-dabaa9a3b3cf","CUMS: quin 400",8,"False","da3adccc-b2ae-45af-81e9-d175c2b76bac","CUMS","False","bfae3a5f-3609-45ad-af97-b14e4794c12c","Quinpirole 400",FALSE,8,12.7,"Mean","g",1.1,"SEM"
"320","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e65f2070-6a56-4e95-9798-fabb011b3348","control quin 100",8,NA,NA,NA,"False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,5,11.4,"Mean","g",0.7,"SEM"
"321","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e65f2070-6a56-4e95-9798-fabb011b3348","control quin 100",8,NA,NA,NA,"False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,6,10.8,"Mean","g",1.1,"SEM"
"322","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e65f2070-6a56-4e95-9798-fabb011b3348","control quin 100",8,NA,NA,NA,"False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,7,10.6,"Mean","g",0.7,"SEM"
"323","7afdb425-b6de-4e15-b02b-16b5e62007ca","Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia","Papp, Mariusz and Willner, Paul and Muscat, Richard","Psychopharmacology",NA,"Male rats were subjected to chronic exposure to very mild unpredictable stress (CMS) for a total of 9 wks. CMS reduced the consumption of a 1% sucrose solution. During Weeks 6 and 7, Ss received quinpirole (0-400 microg/kg) twice weekly. Both CMS-treated Ss and controls showed sensitization to the locomotor stimulant effects of quinpirole. Subsequently, a sustained recovery of sucrose drinking was observed in quinpirole-treated stressed Ss. During Week 8, all Ss received a single pair of place preference conditioning trials, in which quinpirole (200 microg/kg) was administered in a distinctive environment, and vehicle in a different environment. Nonstressed Ss showed an increase in preference for the environment associated with quinpirole, as did stressed Ss that had been sensitized to quinpirole: this effect was absent in untreated stressed Ss. Finally, in Week 9, acute administration of raclopride (150 microg/kg) was found to reverse the recovery of sucrose drinking in quinpirole-treated stressed Ss. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, OLD CASTLE ST, LONDON E1 7NT, ENGLAND","1993","https://dx.doi.org/10.1007/BF02246966","JOUR","*Activity Level and *Dopamine Agonists and *Fluid Intake and *Place Conditioning and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","No","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"Quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","micrograms (ug) per kg","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",15,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,250,300,"Grams (g)","Yes",2024-02-07 17:11:41,"bdf5bd6c-f423-4ff9-9962-a7f0dc79f4b9","sucrose preference","sucrose intake","7d73202e-4ad2-459d-9e54-06eae6d15295","e65f2070-6a56-4e95-9798-fabb011b3348","control quin 100",8,NA,NA,NA,"False","32565c59-84d7-4dc5-a777-fd44e1d49be6","Quinpirole 100",FALSE,8,11.4,"Mean","g",0.8,"SEM"
"324","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Hours","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"32d9d132-5384-440d-aeb1-37c03212b811","sucrose preference","sucrose preference","460e2640-30cb-4256-a580-32f071630a4e","138bcac8-7a7f-4456-9aee-aa2a94d3d2b7","iuGC: vehicle (SPT)",7,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,72.3,"Mean","%",2.3,"SEM"
"325","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Hours","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"32d9d132-5384-440d-aeb1-37c03212b811","sucrose preference","sucrose preference","460e2640-30cb-4256-a580-32f071630a4e","778f674b-ef1d-45fd-8443-b2e5a1af47b7","control: vehicle (SPT)",7,NA,NA,NA,"True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,82.9,"Mean","%",1.2,"SEM"
"326","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other","L-DOPA","Dopamine agonist (e.g. apomorphine, rotigotine)","24","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Oral administration/gavage","Continuous administration","999","Hours","Sucrose/saccharin intake or preference test",4,"Hours","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"32d9d132-5384-440d-aeb1-37c03212b811","sucrose preference","sucrose preference","460e2640-30cb-4256-a580-32f071630a4e","fead7476-fcc9-46ec-bf86-3aa432c4911f","iuGC: L-DOPA (SPT)",7,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","False","e9dff82d-c1d4-4f66-b103-fc9aca2b2329","L-DOPA (24mg/kg)",FALSE,0,84.9,"Mean","%",1.8,"SEM"
"327","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other","L-DOPA","Dopamine agonist (e.g. apomorphine, rotigotine)","24","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Oral administration/gavage","Continuous administration","999","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (NAcc)","09a15756-9f54-4894-9dcc-3979fcc2a09e","13310dad-a8b0-416c-9bf2-6eb7da310a9b","iuGC: L-DOPA (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","False","e9dff82d-c1d4-4f66-b103-fc9aca2b2329","L-DOPA (24mg/kg)",FALSE,0,1.33,"Mean","ng/mg",0.18,"SEM"
"328","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other","L-DOPA","Dopamine agonist (e.g. apomorphine, rotigotine)","24","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Oral administration/gavage","Continuous administration","999","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (Amygdala)","5009e967-2e77-4edb-90bc-6ff400226d3f","13310dad-a8b0-416c-9bf2-6eb7da310a9b","iuGC: L-DOPA (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","False","e9dff82d-c1d4-4f66-b103-fc9aca2b2329","L-DOPA (24mg/kg)",FALSE,0,0.084,"Mean","ng/mg",0.01,"SEM"
"329","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other","L-DOPA","Dopamine agonist (e.g. apomorphine, rotigotine)","24","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Oral administration/gavage","Continuous administration","999","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (NAcc)","a537bcaf-47ee-48f3-93fe-c07380dac1d2","13310dad-a8b0-416c-9bf2-6eb7da310a9b","iuGC: L-DOPA (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","False","e9dff82d-c1d4-4f66-b103-fc9aca2b2329","L-DOPA (24mg/kg)",FALSE,0,1.5,"Mean","ng/mg",0.21,"SEM"
"330","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other","L-DOPA","Dopamine agonist (e.g. apomorphine, rotigotine)","24","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Oral administration/gavage","Continuous administration","999","Hours","Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (Amygdala)","ba0e8079-07d9-431e-b76f-46223935f59d","13310dad-a8b0-416c-9bf2-6eb7da310a9b","iuGC: L-DOPA (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","False","e9dff82d-c1d4-4f66-b103-fc9aca2b2329","L-DOPA (24mg/kg)",FALSE,0,0.053,"Mean","ng/mg",0.01,"SEM"
"331","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (NAcc)","09a15756-9f54-4894-9dcc-3979fcc2a09e","3d6f5c12-e488-4fb5-be05-ca183d7ef34f","iuGC: vehicle (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.73,"Mean","ng/mg",0.17,"SEM"
"332","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (Amygdala)","5009e967-2e77-4edb-90bc-6ff400226d3f","3d6f5c12-e488-4fb5-be05-ca183d7ef34f","iuGC: vehicle (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.04,"Mean","ng/mg",0.01,"SEM"
"333","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (NAcc)","a537bcaf-47ee-48f3-93fe-c07380dac1d2","3d6f5c12-e488-4fb5-be05-ca183d7ef34f","iuGC: vehicle (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.77,"Mean","ng/mg",0.2,"SEM"
"334","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological early life stress (e.g. maternal immune challenge)",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (Amygdala)","ba0e8079-07d9-431e-b76f-46223935f59d","3d6f5c12-e488-4fb5-be05-ca183d7ef34f","iuGC: vehicle (DA DOPAC)",5,"False","0ce90632-afef-408c-9dc4-c5ed18074686","in utero glucocorticoid (iuGC)","True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.03,"Mean","ng/mg",0.01,"SEM"
"335","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (NAcc)","09a15756-9f54-4894-9dcc-3979fcc2a09e","ecb1edf2-757b-4d12-9856-be34188e76b7","control: vehicle (DA DOPAC)",5,NA,NA,NA,"True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,1.16,"Mean","ng/mg",0.17,"SEM"
"336","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (Amygdala)","5009e967-2e77-4edb-90bc-6ff400226d3f","ecb1edf2-757b-4d12-9856-be34188e76b7","control: vehicle (DA DOPAC)",5,NA,NA,NA,"True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.068,"Mean","ng/mg",0.01,"SEM"
"337","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","Dopamine concentration (NAcc)","a537bcaf-47ee-48f3-93fe-c07380dac1d2","ecb1edf2-757b-4d12-9856-be34188e76b7","control: vehicle (DA DOPAC)",5,NA,NA,NA,"True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,1.4,"Mean","ng/mg",0.15,"SEM"
"338","8659337c-8158-4bed-9dde-de0d3ce3d525","Dopaminergic Modulation of Affective and Social Deficits Induced by Prenatal Glucocorticoid Exposure","Borges, S and Coimbra, B and Soares-Cunha, C and Pego, JM and Sousa, N and Rodrigues, AJ","NEUROPSYCHOPHARMACOLOGY",NA,"Prenatal stress or exposure to elevated levels of glucocorticoids (GCs) can impair specific neurobehavioral circuits leading to alterations in emotional processes later in life. In turn, emotional deficits may interfere with the quality and degree of social interaction. Here, by using a comprehensive behavioral approach in combination with the measurement of ultrasonic vocalizations, we show that in utero GC (iuGC)-exposed animals present increased immobility in the forced swimming test, pronounced anhedonic behavior (both anticipatory and consummatory), and an impairment in social interaction at different life stages. Importantly, we also found that social behavioral expression is highly dependent on the affective status of the partner. A profound reduction in mesolimbic dopaminergic transmission was found in iuGC animals, suggesting a key role for dopamine (DA) in the etiology of the observed behavioral deficits. Confirming this idea, we present evidence that a simple pharmacological approach-acute L-3,4-dihydroxyphenylacetic acid (L-DOPA) oral administration, is able to normalize DA levels in iuGC animals, with a concomitant amelioration of several dimensions of the emotional and social behaviors. Interestingly, L-DOPA effects in control individuals were not so straightforward: suggesting that both hypo-and hyperdopaminergia are detrimental in the context of such complex behaviors.",NA,"Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal and ICVS 3Bs PT Govt Associate Lab, Braga, Portugal","2013","10.1038/npp.2013.108","JOUR","anhedonia and social behavior and dopamine and mesolimbic circuit and depression and 50-KHZ ULTRASONIC VOCALIZATIONS and ANTENATAL GLUCOCORTICOIDS and NUCLEUS-ACCUMBENS and MAJOR DEPRESSION and CHILDHOOD TRAUMA and HPA AXIS and BEHAVIOR and RATS and DEXAMETHASONE and STRESS",NA,"WOS:000323165500026",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,999,999,12,14,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-26 13:22:05,"f12dad59-6e5e-455f-b87d-477797a48455","Dopamine and DOPAC concentration","DOPAC concentration (Amygdala)","ba0e8079-07d9-431e-b76f-46223935f59d","ecb1edf2-757b-4d12-9856-be34188e76b7","control: vehicle (DA DOPAC)",5,NA,NA,NA,"True","fa4125ed-af5e-4c1b-859a-0a6e2848b2e2","vehicle",FALSE,0,0.05,"Mean","ng/mg",0.02,"SEM"
"339","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","12","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","107507ee-60f1-4b71-aa75-f3b49ecc975a","CMS/MCAO + ari 10mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","97d68cee-9091-4538-b320-df9581431c75","Aripiprazole 10mg/kg",FALSE,4,1.42,"Mean","g",0.11,"SEM"
"340","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","12","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","107507ee-60f1-4b71-aa75-f3b49ecc975a","CMS/MCAO + ari 10mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","97d68cee-9091-4538-b320-df9581431c75","Aripiprazole 10mg/kg",FALSE,5,1.58,"Mean","g",0.23,"SEM"
"341","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","12","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","107507ee-60f1-4b71-aa75-f3b49ecc975a","CMS/MCAO + ari 10mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","97d68cee-9091-4538-b320-df9581431c75","Aripiprazole 10mg/kg",FALSE,6,2.51,"Mean","g",0.06,"SEM"
"342","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","30","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","1bde2b98-d309-4803-85d6-5d34aa8d07ba","CMS/MCAO + ari 30mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","dcd59b33-f2cd-43e7-a704-58358d6d0ed5","Aripiprazole 30mg/kg",FALSE,4,1.48,"Mean","g",0.23,"SEM"
"343","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","30","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","1bde2b98-d309-4803-85d6-5d34aa8d07ba","CMS/MCAO + ari 30mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","dcd59b33-f2cd-43e7-a704-58358d6d0ed5","Aripiprazole 30mg/kg",FALSE,5,1.51,"Mean","g",0.15,"SEM"
"344","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","30","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","1bde2b98-d309-4803-85d6-5d34aa8d07ba","CMS/MCAO + ari 30mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","dcd59b33-f2cd-43e7-a704-58358d6d0ed5","Aripiprazole 30mg/kg",FALSE,6,2.38,"Mean","g",0.14,"SEM"
"345","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","4310f45b-7317-4561-b84e-d8215c3654ef","Control + vehicle",999,NA,NA,NA,"True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,4,2.33,"Mean","g",0.04,"SEM"
"346","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","4310f45b-7317-4561-b84e-d8215c3654ef","Control + vehicle",999,NA,NA,NA,"True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,5,2.02,"Mean","g",0.43,"SEM"
"347","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","4310f45b-7317-4561-b84e-d8215c3654ef","Control + vehicle",999,NA,NA,NA,"True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,6,2.54,"Mean","g",0.12,"SEM"
"348","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","5f46e2f4-a06c-4450-9eca-a18f0fba743a","CMS/MCAO + vehicle",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,4,1.67,"Mean","g",0.16,"SEM"
"349","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","5f46e2f4-a06c-4450-9eca-a18f0fba743a","CMS/MCAO + vehicle",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,5,1.23,"Mean","g",0.06,"SEM"
"350","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","5f46e2f4-a06c-4450-9eca-a18f0fba743a","CMS/MCAO + vehicle",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","True","cd5eb0f4-621c-46fc-9354-26fd0c8267cd","Vehicle",FALSE,6,1.92,"Mean","g",0.17,"SEM"
"351","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","3","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","9cdb2abd-4661-4284-9d67-75771aefc2da","CMS/MCAO + ari 3mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","f7e0d02b-5f46-4775-9200-7b5c198f99ed","Aripiprazole 3mg/kg",FALSE,4,2.63,"Mean","g",0.09,"SEM"
"352","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","3","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","9cdb2abd-4661-4284-9d67-75771aefc2da","CMS/MCAO + ari 3mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","f7e0d02b-5f46-4775-9200-7b5c198f99ed","Aripiprazole 3mg/kg",FALSE,5,1.81,"Mean","g",0.2,"SEM"
"353","8698bfb8-e435-4518-bc0e-62fac77b626c","Studies in an animal model of post-stroke depression and treatment with antipsychotic aripiprazole","Kim, YR and Yun, YJ and Baek, JU and Shin, HK and Choi, BT","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",NA,NA,NA,"Pusan Natl Univ, Korean Med Sci Res Ctr Hlth Aging, Yangsan, South Korea and Pusan Natl Univ, Dept Integrat Med, Yangsan, South Korea and Pusan Natl Univ, Div Humanities & Social Med, Yangsan, South Korea and Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Yangsan, South Korea","2015",NA,"JOUR",NA,NA,"WOS:000361863000387",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","3","miligrams (mg) per kg","After disease model induction","17","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","2","Days","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",999,10,999,999,999,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-27 16:57:18,"1e95df43-4ff4-463e-99ab-e0b4a6f0081b","exp","Sucrose intake","2d16e347-a618-4583-9a36-91b39de32b7a","9cdb2abd-4661-4284-9d67-75771aefc2da","CMS/MCAO + ari 3mg/kg",999,"False","cc590aef-1e45-428c-a52b-e0e09aa82084","CMS + MCAO","False","f7e0d02b-5f46-4775-9200-7b5c198f99ed","Aripiprazole 3mg/kg",FALSE,6,2.32,"Mean","g",0.09,"SEM"
"354","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","06036c86-ae61-4811-8199-06dd2e8d1494","CMS",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,0,1.41,"Mean","g/kg",0.052,"SEM"
"355","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","06036c86-ae61-4811-8199-06dd2e8d1494","CMS",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,3,1.06,"Mean","g/kg",0.092,"SEM"
"356","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","06036c86-ae61-4811-8199-06dd2e8d1494","CMS",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,7,0.9,"Mean","g/kg",0.036,"SEM"
"357","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","06036c86-ae61-4811-8199-06dd2e8d1494","CMS",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,11,0.81,"Mean","g/kg",0.032,"SEM"
"358","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","06036c86-ae61-4811-8199-06dd2e8d1494","CMS",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,14,0.79,"Mean","g/kg",0.03,"SEM"
"359","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","3bc385a6-bcf6-4e2f-8938-c1c57320e2bf","Control (nor)",6,NA,NA,NA,"True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,0,1.44,"Mean","g/kg",0.022,"SEM"
"360","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","3bc385a6-bcf6-4e2f-8938-c1c57320e2bf","Control (nor)",6,NA,NA,NA,"True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,3,1.43,"Mean","g/kg",0.032,"SEM"
"361","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","3bc385a6-bcf6-4e2f-8938-c1c57320e2bf","Control (nor)",6,NA,NA,NA,"True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,7,1.44,"Mean","g/kg",0.025,"SEM"
"362","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","3bc385a6-bcf6-4e2f-8938-c1c57320e2bf","Control (nor)",6,NA,NA,NA,"True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,11,1.43,"Mean","g/kg",0.023,"SEM"
"363","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","3bc385a6-bcf6-4e2f-8938-c1c57320e2bf","Control (nor)",6,NA,NA,NA,"True","3fdaa858-bc62-43ea-8d5c-db0803ffe97e","Vehicle",FALSE,14,1.43,"Mean","g/kg",0.025,"SEM"
"364","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SIMVASTATIN","Not specified/unclear","10","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","74fbdd88-1887-47dd-bc70-2152f7427210","CMS + SIM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False","39b1c884-fe90-485d-b86a-1c8f5f76813a","Simvastatin",FALSE,0,1.42,"Mean","g/kg",0.035,"SEM"
"365","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SIMVASTATIN","Not specified/unclear","10","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","74fbdd88-1887-47dd-bc70-2152f7427210","CMS + SIM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False","39b1c884-fe90-485d-b86a-1c8f5f76813a","Simvastatin",FALSE,3,1.24,"Mean","g/kg",0.056,"SEM"
"366","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SIMVASTATIN","Not specified/unclear","10","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","74fbdd88-1887-47dd-bc70-2152f7427210","CMS + SIM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False","39b1c884-fe90-485d-b86a-1c8f5f76813a","Simvastatin",FALSE,7,1.25,"Mean","g/kg",0.06,"SEM"
"367","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SIMVASTATIN","Not specified/unclear","10","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","74fbdd88-1887-47dd-bc70-2152f7427210","CMS + SIM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False","39b1c884-fe90-485d-b86a-1c8f5f76813a","Simvastatin",FALSE,11,1.26,"Mean","g/kg",0.03,"SEM"
"368","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SIMVASTATIN","Not specified/unclear","10","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","74fbdd88-1887-47dd-bc70-2152f7427210","CMS + SIM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False","39b1c884-fe90-485d-b86a-1c8f5f76813a","Simvastatin",FALSE,14,1.27,"Mean","g/kg",0.021,"SEM"
"369","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","LEVODOPA;SIMVASTATIN","Dopamine precursor (L-DOPA);Not specified/unclear","200;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d2542d3a-071e-42d0-94dc-7bfc9067d135","CMS + SIM + LEV",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","17bc56ff-1fd9-4419-aec9-408edde60e2e;39b1c884-fe90-485d-b86a-1c8f5f76813a","Levodopa;Simvastatin",FALSE,0,1.41,"Mean","g/kg",0.033,"SEM"
"370","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","LEVODOPA;SIMVASTATIN","Dopamine precursor (L-DOPA);Not specified/unclear","200;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d2542d3a-071e-42d0-94dc-7bfc9067d135","CMS + SIM + LEV",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","17bc56ff-1fd9-4419-aec9-408edde60e2e;39b1c884-fe90-485d-b86a-1c8f5f76813a","Levodopa;Simvastatin",FALSE,3,1.35,"Mean","g/kg",0.035,"SEM"
"371","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","LEVODOPA;SIMVASTATIN","Dopamine precursor (L-DOPA);Not specified/unclear","200;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d2542d3a-071e-42d0-94dc-7bfc9067d135","CMS + SIM + LEV",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","17bc56ff-1fd9-4419-aec9-408edde60e2e;39b1c884-fe90-485d-b86a-1c8f5f76813a","Levodopa;Simvastatin",FALSE,7,1.44,"Mean","g/kg",0.018,"SEM"
"372","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","LEVODOPA;SIMVASTATIN","Dopamine precursor (L-DOPA);Not specified/unclear","200;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d2542d3a-071e-42d0-94dc-7bfc9067d135","CMS + SIM + LEV",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","17bc56ff-1fd9-4419-aec9-408edde60e2e;39b1c884-fe90-485d-b86a-1c8f5f76813a","Levodopa;Simvastatin",FALSE,11,1.44,"Mean","g/kg",0.02,"SEM"
"373","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","LEVODOPA;SIMVASTATIN","Dopamine precursor (L-DOPA);Not specified/unclear","200;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d2542d3a-071e-42d0-94dc-7bfc9067d135","CMS + SIM + LEV",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","17bc56ff-1fd9-4419-aec9-408edde60e2e;39b1c884-fe90-485d-b86a-1c8f5f76813a","Levodopa;Simvastatin",FALSE,14,1.45,"Mean","g/kg",0.013,"SEM"
"374","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BROMOCRIPTINE;SIMVASTATIN","Dopamine agonist (e.g. apomorphine, rotigotine);Not specified/unclear","2;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d78392ac-d499-4217-8c4d-6553c6f204e5","CMS + SIM + BRM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","d84c60db-d45a-46d8-b460-8613b4ae4564;39b1c884-fe90-485d-b86a-1c8f5f76813a","Bromocriptine;Simvastatin",FALSE,0,1.41,"Mean","g/kg",0.036,"SEM"
"375","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BROMOCRIPTINE;SIMVASTATIN","Dopamine agonist (e.g. apomorphine, rotigotine);Not specified/unclear","2;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d78392ac-d499-4217-8c4d-6553c6f204e5","CMS + SIM + BRM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","d84c60db-d45a-46d8-b460-8613b4ae4564;39b1c884-fe90-485d-b86a-1c8f5f76813a","Bromocriptine;Simvastatin",FALSE,3,1.31,"Mean","g/kg",0.034,"SEM"
"376","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BROMOCRIPTINE;SIMVASTATIN","Dopamine agonist (e.g. apomorphine, rotigotine);Not specified/unclear","2;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d78392ac-d499-4217-8c4d-6553c6f204e5","CMS + SIM + BRM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","d84c60db-d45a-46d8-b460-8613b4ae4564;39b1c884-fe90-485d-b86a-1c8f5f76813a","Bromocriptine;Simvastatin",FALSE,7,1.44,"Mean","g/kg",0.018,"SEM"
"377","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BROMOCRIPTINE;SIMVASTATIN","Dopamine agonist (e.g. apomorphine, rotigotine);Not specified/unclear","2;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d78392ac-d499-4217-8c4d-6553c6f204e5","CMS + SIM + BRM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","d84c60db-d45a-46d8-b460-8613b4ae4564;39b1c884-fe90-485d-b86a-1c8f5f76813a","Bromocriptine;Simvastatin",FALSE,11,1.44,"Mean","g/kg",0.02,"SEM"
"378","944c6614-089b-4f41-bf57-ab08e5afb4c0","Alteration in the expression of exon IIC transcripts of brain-derived neurotrophic factor gene by simvastain in chronic mild stress in mice: a possible link with dopaminergic pathway","Rana, DG and Patel, AK and Joshi, CG and Jhala, MK and Goyal, RK","CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",NA,"We have investigated the influence of dopaminergic agents on the expression of brain-derived neurotrophic factor (BDNF) gene in relation with lipid levels in chronic mild stress (CMS). Mice subjected to CMS were treated with simvastatin (10 mg/kg, per os (orally)) along with bromocriptine (2 mg/kg, intraperitoneally (ip)), levodopa (200 mg/kg, ip), or haloperidol (0.1 mg/kg, ip) for 14 days. CMS produced a decrease in sucrose intake and an increase in serum cholesterol and triglycerides levels with a decrease in high-density lipoprotein cholesterol, which were prevented by simvastatin. This was greater when it was combined with bromocriptine or levodopa. Haloperidol significantly prevented the simvastatin-induced increase in sucrose intake but not the alterations in lipids. There was an upregulation in the expression of BDNF exon-IIA and -IIB transcripts by CMS but not the exon-IIC transcripts. Simvastatin could increase expression of exon-IIC transcripts in stressed mice. This was partially increased by bromocriptine. Haloperidol significantly prevented simvastatin-induced increase in expression of BDNF exon-IIC transcripts. The results showed a positive correlation between expression of BDNF exon-IIC transcripts and sucrose intake. In conclusion, our data suggest the involvement of lipid levels and BDNF exon-IIC transcripts in CMS-induced behaviour in mice, possibly through the dopaminergic system.",NA,"Hemchandracharya North Gujarat Univ, Fac Pharm, Patan, Gujarat, India and AAU, CVSAH, Anand, Gujarat, India and Ahmedabad Univ, Inst Life Sci, Ahmadabad 384265, Gujarat, India","2014","10.1139/cjpp-2014-0125","JOUR","BDNF exon II transcripts and cholesterol and depression and dopamine and statins and SERUM-CHOLESTEROL and MAJOR DEPRESSION and LIPID LEVELS and ANTIDEPRESSANT and BDNF and RECEPTORS and MOUSE and FLUOXETINE and INHIBITORS",NA,"WOS:000345558600002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BROMOCRIPTINE;SIMVASTATIN","Dopamine agonist (e.g. apomorphine, rotigotine);Not specified/unclear","2;10","miligrams (mg) per kg;miligrams (mg) per kg","At disease model induction;At disease model induction","14;14","Days;Days",";","Intraperitoneal (IP) injection;Oral administration/gavage","Multiple doses (enter details in comments);Multiple doses (enter details in comments)","0;0","Days;Days","Sucrose/saccharin intake or preference test",14,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","Other","Exact number",6,999,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2024-01-29 12:15:09,"6ea28222-e238-477b-8db4-707e7783add5","spt","Sucrose preference","95c5c0c9-6fb9-4083-9dcc-dfa99110d4d7","d78392ac-d499-4217-8c4d-6553c6f204e5","CMS + SIM + BRM",6,"False","d632a1b7-0284-4dbf-ad56-69b358ef1dc4","CMS","False;False","d84c60db-d45a-46d8-b460-8613b4ae4564;39b1c884-fe90-485d-b86a-1c8f5f76813a","Bromocriptine;Simvastatin",FALSE,14,1.45,"Mean","g/kg",0.013,"SEM"
"379","9cae29ae-39ba-48ca-a4d4-bee7e4a24453","Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression.","Tomaz VS and Chaves Filho AJM and Cordeiro RC and Juc<c3><a1> PM and Soares MVR and Barroso PN and Cristino LMF and Jiang W and Teixeira AL and de Lucena DF and Macedo DS","Journal of affective disorders",NA,"BACKGROUND: Depressed patients present increased plasma levels of lipopolysaccharide (LPS) and neuroinflammatory alterations. Here, we determined the neuroimmune effects of different classes of ADs by using the LPS inflammatory model of depression. METHODS: Male rats received amitriptyline (AMI) a tricyclic, S-citalopram (ESC) a selective serotonin reuptake inhibitor, tranylcypromine (TCP) a monoamine oxidase inhibitor, vortioxetine (VORT) a multimodal AD or saline for ten days. One-hour after the last AD administration, rats were exposed to LPS 0.83mg/kg or saline and 24h later were tested for depressive-like behavior. Plasma corticosterone, brain levels of nitrite, pro- and anti-inflammatory cytokines, phospho-cAMP Response Element-Binding Protein (CREB) and nuclear factor (NF)-kB p 65 were determined. RESULTS: LPS induced despair-like, impaired motivation/self-care behavior and caused anhedonia. All ADs prevented LPS-induced despair-like behavior, but only VORT rescued impaired self-care behavior. All ADs prevented LPS-induced increase in brain pro-inflammatory cytokines [interleukin (IL)-1 and IL-6] and T-helper 1 cytokines [tumor necrosis factor (TNF)- and interferon-]. VORT increased striatal and hypothalamic IL-4 levels. All ADs prevented LPS-induced neuroendocrine alterations represented by increased levels of hypothalamic nitrite and plasma corticosterone response. VORT and ESC prevented LPS-induced increase in NF-kBp65 hippocampal expression, while ESC, TCP and VORT, but not IMI, prevented the alterations in phospho-CREB expression. LIMITATIONS: LPS model helps to understand depression in a subset of depressed patients with immune activation. The levels of neurotransmitters were not determined. CONCLUSION: This study provides new evidence for the immunomodulatory effects of ADs, and shows a possible superior anti-inflammatory profile of TCP and VORT.",NA,"Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Department of Microbiology and Immunology, and Department of Medicine, Infectious and Diseases, Medical University of South Carolina, Charleston, South Carolina, USA. and Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, and University of Texas Health Science Center at Houston, Houston, Texas, USA: Santa and Casa BH Ensino e Pesquisa, Belo Horizonte, Minas Gerais, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil: National Institute for Translational Medicine (INCT-TM, and CNPq), Ribeiro Preto, SP, Brazil.. Electronic address: danielle.macedo@ufc.br.","2020","10.1016/j.jad.2020.03.022","Journal Article and Research Support, Non-U.S. Gov't","Antidepressants and Cytokines and Depression and Lipopolysaccharide and Neuroinflammation and Vortioxetine",NA,"pubmed-32174477",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","MAO inhibitor (Selegiline, Rasagiline)","TRANCYLCYPROMINE","MAO inhibitor (Selegiline, Rasagiline)","10","miligrams (mg) per kg","Prior to disease model induction","10","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","1","Hours","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 10:38:58,"177518f1-aacc-40fa-91b2-24c6b0475aa2","exp","sucrose consumption","d6c2cbdf-4adc-44d3-a9fd-b788f5b9f48d","20b555b8-cc32-4d0a-9edf-9dea16fe224b","LPS + TCP",8,"False","19d84874-8440-43af-ba28-8a11a401095d","LPS","False","a8bce662-253e-4b25-91e6-84f9a1050a95","tranylcypromine (TCP)",FALSE,0,65,"Mean","%",5,"SEM"
"380","9cae29ae-39ba-48ca-a4d4-bee7e4a24453","Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression.","Tomaz VS and Chaves Filho AJM and Cordeiro RC and Juc<c3><a1> PM and Soares MVR and Barroso PN and Cristino LMF and Jiang W and Teixeira AL and de Lucena DF and Macedo DS","Journal of affective disorders",NA,"BACKGROUND: Depressed patients present increased plasma levels of lipopolysaccharide (LPS) and neuroinflammatory alterations. Here, we determined the neuroimmune effects of different classes of ADs by using the LPS inflammatory model of depression. METHODS: Male rats received amitriptyline (AMI) a tricyclic, S-citalopram (ESC) a selective serotonin reuptake inhibitor, tranylcypromine (TCP) a monoamine oxidase inhibitor, vortioxetine (VORT) a multimodal AD or saline for ten days. One-hour after the last AD administration, rats were exposed to LPS 0.83mg/kg or saline and 24h later were tested for depressive-like behavior. Plasma corticosterone, brain levels of nitrite, pro- and anti-inflammatory cytokines, phospho-cAMP Response Element-Binding Protein (CREB) and nuclear factor (NF)-kB p 65 were determined. RESULTS: LPS induced despair-like, impaired motivation/self-care behavior and caused anhedonia. All ADs prevented LPS-induced despair-like behavior, but only VORT rescued impaired self-care behavior. All ADs prevented LPS-induced increase in brain pro-inflammatory cytokines [interleukin (IL)-1 and IL-6] and T-helper 1 cytokines [tumor necrosis factor (TNF)- and interferon-]. VORT increased striatal and hypothalamic IL-4 levels. All ADs prevented LPS-induced neuroendocrine alterations represented by increased levels of hypothalamic nitrite and plasma corticosterone response. VORT and ESC prevented LPS-induced increase in NF-kBp65 hippocampal expression, while ESC, TCP and VORT, but not IMI, prevented the alterations in phospho-CREB expression. LIMITATIONS: LPS model helps to understand depression in a subset of depressed patients with immune activation. The levels of neurotransmitters were not determined. CONCLUSION: This study provides new evidence for the immunomodulatory effects of ADs, and shows a possible superior anti-inflammatory profile of TCP and VORT.",NA,"Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Department of Microbiology and Immunology, and Department of Medicine, Infectious and Diseases, Medical University of South Carolina, Charleston, South Carolina, USA. and Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, and University of Texas Health Science Center at Houston, Houston, Texas, USA: Santa and Casa BH Ensino e Pesquisa, Belo Horizonte, Minas Gerais, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil: National Institute for Translational Medicine (INCT-TM, and CNPq), Ribeiro Preto, SP, Brazil.. Electronic address: danielle.macedo@ufc.br.","2020","10.1016/j.jad.2020.03.022","Journal Article and Research Support, Non-U.S. Gov't","Antidepressants and Cytokines and Depression and Lipopolysaccharide and Neuroinflammation and Vortioxetine",NA,"pubmed-32174477",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 10:38:58,"177518f1-aacc-40fa-91b2-24c6b0475aa2","exp","sucrose consumption","d6c2cbdf-4adc-44d3-a9fd-b788f5b9f48d","6f171883-9c7f-40a4-8dbd-f35193c83605","control",8,NA,NA,NA,NA,NA,NA,FALSE,0,82,"Mean","%",3.3,"SEM"
"381","9cae29ae-39ba-48ca-a4d4-bee7e4a24453","Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression.","Tomaz VS and Chaves Filho AJM and Cordeiro RC and Juc<c3><a1> PM and Soares MVR and Barroso PN and Cristino LMF and Jiang W and Teixeira AL and de Lucena DF and Macedo DS","Journal of affective disorders",NA,"BACKGROUND: Depressed patients present increased plasma levels of lipopolysaccharide (LPS) and neuroinflammatory alterations. Here, we determined the neuroimmune effects of different classes of ADs by using the LPS inflammatory model of depression. METHODS: Male rats received amitriptyline (AMI) a tricyclic, S-citalopram (ESC) a selective serotonin reuptake inhibitor, tranylcypromine (TCP) a monoamine oxidase inhibitor, vortioxetine (VORT) a multimodal AD or saline for ten days. One-hour after the last AD administration, rats were exposed to LPS 0.83mg/kg or saline and 24h later were tested for depressive-like behavior. Plasma corticosterone, brain levels of nitrite, pro- and anti-inflammatory cytokines, phospho-cAMP Response Element-Binding Protein (CREB) and nuclear factor (NF)-kB p 65 were determined. RESULTS: LPS induced despair-like, impaired motivation/self-care behavior and caused anhedonia. All ADs prevented LPS-induced despair-like behavior, but only VORT rescued impaired self-care behavior. All ADs prevented LPS-induced increase in brain pro-inflammatory cytokines [interleukin (IL)-1 and IL-6] and T-helper 1 cytokines [tumor necrosis factor (TNF)- and interferon-]. VORT increased striatal and hypothalamic IL-4 levels. All ADs prevented LPS-induced neuroendocrine alterations represented by increased levels of hypothalamic nitrite and plasma corticosterone response. VORT and ESC prevented LPS-induced increase in NF-kBp65 hippocampal expression, while ESC, TCP and VORT, but not IMI, prevented the alterations in phospho-CREB expression. LIMITATIONS: LPS model helps to understand depression in a subset of depressed patients with immune activation. The levels of neurotransmitters were not determined. CONCLUSION: This study provides new evidence for the immunomodulatory effects of ADs, and shows a possible superior anti-inflammatory profile of TCP and VORT.",NA,"Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Department of Microbiology and Immunology, and Department of Medicine, Infectious and Diseases, Medical University of South Carolina, Charleston, South Carolina, USA. and Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, and University of Texas Health Science Center at Houston, Houston, Texas, USA: Santa and Casa BH Ensino e Pesquisa, Belo Horizonte, Minas Gerais, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil. and Neuropharmacology Laboratory, Drug Research and Development Center, Department of and Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, and Fortaleza, CE, Brazil: National Institute for Translational Medicine (INCT-TM, and CNPq), Ribeiro Preto, SP, Brazil.. Electronic address: danielle.macedo@ufc.br.","2020","10.1016/j.jad.2020.03.022","Journal Article and Research Support, Non-U.S. Gov't","Antidepressants and Cytokines and Depression and Lipopolysaccharide and Neuroinflammation and Vortioxetine",NA,"pubmed-32174477",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","MAO inhibitor (Selegiline, Rasagiline)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Lower bound of range (put range in comments)",999,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 10:38:58,"177518f1-aacc-40fa-91b2-24c6b0475aa2","exp","sucrose consumption","d6c2cbdf-4adc-44d3-a9fd-b788f5b9f48d","bc67f053-f8b8-4f99-9714-6222bd7f8409","LPS",8,"False","19d84874-8440-43af-ba28-8a11a401095d","LPS",NA,NA,NA,FALSE,0,51,"Mean","%",3.5,"SEM"
"382","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",3,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",213.63,22.35,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 3 week","06aef8a4-9dd1-4b63-8fb4-7a777994e70a","165b2c9d-326a-438f-ba8d-9d3171940305","sham control",8,NA,NA,NA,"True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,9.75,"Mean","ml/hour",4.71,"SD"
"383","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",1,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",213.63,22.35,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 1 week","553142bd-660b-473e-8072-9ab3087496da","165b2c9d-326a-438f-ba8d-9d3171940305","sham control",8,NA,NA,NA,"True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,8.13,"Mean","ml/hour",5.08,"SD"
"384","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",2,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",213.63,22.35,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 2 week","66f0c543-45f9-4e4d-8688-e95241b2871d","165b2c9d-326a-438f-ba8d-9d3171940305","sham control",8,NA,NA,NA,"True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,8.88,"Mean","ml/hour",3.18,"SD"
"385","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",213.63,22.35,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 4 week","fb8091ff-71b3-427b-a85e-3746a3793b4d","165b2c9d-326a-438f-ba8d-9d3171940305","sham control",8,NA,NA,NA,"True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,8.63,"Mean","ml/hour",3.46,"SD"
"386","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",3,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",216.38,16.92,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 3 week","06aef8a4-9dd1-4b63-8fb4-7a777994e70a","29e521de-4b04-4094-b464-672466c4aaa9","CMS + Aripiprazole",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","False","45e240a2-2ae4-48d8-bb63-f959cacfb324","Aripiprazole 2.5mg/kg",FALSE,0,8.14,"Mean","ml/hour",2.48,"SD"
"387","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",1,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",216.38,16.92,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 1 week","553142bd-660b-473e-8072-9ab3087496da","29e521de-4b04-4094-b464-672466c4aaa9","CMS + Aripiprazole",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","False","45e240a2-2ae4-48d8-bb63-f959cacfb324","Aripiprazole 2.5mg/kg",FALSE,0,7.88,"Mean","ml/hour",5.41,"SD"
"388","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",2,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",216.38,16.92,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 2 week","66f0c543-45f9-4e4d-8688-e95241b2871d","29e521de-4b04-4094-b464-672466c4aaa9","CMS + Aripiprazole",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","False","45e240a2-2ae4-48d8-bb63-f959cacfb324","Aripiprazole 2.5mg/kg",FALSE,0,5.38,"Mean","ml/hour",4.96,"SD"
"389","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",216.38,16.92,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 4 week","fb8091ff-71b3-427b-a85e-3746a3793b4d","29e521de-4b04-4094-b464-672466c4aaa9","CMS + Aripiprazole",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","False","45e240a2-2ae4-48d8-bb63-f959cacfb324","Aripiprazole 2.5mg/kg",FALSE,0,8.43,"Mean","ml/hour",3.04,"SD"
"390","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",3,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",219.63,22.69,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 3 week","06aef8a4-9dd1-4b63-8fb4-7a777994e70a","ba4c4b17-7112-48d5-a1d3-802687c6ac8a","CMS + Vehicle",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,2.88,"Mean","ml/hour",1.46,"SD"
"391","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",1,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",219.63,22.69,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 1 week","553142bd-660b-473e-8072-9ab3087496da","ba4c4b17-7112-48d5-a1d3-802687c6ac8a","CMS + Vehicle",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,4.25,"Mean","ml/hour",1.75,"SD"
"392","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",2,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",219.63,22.69,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 2 week","66f0c543-45f9-4e4d-8688-e95241b2871d","ba4c4b17-7112-48d5-a1d3-802687c6ac8a","CMS + Vehicle",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,4.38,"Mean","ml/hour",2.62,"SD"
"393","9ce9afbd-f89d-4f4f-8d42-354cab83947e","Evaluating the antidepressant efficacy of aripiprazole using a chronic mild stress model: An experimental study","Eren, Ibrahim and Demirdas, Arif and Inanli, Ikbal Civi","Psychiatry and Clinical Psychopharmacology",NA,"Introduction: Aripiprazole is a partial agonist of dopamine D2 and D3 and serotonin 5-HT1A, 5-HT2c- and 5-HT7 receptors, and it is also an antagonist of serotonin 5-HT2A and 5-HT6 receptors. Partial D2 receptor agonism is thought to stabilize dopaminergic neurotransmission in the mesolimbic and mesocortical pathways. Dysregulation in the dopamine and serotonin systems is known to be one of the factors that is responsible for the etiology of depression. In this study, we aimed to evaluate the antidepressant potential of aripiprazole in rats by studying its effects on dopamine and serotonin receptors. Method: In this study, male Wistar Albino rats of 8-week old were used. They were divided into 4 groups, each of which consisted of 8 rats. As a depression model, the Chronic Mild Stress (CMS) model was used for four weeks on the rats. The first group was the control group and that received saline as a placebo without CMS. For the second group, aripiprazole (2.5 mg/kg) was administered with CMS: for the third group, escitalopram (10 mg/kg) was administered with CMS and for fourth group a placebo (serum physiologic) was given with CMS. Additionally a sucrose consumption test was performed before and after the CMS model. Results: Sucrose intake at the baseline and within the first week of the study did not differ among the groups. The sucrose consumption of the group with CMS was significantly lower than that of the control group during the second, third and fourth weeks. While the consumption of sucrose in the groups who received aripiprazole and escitalopram did not differ from the group which was exposed to CMS at the beginning and during the first and second weeks, it was significantly higher at the third and fourth weeks. The sucrose consumption values of the groups that received aripiprazole and escitalopram were not different from the control group throughout the study. Conclusion: In this study, aripiprazole has been shown to produce an antidepressant effect comparable to that of escitalopram in rats using a model of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Eren, Ibrahim: Konya Egitim ve Arastirma Hastanesi, Psikiyatri Klinigi, Yazir Mahalesi Turgut Ozal Caddesi No. 14/D, Selfuklu, Konya, Turkey, drieren@yahoo.com and Eren, Ibrahim: drieren@yahoo.com","2014","https://dx.doi.org/10.5455/bcp.20130313045200","JOUR","*Antidepressant Drugs and *Drugs and *Aripiprazole and Rats and Stress",NA,"PsychINFO-1017-7833-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,8,999,999,999,"Weeks","At treatment",219.63,22.69,999,999,"Grams (g)","No",2024-01-31 16:16:30,"bda5a765-e745-4e28-bcdb-fca9c2f74e44","SPT (table 2)","Sucrose Consumption Test 4 week","fb8091ff-71b3-427b-a85e-3746a3793b4d","ba4c4b17-7112-48d5-a1d3-802687c6ac8a","CMS + Vehicle",8,"False","11777c7c-ca54-432f-bab8-d83eda9655d6","CUMS","True","4985dba2-a65d-48a6-817b-a8f0b113cf1a","Vehicle",FALSE,0,2.63,"Mean","ml/hour",1.06,"SD"
"394","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,1,55.38,"Mean","% of total daily liquid intake",6.92,"SEM"
"395","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,2,73.08,"Mean","% of total daily liquid intake",6.93,"SEM"
"396","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,3,64.61,"Mean","% of total daily liquid intake",6.16,"SEM"
"397","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,4,73.08,"Mean","% of total daily liquid intake",8.46,"SEM"
"398","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,5,63.85,"Mean","% of total daily liquid intake",5.39,"SEM"
"399","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,6,71.54,"Mean","% of total daily liquid intake",8.46,"SEM"
"400","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,7,45.38,"Mean","% of total daily liquid intake",10,"SEM"
"401","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,8,53.08,"Mean","% of total daily liquid intake",13.08,"SEM"
"402","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,9,70,"Mean","% of total daily liquid intake",10.76,"SEM"
"403","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,10,48.46,"Mean","% of total daily liquid intake",8.46,"SEM"
"404","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,11,71.54,"Mean","% of total daily liquid intake",10,"SEM"
"405","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,12,61.54,"Mean","% of total daily liquid intake",10,"SEM"
"406","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,13,63.08,"Mean","% of total daily liquid intake",8.31,"SEM"
"407","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,14,44.61,"Mean","% of total daily liquid intake",15.39,"SEM"
"408","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,15,50.77,"Mean","% of total daily liquid intake",13.85,"SEM"
"409","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,16,58.46,"Mean","% of total daily liquid intake",13.85,"SEM"
"410","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,17,60,"Mean","% of total daily liquid intake",3.85,"SEM"
"411","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,18,61.54,"Mean","% of total daily liquid intake",10.77,"SEM"
"412","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,19,64.61,"Mean","% of total daily liquid intake",13.85,"SEM"
"413","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","3bd45674-e161-45cd-8873-1a661afb983d","MPTP (black 2a)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP",NA,NA,NA,FALSE,20,6.61,"Mean","% of total daily liquid intake",23.08,"SEM"
"414","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,1,67.69,"Mean","% of total daily liquid intake",9.23,"SEM"
"415","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,2,88.46,"Mean","% of total daily liquid intake",6.92,"SEM"
"416","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,3,72.31,"Mean","% of total daily liquid intake",8.47,"SEM"
"417","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,4,89.23,"Mean","% of total daily liquid intake",6.15,"SEM"
"418","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,5,54.61,"Mean","% of total daily liquid intake",14.62,"SEM"
"419","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,6,86.15,"Mean","% of total daily liquid intake",6.15,"SEM"
"420","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,7,76.92,"Mean","% of total daily liquid intake",9.23,"SEM"
"421","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,8,90,"Mean","% of total daily liquid intake",5.38,"SEM"
"422","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,9,88.46,"Mean","% of total daily liquid intake",7.69,"SEM"
"423","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,10,76.92,"Mean","% of total daily liquid intake",6.15,"SEM"
"424","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,11,90.77,"Mean","% of total daily liquid intake",6.92,"SEM"
"425","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,12,83.08,"Mean","% of total daily liquid intake",6.69,"SEM"
"426","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,13,97.69,"Mean","% of total daily liquid intake",5.38,"SEM"
"427","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,14,83.08,"Mean","% of total daily liquid intake",6.16,"SEM"
"428","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,15,90,"Mean","% of total daily liquid intake",3.85,"SEM"
"429","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,16,87.69,"Mean","% of total daily liquid intake",6.92,"SEM"
"430","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,17,94.61,"Mean","% of total daily liquid intake",4.62,"SEM"
"431","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,18,75.38,"Mean","% of total daily liquid intake",9.23,"SEM"
"432","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,19,91.54,"Mean","% of total daily liquid intake",6.16,"SEM"
"433","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","cdf277a6-9b04-4515-adc3-be1c63ca6b07","Control (white 2a-c)",6,NA,NA,NA,NA,NA,NA,FALSE,20,78.46,"Mean","% of total daily liquid intake",2.38,"SEM"
"434","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,1,66.41,"Mean","% of total daily liquid intake",10.68,"SEM"
"435","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,2,82.44,"Mean","% of total daily liquid intake",12.21,"SEM"
"436","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,3,60.3,"Mean","% of total daily liquid intake",16.03,"SEM"
"437","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,4,65.65,"Mean","% of total daily liquid intake",16.8,"SEM"
"438","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,5,58.01,"Mean","% of total daily liquid intake",22.14,"SEM"
"439","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,6,70.99,"Mean","% of total daily liquid intake",13.74,"SEM"
"440","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,7,58.01,"Mean","% of total daily liquid intake",16.03,"SEM"
"441","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,8,64.88,"Mean","% of total daily liquid intake",16.03,"SEM"
"442","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,9,70.23,"Mean","% of total daily liquid intake",14.51,"SEM"
"443","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,10,66.41,"Mean","% of total daily liquid intake",9.16,"SEM"
"444","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,11,62.59,"Mean","% of total daily liquid intake",17.56,"SEM"
"445","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,12,66.41,"Mean","% of total daily liquid intake",12.21,"SEM"
"446","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,13,66.41,"Mean","% of total daily liquid intake",16.79,"SEM"
"447","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,14,63.36,"Mean","% of total daily liquid intake",11.38,"SEM"
"448","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,15,71.75,"Mean","% of total daily liquid intake",14.5,"SEM"
"449","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,16,63.36,"Mean","% of total daily liquid intake",18.33,"SEM"
"450","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,17,74.04,"Mean","% of total daily liquid intake",14.51,"SEM"
"451","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,18,60.3,"Mean","% of total daily liquid intake",12.98,"SEM"
"452","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,19,67.94,"Mean","% of total daily liquid intake",14.51,"SEM"
"453","a43a604e-1a22-4078-bf0d-6a2451216d5d","Effect of parlodel on the development of a depressive syndrome induced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rats","Krupina, N.A. and Orlova, I.N. and Kryzhanovskii, G N","Bulletin of Experimental Biology and Medicine",NA,"Effects caused by the chronic administration of Parlodel on the development of behavioral signs of depression in rats are studied using the new model of depressive syndrome induced by the systemic administration of MPTP. Pretreatment with Parlodel prevents locomotor depression, weight loss, reduction of liquid intake, a decline of the preference of sucrose solution over water, and a rise of the depression index and promotes a quicker restoration of exploratory activity, i.e., it safeguards rats from manifestating the behavioral signs of MPTP-induced depression. <c2><a9> 1996 Plenum Publishing Corporation.",NA,"Laboratory of General Pathology of the Nervous System, Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russian Federation","1995","10.1007/BF02444669","JOUR","depressive syndrome and MPTP and Parlodel and rats",NA,"SCOPUS-15738221 (ISSN)",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","No","No","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BROMOCRIPTINE","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","Prior to disease model induction","12","Days",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0.875","Hours","Sucrose/saccharin intake or preference test",18,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",6,999,999,999,999,"Days","At recruitment to study",999,999,250,350,"Grams (g)","Yes",2024-02-12 12:04:35,"29a2b783-1a47-43f5-94f8-22cccaf8959f","sucrose intake","Sucrose intake","4b6a775c-bc61-4fc7-9e64-44647ac151f8","ead7a0aa-f6c9-4b31-956b-0da4eb8152c3","MPTP + parlodel (black 2c)",6,"False","8799b9d3-0342-4206-9dce-ba39f6574e84","MPTP","False","79af8d13-c104-4613-b734-1b0863cbf5a5","Bromocriptine (Parlodel)",FALSE,20,67.17,"Mean","% of total daily liquid intake",9.16,"SEM"
"454","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","11b44618-48d2-4487-938b-2518b2be073e","CUMS: 2mg/kg then 0.1mg/kg twice weekly",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","e9500b73-7a6e-495a-b1e9-27d3cca0f5c0","Pramiprexole (2mg/kg) twice weekly",FALSE,0,8.4,"Mean","g",0.8,"SEM"
"455","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","11b44618-48d2-4487-938b-2518b2be073e","CUMS: 2mg/kg then 0.1mg/kg twice weekly",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","e9500b73-7a6e-495a-b1e9-27d3cca0f5c0","Pramiprexole (2mg/kg) twice weekly",FALSE,0,1.53,"Mean","g",0.97,"SEM"
"456","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","18e13445-9ce9-41de-99b2-9868d9e684be","control: 2mg/kg then 0,1 twice weekly",11,NA,NA,NA,"False","e9500b73-7a6e-495a-b1e9-27d3cca0f5c0","Pramiprexole (2mg/kg) twice weekly",FALSE,0,13.92,"Mean","g",0.87,"SEM"
"457","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","18e13445-9ce9-41de-99b2-9868d9e684be","control: 2mg/kg then 0,1 twice weekly",11,NA,NA,NA,"False","e9500b73-7a6e-495a-b1e9-27d3cca0f5c0","Pramiprexole (2mg/kg) twice weekly",FALSE,0,6,"Mean","g",0.73,"SEM"
"458","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","2418f823-52c6-49e6-a8dc-e60ef751366e","control: 1mg/kg twice weekly",11,NA,NA,NA,"False","5be1585e-9fda-4344-b05f-49270630abbf","Pramiprexole (1mg/kg) twice weekly",FALSE,0,12.6,"Mean","g",1.1,"SEM"
"459","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","2418f823-52c6-49e6-a8dc-e60ef751366e","control: 1mg/kg twice weekly",11,NA,NA,NA,"False","5be1585e-9fda-4344-b05f-49270630abbf","Pramiprexole (1mg/kg) twice weekly",FALSE,0,6.15,"Mean","g",1.12,"SEM"
"460","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","4cf7d2cd-dce2-42fa-84b8-0676c06f1f28","CUMS: 1mg/kg od",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","4571c6dd-809b-4040-a60c-57eed8a88284","Pramiprexole (1mg/kg) daily",FALSE,0,14.7,"Mean","g",0.8,"SEM"
"461","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","4cf7d2cd-dce2-42fa-84b8-0676c06f1f28","CUMS: 1mg/kg od",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","4571c6dd-809b-4040-a60c-57eed8a88284","Pramiprexole (1mg/kg) daily",FALSE,0,6.59,"Mean","g",0.97,"SEM"
"462","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","4d0f108d-5b26-4944-9610-8492ffbb5269","control: 1mg/kg od",11,NA,NA,NA,"False","4571c6dd-809b-4040-a60c-57eed8a88284","Pramiprexole (1mg/kg) daily",FALSE,0,17.1,"Mean","g",0.9,"SEM"
"463","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","4d0f108d-5b26-4944-9610-8492ffbb5269","control: 1mg/kg od",11,NA,NA,NA,"False","4571c6dd-809b-4040-a60c-57eed8a88284","Pramiprexole (1mg/kg) daily",FALSE,0,6.62,"Mean","g",0.62,"SEM"
"464","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","763da86b-62af-4c11-ab9b-a12c12d80f26","CUMS: 2mg/kg then 0.1mg/kg od",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","53ed1424-1475-41ae-8180-b8fd2bd9d2ff","Pramiprexole (2mg/kg) daily",FALSE,0,8.65,"Mean","g",0.9,"SEM"
"465","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","763da86b-62af-4c11-ab9b-a12c12d80f26","CUMS: 2mg/kg then 0.1mg/kg od",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","53ed1424-1475-41ae-8180-b8fd2bd9d2ff","Pramiprexole (2mg/kg) daily",FALSE,0,2.54,"Mean","g",1.2,"SEM"
"466","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","8786619d-c02e-4800-98b4-e9de4551938e","control: 2mg/kg then 0,1 daily",11,NA,NA,NA,"False","53ed1424-1475-41ae-8180-b8fd2bd9d2ff","Pramiprexole (2mg/kg) daily",FALSE,0,12.95,"Mean","g",0.83,"SEM"
"467","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","8786619d-c02e-4800-98b4-e9de4551938e","control: 2mg/kg then 0,1 daily",11,NA,NA,NA,"False","53ed1424-1475-41ae-8180-b8fd2bd9d2ff","Pramiprexole (2mg/kg) daily",FALSE,0,5.83,"Mean","g",0.9,"SEM"
"468","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","cefe8d83-8363-4a58-b74c-303ead339c74","control vehicle",11,NA,NA,NA,"True","065bbfb6-58ef-4b44-8260-54d0f490858c","vehicle",FALSE,0,11.7,"Mean","g",0.6,"SEM"
"469","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","cefe8d83-8363-4a58-b74c-303ead339c74","control vehicle",11,NA,NA,NA,"True","065bbfb6-58ef-4b44-8260-54d0f490858c","vehicle",FALSE,0,5.18,"Mean","g",0.57,"SEM"
"470","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","d7f275c4-7557-480f-b19b-5ae506b47deb","CUMS: 1mg/kg twice weekly",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","5be1585e-9fda-4344-b05f-49270630abbf","Pramiprexole (1mg/kg) twice weekly",FALSE,0,8,"Mean","g",0.93,"SEM"
"471","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","PRAMIPREXOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","10","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","0","Weeks","Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","d7f275c4-7557-480f-b19b-5ae506b47deb","CUMS: 1mg/kg twice weekly",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","False","5be1585e-9fda-4344-b05f-49270630abbf","Pramiprexole (1mg/kg) twice weekly",FALSE,0,1.16,"Mean","g",0.8,"SEM"
"472","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",6,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","sucrose intake (fig 4)","50f14512-a98c-4e6e-ad8e-56d6a1b0be13","debb28da-ca4b-4a8d-9f30-2958fc03f33c","CUMS vehicle",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","True","065bbfb6-58ef-4b44-8260-54d0f490858c","vehicle",FALSE,0,8.65,"Mean","g",0.9,"SEM"
"473","a47258ef-5b15-443e-b043-07c1f11659ed","Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","Willner, Paul and Lappas, Spiros and Cheeta, Survjit and Muscat, Richard","Psychopharmacology",NA,"Studied the effects of pramipexole (PPX, [SND-919]), a dopamine D2 agonist, during 7-9 wks of chronic treatment. PPX reversed the suppression of sucrose intake in stressed male rats, increasing sucrose intakes above the levels seen in untreated nonstressed controls. PPX also increased sucrose intake in nonstressed Ss: these effects were accompanied by increases in water intake and tended to correlate with weight loss. Intermittent PPX treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Results indicate that PPX exerts rapid anti-anhedonic effects in the chronic mild stress model. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH, DEPT PSYCHOL, LONDON E1 7NT, ENGLAND","1994","https://dx.doi.org/10.1007/BF02245568","JOUR","*Anhedonia and *Dopamine Agonists and *Stress and Rats",NA,"PsychINFO-0033-3158-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Matched-pairs randomisation","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",5,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Other","Exact number",11,NA,NA,NA,NA,NA,"At recruitment to study",350,NA,NA,NA,"Grams (g)","Yes",2024-01-29 12:38:45,"e979f1f0-3e35-4dd7-8c02-e2cb0d3f7dbd","Fig 4","excess sucrose over water intake (fig 4)","8b433102-ee98-4ea7-ad57-b39ef51e73e0","debb28da-ca4b-4a8d-9f30-2958fc03f33c","CUMS vehicle",11,"False","a7dd6d5e-65e6-48c3-b354-456249a177a1","CUMS","True","065bbfb6-58ef-4b44-8260-54d0f490858c","vehicle",FALSE,0,2,"Mean","g",1,"SEM"
"474","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3907ba82-8f5c-4214-9189-525810d2ade0","CMS + vehicle",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,0,70.09,"Mean","%",13.29,"SEM"
"475","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3907ba82-8f5c-4214-9189-525810d2ade0","CMS + vehicle",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,2,50,"Mean","%",6.5,"SEM"
"476","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3907ba82-8f5c-4214-9189-525810d2ade0","CMS + vehicle",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,4,48.7,"Mean","%",10.86,"SEM"
"477","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3aa02fc3-5699-401e-a2c1-fd905afcff50","CMS + BU10",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","63b69370-0f6b-46d5-8e2b-e4658ec7deab","3 ,2-hydroxybakuchiol (Bu) 10",FALSE,0,72.69,"Mean","%",14.61,"SEM"
"478","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3aa02fc3-5699-401e-a2c1-fd905afcff50","CMS + BU10",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","63b69370-0f6b-46d5-8e2b-e4658ec7deab","3 ,2-hydroxybakuchiol (Bu) 10",FALSE,2,72.8,"Mean","%",6.2,"SEM"
"479","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","3aa02fc3-5699-401e-a2c1-fd905afcff50","CMS + BU10",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","63b69370-0f6b-46d5-8e2b-e4658ec7deab","3 ,2-hydroxybakuchiol (Bu) 10",FALSE,4,92.3,"Mean","%",8.91,"SEM"
"480","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","8beed781-bb77-418c-9fc3-0a18a5fa52b3","CMS + bupropion",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","8e7c4a04-047b-41a3-b225-3d79909e59d3","Bupropion 2.5",FALSE,0,71.95,"Mean","%",4.18,"SEM"
"481","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","8beed781-bb77-418c-9fc3-0a18a5fa52b3","CMS + bupropion",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","8e7c4a04-047b-41a3-b225-3d79909e59d3","Bupropion 2.5",FALSE,2,73.4,"Mean","%",5.4,"SEM"
"482","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","8beed781-bb77-418c-9fc3-0a18a5fa52b3","CMS + bupropion",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","8e7c4a04-047b-41a3-b225-3d79909e59d3","Bupropion 2.5",FALSE,4,99.4,"Mean","%",11.72,"SEM"
"483","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","9be4b325-0261-4a59-b748-dcdb823820ed","Control + vehicle",10,NA,NA,NA,"True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,0,100,"Mean","%",12.94,"SEM"
"484","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","9be4b325-0261-4a59-b748-dcdb823820ed","Control + vehicle",10,NA,NA,NA,"True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,2,100,"Mean","%",16,"SEM"
"485","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","9be4b325-0261-4a59-b748-dcdb823820ed","Control + vehicle",10,NA,NA,NA,"True","67319ddd-66e2-41d6-aa13-19315667c44a","Vehicle",FALSE,4,100,"Mean","%",14.04,"SEM"
"486","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","fec3fbf2-d2c1-43ad-850f-357f680a61fa","CMS + BU 2.5",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","e4af4465-c073-4573-8e80-ee9b355d4a4b","3 ,2-hydroxybakuchiol (Bu) 2,5",FALSE,0,72.82,"Mean","%",10.29,"SEM"
"487","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","fec3fbf2-d2c1-43ad-850f-357f680a61fa","CMS + BU 2.5",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","e4af4465-c073-4573-8e80-ee9b355d4a4b","3 ,2-hydroxybakuchiol (Bu) 2,5",FALSE,2,60,"Mean","%",7.5,"SEM"
"488","afca2f86-9178-4cf9-add6-482feb6408c7","Delta(3),2-Hydroxybakuchiol Attenuates Depression in Multiple Rodent Models Possibly by Inhibition of Monoamine Transporters in Brain","Zhao, G and Guo, LH and Huang, W and Hu, JL","EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE",NA,"Delta(3),2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Delta(3),2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Delta(3),2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Delta(3),2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test Delta(3),2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Delta(3),2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Delta(3),2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Delta(3),2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.",NA,"Dahua Hosp, Internal Div Tradit Chinese Med, Shanghai 200237, Peoples R China and Jiangsu Univ, Teaching Hosp, Shanghai 200237, Peoples R China and Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China and Shanghai Univ Tradit Chinese Med, Engn Res Ctr Modern Preparat Technol Tradit Chine, Minist Educ, Shanghai 201203, Peoples R China","2018","10.1155/2018/1325141","JOUR","CHRONIC MILD STRESS and ANIMAL-MODELS and BEHAVIORAL DESPAIR and BAKUCHIOL and MICE and RAT",NA,"WOS:000437123300001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","3 ,2-hydroxybakuchiol","DAT inhibitor (Methylphenidate, Bupropion)","2.5","miligrams (mg) per kg","After disease model induction","4","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","4","Weeks","Sucrose/saccharin intake or preference test",4,"Weeks","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,999,999,"Days","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 17:21:21,"8cd004b3-d32d-4cec-8e1f-251eb8134ed7","exp","Sucrose preference","518de445-3ab4-4d28-941e-7a5a97a9fd3a","fec3fbf2-d2c1-43ad-850f-357f680a61fa","CMS + BU 2.5",10,"False","07121607-5b66-4e94-8b0c-6c6d232b2d15","CMS","False","e4af4465-c073-4573-8e80-ee9b355d4a4b","3 ,2-hydroxybakuchiol (Bu) 2,5",FALSE,4,68.12,"Mean","%",12.27,"SEM"
"489","b0874db2-b84c-479d-9ad3-e6b3875ce83e","Behavioural effects of APH199, a selective dopamine D4 receptor agonist, in animal models.","Chestnykh D and Gra<c3><9f>l F and Pfeifer C and D<c3><bc>lk J and Ebner C and Walters M and von H<c3><b6>rsten S and Kornhuber J and Kalinichenko LS and Heinrich M and M<c3><bc>ller CP","Psychopharmacology",NA,"RATIONALE: The dopamine D4 receptors (DRD4) play a key role in numerous brain functions and are involved in the pathogenesis of various psychiatric disorders. DRD4 ligands have been shown to moderate anxiety, reward and depression-like behaviours, and cognitive impairments. Despite a series of promising but ambiguous findings, the therapeutic advantages of DRD4 stimulation remain elusive. OBJECTIVES: The investigation focused on the behavioural effects of the recently developed DRD4 agonist, APH199, to evaluate its impact on anxiety, anhedonia, behavioural despair, establishment and retrieval of alcohol reinforcement, and amphetamine (AMPH)-induced symptoms. METHODS: Male C57BL/6J mice and Sprague-Dawley rats were examined in five independent experiments. We assessed APH199 (0.1-5mg/kg, i.p.) effects on a broad range of behavioural parameters in the open field (OF) test, conditioned place preference test (CPP), elevated plus maze (EPM), light-dark box (LDB), novelty suppressed feeding (NSF), forced swim test (FST), sucrose preference test (SPT), AMPH-induced hyperlocomotion test (AIH), and prepulse inhibition (PPI) of the acoustic startle response in AMPH-sensitized rats. RESULTS: APH199 caused mild and sporadic anxiolytic and antidepressant effects in EPM and FST, but no remarkable impact on behaviour in other tests in mice. However, we found a significant increase in AMPH-induced hyperactivity, suggesting an exaggeration of the psychotic-like responses in the AMPH-sensitized rats. CONCLUSIONS: Our data challenged the hypothesis of the therapeutic benefits of DRD4 agonists, pointing out a possible aggravation of psychosis. We suggest a need for further preclinical studies to ensure the safety of antipsychotics with DRD4 stimulating properties.",NA,"Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Experimental Therapy, Preclinical Experimental Center, and Friedrich-Alexander-University of Erlangen-Nuremberg, Palmsanlage 5, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. Christian.Mueller@uk-erlangen.de. and Centre for Drug Research, University Sains Malaysia, Penang, Minden, Malaysia. and Christian.Mueller@uk-erlangen.de.","2023","10.1007/s00213-023-06347-1","Journal Article","APH199 and Alcohol and Anxiety and DRD4 agonist and Depression and Psychosis and Schizophrenia",NA,"pubmed-36854793",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"APH199","Dopamine agonist (e.g. apomorphine, rotigotine)","0.5","miligrams (mg) per kg","At disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",12,999,999,NA,NA,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-23 11:09:28,"6579410b-02f1-4db2-8109-06154743006b","SPT","Sucrose preference test","8cafc2e2-2bab-4aaa-9ac8-3ed066800565","31e36c62-e5f6-4dd1-9840-d78ee016e7b4","APH199 0.5mg/kg",11,NA,NA,NA,"False","8987e129-f732-47a2-880a-adf9bedf8089","APH199 0.5mg/kg",FALSE,0,69.81,"Mean","%",4.71,"SEM"
"490","b0874db2-b84c-479d-9ad3-e6b3875ce83e","Behavioural effects of APH199, a selective dopamine D4 receptor agonist, in animal models.","Chestnykh D and Gra<c3><9f>l F and Pfeifer C and D<c3><bc>lk J and Ebner C and Walters M and von H<c3><b6>rsten S and Kornhuber J and Kalinichenko LS and Heinrich M and M<c3><bc>ller CP","Psychopharmacology",NA,"RATIONALE: The dopamine D4 receptors (DRD4) play a key role in numerous brain functions and are involved in the pathogenesis of various psychiatric disorders. DRD4 ligands have been shown to moderate anxiety, reward and depression-like behaviours, and cognitive impairments. Despite a series of promising but ambiguous findings, the therapeutic advantages of DRD4 stimulation remain elusive. OBJECTIVES: The investigation focused on the behavioural effects of the recently developed DRD4 agonist, APH199, to evaluate its impact on anxiety, anhedonia, behavioural despair, establishment and retrieval of alcohol reinforcement, and amphetamine (AMPH)-induced symptoms. METHODS: Male C57BL/6J mice and Sprague-Dawley rats were examined in five independent experiments. We assessed APH199 (0.1-5mg/kg, i.p.) effects on a broad range of behavioural parameters in the open field (OF) test, conditioned place preference test (CPP), elevated plus maze (EPM), light-dark box (LDB), novelty suppressed feeding (NSF), forced swim test (FST), sucrose preference test (SPT), AMPH-induced hyperlocomotion test (AIH), and prepulse inhibition (PPI) of the acoustic startle response in AMPH-sensitized rats. RESULTS: APH199 caused mild and sporadic anxiolytic and antidepressant effects in EPM and FST, but no remarkable impact on behaviour in other tests in mice. However, we found a significant increase in AMPH-induced hyperactivity, suggesting an exaggeration of the psychotic-like responses in the AMPH-sensitized rats. CONCLUSIONS: Our data challenged the hypothesis of the therapeutic benefits of DRD4 agonists, pointing out a possible aggravation of psychosis. We suggest a need for further preclinical studies to ensure the safety of antipsychotics with DRD4 stimulating properties.",NA,"Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Experimental Therapy, Preclinical Experimental Center, and Friedrich-Alexander-University of Erlangen-Nuremberg, Palmsanlage 5, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. Christian.Mueller@uk-erlangen.de. and Centre for Drug Research, University Sains Malaysia, Penang, Minden, Malaysia. and Christian.Mueller@uk-erlangen.de.","2023","10.1007/s00213-023-06347-1","Journal Article","APH199 and Alcohol and Anxiety and DRD4 agonist and Depression and Psychosis and Schizophrenia",NA,"pubmed-36854793",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",12,999,999,NA,NA,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-23 11:09:28,"6579410b-02f1-4db2-8109-06154743006b","SPT","Sucrose preference test","8cafc2e2-2bab-4aaa-9ac8-3ed066800565","44a25861-4751-411c-ac07-71d2ea3d3c96","Vehicle",10,NA,NA,NA,"True","efb4d2df-2a55-4df4-929b-ca538c08a5e3","vehicle",FALSE,0,69.71,"Mean","%",5.01,"SEM"
"491","b0874db2-b84c-479d-9ad3-e6b3875ce83e","Behavioural effects of APH199, a selective dopamine D4 receptor agonist, in animal models.","Chestnykh D and Gra<c3><9f>l F and Pfeifer C and D<c3><bc>lk J and Ebner C and Walters M and von H<c3><b6>rsten S and Kornhuber J and Kalinichenko LS and Heinrich M and M<c3><bc>ller CP","Psychopharmacology",NA,"RATIONALE: The dopamine D4 receptors (DRD4) play a key role in numerous brain functions and are involved in the pathogenesis of various psychiatric disorders. DRD4 ligands have been shown to moderate anxiety, reward and depression-like behaviours, and cognitive impairments. Despite a series of promising but ambiguous findings, the therapeutic advantages of DRD4 stimulation remain elusive. OBJECTIVES: The investigation focused on the behavioural effects of the recently developed DRD4 agonist, APH199, to evaluate its impact on anxiety, anhedonia, behavioural despair, establishment and retrieval of alcohol reinforcement, and amphetamine (AMPH)-induced symptoms. METHODS: Male C57BL/6J mice and Sprague-Dawley rats were examined in five independent experiments. We assessed APH199 (0.1-5mg/kg, i.p.) effects on a broad range of behavioural parameters in the open field (OF) test, conditioned place preference test (CPP), elevated plus maze (EPM), light-dark box (LDB), novelty suppressed feeding (NSF), forced swim test (FST), sucrose preference test (SPT), AMPH-induced hyperlocomotion test (AIH), and prepulse inhibition (PPI) of the acoustic startle response in AMPH-sensitized rats. RESULTS: APH199 caused mild and sporadic anxiolytic and antidepressant effects in EPM and FST, but no remarkable impact on behaviour in other tests in mice. However, we found a significant increase in AMPH-induced hyperactivity, suggesting an exaggeration of the psychotic-like responses in the AMPH-sensitized rats. CONCLUSIONS: Our data challenged the hypothesis of the therapeutic benefits of DRD4 agonists, pointing out a possible aggravation of psychosis. We suggest a need for further preclinical studies to ensure the safety of antipsychotics with DRD4 stimulating properties.",NA,"Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Experimental Therapy, Preclinical Experimental Center, and Friedrich-Alexander-University of Erlangen-Nuremberg, Palmsanlage 5, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. and Department of Chemistry and Pharmacy, Friedrich-Alexander-University of and Erlangen-Nuremberg, Nikolaus-Fiebiger-Str. 10, 91058, Erlangen, Germany. and Department of Psychiatry and Psychotherapy, University Clinic, and Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, and Erlangen, Germany. Christian.Mueller@uk-erlangen.de. and Centre for Drug Research, University Sains Malaysia, Penang, Minden, Malaysia. and Christian.Mueller@uk-erlangen.de.","2023","10.1007/s00213-023-06347-1","Journal Article","APH199 and Alcohol and Anxiety and DRD4 agonist and Depression and Psychosis and Schizophrenia",NA,"pubmed-36854793",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"APH199","Dopamine agonist (e.g. apomorphine, rotigotine)","5","miligrams (mg) per kg","At disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",12,999,999,NA,NA,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","No",2024-01-23 11:09:28,"6579410b-02f1-4db2-8109-06154743006b","SPT","Sucrose preference test","8cafc2e2-2bab-4aaa-9ac8-3ed066800565","b58c535d-8dba-4359-b630-82e3cb7d2cf6","APH199 5mg/kg",10,NA,NA,NA,"False","b5aa8988-b973-43b9-b326-9fb029bd7b2e","APH199 5mg/kg",FALSE,0,68,"Mean","%",4.9,"SEM"
"492","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","1809ba35-7956-4103-bbf2-942ca65c2d92","impir stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,0,8.1,"Mean","nr",0.7,"SEM"
"493","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","1809ba35-7956-4103-bbf2-942ca65c2d92","impir stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,1,8.5,"Mean","nr",0.9,"SEM"
"494","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","1809ba35-7956-4103-bbf2-942ca65c2d92","impir stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,5,12.6,"Mean","nr",1.1,"SEM"
"495","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8c8e648b-c6cf-4e4b-a672-f42601acae72","stress veh exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,0,8.3,"Mean","nr",0.8,"SEM"
"496","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8c8e648b-c6cf-4e4b-a672-f42601acae72","stress veh exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,1,7.8,"Mean","nr",0.5,"SEM"
"497","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8c8e648b-c6cf-4e4b-a672-f42601acae72","stress veh exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,5,7.4,"Mean","nr",0.4,"SEM"
"498","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8ce38819-332f-44ae-8e46-e7198f555e91","con veh exp1",10,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,0,14.2,"Mean","nr",0.9,"SEM"
"499","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8ce38819-332f-44ae-8e46-e7198f555e91","con veh exp1",10,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,1,12,"Mean","nr",1.4,"SEM"
"500","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","8ce38819-332f-44ae-8e46-e7198f555e91","con veh exp1",10,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,5,13.9,"Mean","nr",0.8,"SEM"
"501","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","a185ce94-bbfa-48a5-958e-2b5585345636","impir control  exp1",10,NA,NA,NA,"False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,0,14.3,"Mean","nr",0.9,"SEM"
"502","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","a185ce94-bbfa-48a5-958e-2b5585345636","impir control  exp1",10,NA,NA,NA,"False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,1,11.9,"Mean","nr",0.7,"SEM"
"503","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","a185ce94-bbfa-48a5-958e-2b5585345636","impir control  exp1",10,NA,NA,NA,"False","159077a7-e4e7-498f-bbeb-d52c59ae2139","Impiramine p.o",FALSE,5,13.9,"Mean","nr",0.8,"SEM"
"504","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","bc45fc1b-e6e8-4e37-b928-1964b67a8354","amph 0,5 control exp1",10,NA,NA,NA,"False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,0,14.2,"Mean","nr",0.9,"SEM"
"505","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","bc45fc1b-e6e8-4e37-b928-1964b67a8354","amph 0,5 control exp1",10,NA,NA,NA,"False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,1,11.6,"Mean","nr",1.4,"SEM"
"506","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","bc45fc1b-e6e8-4e37-b928-1964b67a8354","amph 0,5 control exp1",10,NA,NA,NA,"False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,5,13.6,"Mean","nr",1.3,"SEM"
"507","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","f3e45ae7-72e0-4115-a018-463d64c61bdd","amph 0,5 stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,0,8.2,"Mean","nr",0.7,"SEM"
"508","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","f3e45ae7-72e0-4115-a018-463d64c61bdd","amph 0,5 stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,1,8.6,"Mean","nr",1.3,"SEM"
"509","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","0.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"84f32a3d-dd8c-48cb-87e2-2525b5e845de","exp 1","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","f3e45ae7-72e0-4115-a018-463d64c61bdd","amph 0,5 stress exp1",10,"False","21e342c8-52cb-4a88-80e0-d765c2b70cef","CUMS","False","18712e02-52ae-4630-826a-a08ed3b100e5","Amphetamine 0.5mg/kg",FALSE,5,7.9,"Mean","nr",0.5,"SEM"
"510","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2188171f-3065-4942-9249-d8e629ae6502","con veh exp2",8,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,0,13.1,"Mean","nr",0.8,"SEM"
"511","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2188171f-3065-4942-9249-d8e629ae6502","con veh exp2",8,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,1,12.4,"Mean","nr",0.7,"SEM"
"512","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2188171f-3065-4942-9249-d8e629ae6502","con veh exp2",8,NA,NA,NA,"True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,5,12.8,"Mean","nr",0.5,"SEM"
"513","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2856dad6-72a3-4ef4-a713-979b363c66c7","imip contr exp2",8,NA,NA,NA,"False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,0,13.2,"Mean","nr",0.5,"SEM"
"514","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2856dad6-72a3-4ef4-a713-979b363c66c7","imip contr exp2",8,NA,NA,NA,"False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,1,12.1,"Mean","nr",0.4,"SEM"
"515","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","2856dad6-72a3-4ef4-a713-979b363c66c7","imip contr exp2",8,NA,NA,NA,"False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,5,12.5,"Mean","nr",0.4,"SEM"
"516","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4360d5ba-42b7-4470-ace6-1d5db455df80","imip stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,0,8.1,"Mean","nr",0.9,"SEM"
"517","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4360d5ba-42b7-4470-ace6-1d5db455df80","imip stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,1,7.2,"Mean","nr",0.8,"SEM"
"518","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","IMPIRAMINE","Other","10","miligrams (mg) per kg","At disease model induction","6","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4360d5ba-42b7-4470-ace6-1d5db455df80","imip stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","c5416750-ce2b-4e2b-9bf2-311001c364dd","Impiramine i.p",FALSE,5,13.4,"Mean","nr",0.7,"SEM"
"519","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","49016733-b01d-4465-8a2c-49ccbb4adf80","amph 1,5 stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,0,8.9,"Mean","nr",1.1,"SEM"
"520","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","49016733-b01d-4465-8a2c-49ccbb4adf80","amph 1,5 stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,1,8,"Mean","nr",1.1,"SEM"
"521","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","49016733-b01d-4465-8a2c-49ccbb4adf80","amph 1,5 stress exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,5,7.4,"Mean","nr",1.9,"SEM"
"522","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4cead918-5a66-4c55-a099-d83c47cb7cf3","amph 1,5 contr exp2",8,NA,NA,NA,"False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,0,13.2,"Mean","nr",1.2,"SEM"
"523","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4cead918-5a66-4c55-a099-d83c47cb7cf3","amph 1,5 contr exp2",8,NA,NA,NA,"False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,1,12.4,"Mean","nr",0.9,"SEM"
"524","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"D-AMPHETAMINE","Enhancement of dopamine release (Amphetamine, Methamphetamine)","1.5","miligrams (mg) per kg","At disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","4cead918-5a66-4c55-a099-d83c47cb7cf3","amph 1,5 contr exp2",8,NA,NA,NA,"False","b825441f-7144-477a-94d1-f0c1953128c6","Amphetamine 1.5mg/kg",FALSE,5,8.2,"Mean","nr",1.1,"SEM"
"525","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","62e5e69d-3996-4895-87d9-04c53583715e","stress veh exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,0,8.2,"Mean","nr",0.8,"SEM"
"526","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","62e5e69d-3996-4895-87d9-04c53583715e","stress veh exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,1,7.9,"Mean","nr",1.1,"SEM"
"527","b9431d3c-aff1-4b31-a3a3-b2dfef5f67fe","Pharmacological validation of the chronic mild stress model of depression","Papp, M and Moryl, E and Willner, P","EUROPEAN JOURNAL OF PHARMACOLOGY",NA,"Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions, and this effect was reversed by chronic treatment with a variety of antidepressant drugs. The present study reports three experiments examining the effects in this model of further antidepressant agents, a number of non-antidepressants, and some compounds of indeterminate clinical status. Male Wistar rats were exposed sequentially to a variety of mild stressors, which continued throught the experiments. Drug treatments commenced after 3 weeks of stress, by which time intake of a 1% sucrose solution (measured in a 1-h weekly test) was significantly depressed. No drug effects were seen after 1 week of treatment. Normal levels of sucrose drinking were seen following chronic (3-5 weeks) of treatment with the antidepressants imipramine (10 mg/kg per day), brofaromine (20 mg/kg per day), and buspirone (5 mg/kg per day). Positive effects were also seen following chronic treatment with atropine (1 mg/kg per day) and mepyramine (5 mg/kg per day). d-Amphetamine (1 and 3 mg/kg per day), the neuroleptics haloperidol and chlorprothixene (1 mg/kg per day), and morphine (administered at doses rising to 110 mg/kg per day) were ineffective: amphetamine (3 mg/kg) and morphine decreased sucrose intake in control animals. No inferences can be drawn from the effects of atropine and mepyramine, which are of indeterminate clinical status: data from the other seven agents tested support the hypothesis that the chronic mild stress model responds appropriately to antidepressant and non-antidepressant agents.",NA,"UNIV COLL SWANSEA, DEPT PSYCHOL, SWANSEA SA2 8PP, W GLAM, WALES and POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND","1996","10.1016/0014-2999(95)00697-4","JOUR","stress, chronic, mild and depression, animal model and pharmacological validation and INDUCED ANHEDONIA and MAJOR DEPRESSION and ANIMAL-MODEL and ANTIDEPRESSANTS and NEUROLEPTICS and HYPOTHESIS and MECHANISM and BUSPIRONE and HISTAMINE and DESPAIR",NA,"WOS:A1996TU21000002",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",22,"Hours","Exact value (in table or text)","One of several measurements with different parameters","Continuous",FALSE,"Male","wt","Rat","Wistar (rat)","Exact number",8,NA,NA,NA,NA,NA,"At recruitment to study",NA,NA,300,350,"Grams (g)","Yes",2023-12-15 10:26:24,"8d360d55-122e-42b7-864d-52c9049b6cd6","exp 2","sucrose intake","65d4248a-5575-4841-8819-dc242dc26f73","62e5e69d-3996-4895-87d9-04c53583715e","stress veh exp2",8,"False","2aa14627-9560-47aa-8780-0e1ad1e5533e","CUMS 2","True","d660a082-d48e-4ebe-9d0e-560433dfabc9","vehicle",FALSE,5,6.6,"Mean","nr",0.5,"SEM"
"528","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","QUINPIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","0.877","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","-1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Sucrose preference","5de017a7-64e0-4abd-adf3-93808a121f5b","18ab850b-a1b5-4ee8-953a-649de4a8e180","CUS + quinpirole",12,"False","c24f4373-c720-4b47-9b62-1e289140dc1d","CUS","False","417eb2a3-0cca-4852-8120-1b12566fbcab","Quinpirole",FALSE,0,71.78,"Mean","%",2.77,"SEM"
"529","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"QUINPIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","0.877","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","-1","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Sucrose preference","5de017a7-64e0-4abd-adf3-93808a121f5b","43a7592d-4663-40cb-afa9-5427454c8c61","Control + quinpirole",12,NA,NA,NA,"False","417eb2a3-0cca-4852-8120-1b12566fbcab","Quinpirole",FALSE,0,74.85,"Mean","%",6.02,"SEM"
"530","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"QUINPIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","0.877","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","-1","Hours","Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","relative band intensity of D2R NAc","81398251-5177-471a-8595-5f58d35f6922","43a7592d-4663-40cb-afa9-5427454c8c61","Control + quinpirole",12,NA,NA,NA,"False","417eb2a3-0cca-4852-8120-1b12566fbcab","Quinpirole",FALSE,0,90.27,"Mean","relative intensity (%) VS control",5.09,"SEM"
"531","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"QUINPIROLE","Dopamine agonist (e.g. apomorphine, rotigotine)","0.877","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","-1","Hours","Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Dopamine concentration NAc","ded94b78-1236-485d-af2a-2b9dee71b4c6","43a7592d-4663-40cb-afa9-5427454c8c61","Control + quinpirole",12,NA,NA,NA,"False","417eb2a3-0cca-4852-8120-1b12566fbcab","Quinpirole",FALSE,0,3.29,"Mean","ng/ml",0.4,"SEM"
"532","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Sucrose preference","5de017a7-64e0-4abd-adf3-93808a121f5b","5a220a43-f34f-4054-8959-84f58bdc6f5c","CUS + vehicle",12,"False","c24f4373-c720-4b47-9b62-1e289140dc1d","CUS","True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,75.42,"Mean","%",2.87,"SEM"
"533","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","relative band intensity of D2R NAc","81398251-5177-471a-8595-5f58d35f6922","5a220a43-f34f-4054-8959-84f58bdc6f5c","CUS + vehicle",12,"False","c24f4373-c720-4b47-9b62-1e289140dc1d","CUS","True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,84.58,"Mean","relative intensity (%) VS control",4.2,"SEM"
"534","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Dopamine concentration NAc","ded94b78-1236-485d-af2a-2b9dee71b4c6","5a220a43-f34f-4054-8959-84f58bdc6f5c","CUS + vehicle",12,"False","c24f4373-c720-4b47-9b62-1e289140dc1d","CUS","True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,3.3,"Mean","ng/ml",0.3,"SEM"
"535","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Sucrose preference","5de017a7-64e0-4abd-adf3-93808a121f5b","a165e39b-4d1d-4246-ac4e-07c26d73e44a","Control + vehicle",12,NA,NA,NA,"True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,87.76,"Mean","%",1.87,"SEM"
"536","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","relative band intensity of D2R NAc","81398251-5177-471a-8595-5f58d35f6922","a165e39b-4d1d-4246-ac4e-07c26d73e44a","Control + vehicle",12,NA,NA,NA,"True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,100,"Mean","relative intensity (%) VS control",2.14,"SEM"
"537","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Dopamine-related non behavioural outcome",26,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Dopamine concentration NAc","ded94b78-1236-485d-af2a-2b9dee71b4c6","a165e39b-4d1d-4246-ac4e-07c26d73e44a","Control + vehicle",12,NA,NA,NA,"True","93e28dc3-ab7c-4afb-b67d-a3e362ca9099","vehicle",FALSE,0,5.49,"Mean","ng/ml",0.71,"SEM"
"538","ba974496-6eec-4c1c-a1f0-fdb1121d85d3","Involvement of D2 receptor in the NAc in chronic unpredictable stress-induced depression-like behaviors","Qiao, Hui and Yang, Sha and Xu, Chang and Ma, Xin-Ming and An, Shu-Cheng","Stress: The International Journal on the Biology of Stress",NA,"D2 receptors (D2Rs) located in both pre- and postsynaptic membranes of medium spiny neurons (MSNs) in the nucleus accumbens (NAc) are involved in the stress response and associated behaviors. The role of D2Rs in chronic unpredictable stress (CUS)-induced depression-like behaviors is not clear. Quinpirole (a D2R agonist) and eticlopride (a D2R antagonist) were stereotactically delivered into the NAc before Sprague Dawley rats underwent CUS. CUS-induced depression-like behaviors were accompanied by a significant decrease in both the dopamine (DA) level and D2R expression in the NAc. Eticlopride reversed CUS-induced depression-like behavior and rescued the DA levels in the NAc, and microinjection of DA into the NAc of CUS individuals had the same effect as eticlopride. By contrast, delivery of quinpirole into the NAc of control animals induced depression-like behaviors accompanied by a decrease in the DA level in the NAc. These results show that DA plays a key role in CUS-induced depression-like behaviors and the D2R exerts a presynaptic negative feedback on DA levels during CUS. Microinjection of quinpirole into the NAc also decreased the level of the kalirin-7 protein in the NAc of both control and stressed animals, while eticlopride increased its level in the NAc of rats. In agreement with these results, intraperitoneal injection of eticlopride in mice also caused an increase in both the kalirin-7 protein level in the NAc and spine density in MSNs, while quinpirole reduced them. These results suggest that regulation of kalirin-7 through D2R in the NAc is a general pathway in rats and mice, and is involved in CUS-induced depression-like behaviors. Kalirin-7 may be directly regulated through the D2R postsynaptic pathway or indirectly through the presynaptic pathway in the NAc. The interaction between D2R and kalirin-7 needs to be investigated further. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Ma, Xin-Ming: Shaaxi Normal University, Mailbox 100, 620 West Chang'an Street, Shaanxi Province, Xi'an, China, 710119, ma@nso.uchc.edu and Ma, Xin-Ming: ma@nso.uchc.edu, An, Shu-Cheng: shuchengan@snnu.edu.cn","2020","https://dx.doi.org/10.1080/10253890.2019.1673361","JOUR","*Chronic Stress and *Dopamine and *Nucleus Accumbens and *Quinpirole and *Rats and Animal Behavior and Proteins and Stress",NA,"PsychINFO-1025-3890-ISSN",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","DOPAMINE","Dopamine agonist (e.g. apomorphine, rotigotine)","3.83","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",12,999,999,8,9,"Weeks","At recruitment to study",999,999,250,280,"Grams (g)","Yes",2024-01-23 16:56:33,"cc3966c3-4871-49ca-98c8-fa0f399db78d","all","Sucrose preference","5de017a7-64e0-4abd-adf3-93808a121f5b","deee5794-a52e-47db-bb1b-b28e2b4cddb2","CUS + dopamine",12,"False","c24f4373-c720-4b47-9b62-1e289140dc1d","CUS","False","9318b3e4-5e55-43d2-94d7-3ac99836c0c7","Dopamine",FALSE,0,80.93,"Mean","%",2.74,"SEM"
"539","bb384706-977a-4add-9db5-49036e7d8003","Haloperidol and aripiprazole affects CRH system and behaviour of animals exposed to chronic mild stress.","Osacka J and Kiss A and Mach M and Tillinger A and Koprdova R","Neurochemistry international",NA,"CRH system integrates responses to stress challenges, whereas antipsychotics may impinge on this process. Effect of haloperidol (HAL) and aripiprazole (ARI) on chronic mild stress (CMS) induced neurobehavioral and CRH/CRHR1 system changes was studied in functionally interconnected rat brain areas including prefrontal cortex (PFC), bed nucleus of the stria terminalis (BNST), hypothalamic paraventricular nucleus (PVN), hippocampus (HIP), and amygdala (AMY). Animals were exposed to CMS for 3-weeks and since the 7th day of CMS injected with vehicle (VEH), HAL (1mg/kg) or ARI (10mg/kg) for 4-weeks. Expression levels of CRH, CRHR1, and c-fos genes and anxiety-like and anhedonia behavioural patterns were evaluated. CMS in VEH animals suppressed CRH gene expression in the PFC and BNST, c-fos expression in all areas, except HIP, and increased CRHR1 gene expression in the HIP. Antipsychotics decreased CRH gene expression in all areas, except HIP and by CMS elevated CRHR1 expression in the HIP (ARI also in AMY). CMS and antipsychotics decreased the sucrose preference. Aripiprazole prevented CRH expression decrease in the BNST and sucrose preference induced by CMS. Haloperidol increased time spent in the EPM open arms. These data indicate that HAL and ARI selectively influenced behavioural parameters and CRH/CRHR1 gene expression levels in CMS animals.",NA,"Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. Electronic address: romana.koprdova@savba.sk.","2022","10.1016/j.neuint.2021.105224","Journal Article and Research Support, Non-U.S. Gov't","Aripiprazole and Behaviour and CRH system and Chronic mild stress and Haloperidol",NA,"pubmed-34798194",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,999,999,7,9,"Weeks","At recruitment to study",999,999,270,290,"Grams (g)","Yes",2023-12-14 12:44:58,"9e76ff32-1ffb-40ce-bc6d-7c630efde9ee","sucrose preference test","sucrose preference","1ff5a74f-a4ad-4551-87d8-7aa9bd6e1b7c","1156026e-716c-40d4-b9b4-af95c9f17281","control: vehicle",10,NA,NA,NA,"True","2e621181-1626-428c-9a95-1a134a2e74b4","Vehicle",FALSE,0,88.37,"Mean","%",3.27,"SEM"
"540","bb384706-977a-4add-9db5-49036e7d8003","Haloperidol and aripiprazole affects CRH system and behaviour of animals exposed to chronic mild stress.","Osacka J and Kiss A and Mach M and Tillinger A and Koprdova R","Neurochemistry international",NA,"CRH system integrates responses to stress challenges, whereas antipsychotics may impinge on this process. Effect of haloperidol (HAL) and aripiprazole (ARI) on chronic mild stress (CMS) induced neurobehavioral and CRH/CRHR1 system changes was studied in functionally interconnected rat brain areas including prefrontal cortex (PFC), bed nucleus of the stria terminalis (BNST), hypothalamic paraventricular nucleus (PVN), hippocampus (HIP), and amygdala (AMY). Animals were exposed to CMS for 3-weeks and since the 7th day of CMS injected with vehicle (VEH), HAL (1mg/kg) or ARI (10mg/kg) for 4-weeks. Expression levels of CRH, CRHR1, and c-fos genes and anxiety-like and anhedonia behavioural patterns were evaluated. CMS in VEH animals suppressed CRH gene expression in the PFC and BNST, c-fos expression in all areas, except HIP, and increased CRHR1 gene expression in the HIP. Antipsychotics decreased CRH gene expression in all areas, except HIP and by CMS elevated CRHR1 expression in the HIP (ARI also in AMY). CMS and antipsychotics decreased the sucrose preference. Aripiprazole prevented CRH expression decrease in the BNST and sucrose preference induced by CMS. Haloperidol increased time spent in the EPM open arms. These data indicate that HAL and ARI selectively influenced behavioural parameters and CRH/CRHR1 gene expression levels in CMS animals.",NA,"Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. Electronic address: romana.koprdova@savba.sk.","2022","10.1016/j.neuint.2021.105224","Journal Article and Research Support, Non-U.S. Gov't","Aripiprazole and Behaviour and CRH system and Chronic mild stress and Haloperidol",NA,"pubmed-34798194",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","At disease model induction","28","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Days","Sucrose/saccharin intake or preference test",0,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",11,999,999,7,9,"Weeks","At recruitment to study",999,999,270,290,"Grams (g)","Yes",2023-12-14 12:44:58,"9e76ff32-1ffb-40ce-bc6d-7c630efde9ee","sucrose preference test","sucrose preference","1ff5a74f-a4ad-4551-87d8-7aa9bd6e1b7c","609628bd-d473-4ae4-926f-6a0056f6d698","CMS: Aripiprazole (10mg)",11,"False","9cc13f8e-df64-4c4f-97f3-4f0ac7bcb830","CMS","False","218fa2ad-4c95-416a-b728-4f1200996c0a","Aripiprazole 10mg/kg",FALSE,0,68.41,"Mean","%",1.55,"SEM"
"541","bb384706-977a-4add-9db5-49036e7d8003","Haloperidol and aripiprazole affects CRH system and behaviour of animals exposed to chronic mild stress.","Osacka J and Kiss A and Mach M and Tillinger A and Koprdova R","Neurochemistry international",NA,"CRH system integrates responses to stress challenges, whereas antipsychotics may impinge on this process. Effect of haloperidol (HAL) and aripiprazole (ARI) on chronic mild stress (CMS) induced neurobehavioral and CRH/CRHR1 system changes was studied in functionally interconnected rat brain areas including prefrontal cortex (PFC), bed nucleus of the stria terminalis (BNST), hypothalamic paraventricular nucleus (PVN), hippocampus (HIP), and amygdala (AMY). Animals were exposed to CMS for 3-weeks and since the 7th day of CMS injected with vehicle (VEH), HAL (1mg/kg) or ARI (10mg/kg) for 4-weeks. Expression levels of CRH, CRHR1, and c-fos genes and anxiety-like and anhedonia behavioural patterns were evaluated. CMS in VEH animals suppressed CRH gene expression in the PFC and BNST, c-fos expression in all areas, except HIP, and increased CRHR1 gene expression in the HIP. Antipsychotics decreased CRH gene expression in all areas, except HIP and by CMS elevated CRHR1 expression in the HIP (ARI also in AMY). CMS and antipsychotics decreased the sucrose preference. Aripiprazole prevented CRH expression decrease in the BNST and sucrose preference induced by CMS. Haloperidol increased time spent in the EPM open arms. These data indicate that HAL and ARI selectively influenced behavioural parameters and CRH/CRHR1 gene expression levels in CMS animals.",NA,"Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. and Biomedical Research Center, Institute of Experimental Endocrinology, Slovak and Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovakia. and Centre of Experimental Medicine, Institute of Experimental Pharmacology and and Toxicology, Slovak Academy of Sciences, Dubravska cesta 9, 841 04, Bratislava, and Slovakia. Electronic address: romana.koprdova@savba.sk.","2022","10.1016/j.neuint.2021.105224","Journal Article and Research Support, Non-U.S. Gov't","Aripiprazole and Behaviour and CRH system and Chronic mild stress and Haloperidol",NA,"pubmed-34798194",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Unclear","Yes","Yes","Yes","No","No","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Days","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",11,999,999,7,9,"Weeks","At recruitment to study",999,999,270,290,"Grams (g)","Yes",2023-12-14 12:44:58,"9e76ff32-1ffb-40ce-bc6d-7c630efde9ee","sucrose preference test","sucrose preference","1ff5a74f-a4ad-4551-87d8-7aa9bd6e1b7c","766183a8-dae3-47d7-8ec7-613f01272789","CMS: vehicle",11,"False","9cc13f8e-df64-4c4f-97f3-4f0ac7bcb830","CMS","True","2e621181-1626-428c-9a95-1a134a2e74b4","Vehicle",FALSE,0,71.89,"Mean","%",3.88,"SEM"
"542","be004a09-1836-4176-9a5e-8b2e4e724817","Orbital frontal cortex D1 dopamine receptor modulate glutamate and NMDA receptor in depression induced by chronic unpredictable mild stress","Wu, Shuai and An, Shucheng and Chen, Huibin and Li, Fei","Acta Psychologica Sinica",NA,"Stressors play a pivotal role in the occurrence of depressive illnesses. Disorders of monoamine neurotransmitters and their receptors may be the fundamental causes of depression. Additionally, abnormal expression of glutamic acid (Glu) and its receptor may be a major reason for depression. Consequently, the study of the relationship between monoamine and glutamic acid neurotransmitter in stress-induced depression has significances to reveal the profound mechanism of depression. NR2B subunits which are highly expressed in the cortex, hippocampus and olfactory bulb, are one of the key subunits of NMDA receptors. Orbital frontal cortex (orbital frontal cortex, OFC), which plays a significant role in higher brain function, such as emotional and complex behavior, is one of the major sub-regions of prefrontal. This study was to investigate the effect of orbital frontal cortex D1 dopamine receptor on Glu and its receptors, especially on NR2B subunits of N-methyl-D-aspartic acid (NMDA) receptors in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intra-orbital frontal cortex microinjections of D1 dopamine receptor agonist SKF38393 and its antagonist SCH23390 were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of sucrose preference test, open-field test and tail suspension test. The concentration of Glu and the expression of NR2B subunits in orbital frontal cortex were detected by high-performance liquid chromatography (HPLC) and Western blot (WB) respectively. In comparison to control groups, depression-like behavioral changes were observed in CUMS rats, the concentration of dopamine and its D1 receptor were decreased: conversely, the increase of Glu and NR2B subunits of its NMDA receptors were observed in orbital frontal cortex. Depression-like behavioral of CUMS rats was obviously improved after pretreatment with injection of SKF38393, the expression of Glu and NR2B subunits of its NMDA receptors were also decreased. Normal rats showed depression-like behavioral which similar to the CUMS rats after pretreatment with injection of D1 dopamine receptor antagonist SCH23390, meanwhile, in orbital frontal cortex the expression of Glu and NR2B subunits of its NMDA receptors were significantly increased. These results suggest that the lowered dopamine release may be caused by chronic unpredictable mild stress, as the result of insufficient dopamine, orbital frontal cortex releases extra amounts of glutamic acid and its NMDA receptors are over activated. All those above then may lead to depression. Antidepressant effect of dopamine may be functioned by inhibiting the expression of Glu and NR2B subunits of its NMDA receptors. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"An, Shucheng: College of Life Science, Shaanxi Normal University, Xi'an, China, 710062, shuchengan@snnu.edu.cn and An, Shucheng: shuchengan@snnu.edu.cn","2014",NA,"JOUR","*Dopamine and *Neural Receptors and *Prefrontal Cortex and *Stress and Rats",NA,"PsychINFO-0439-755X-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,"SCH23390","Dopamine agonist (e.g. apomorphine, rotigotine)","2","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,NA,NA,NA,"Days","At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 11:23:15,"38dbb3e0-7eb2-45d5-b76c-c90b8c057116","EXP","sucrose consumption %","bd5d4fe4-1353-45fc-ab57-0a9a03186a92","2e24d3af-afd8-49fc-9305-4b851a4e551c","SCH",6,NA,NA,NA,"False","721b074f-4ede-4480-ab63-1c75ff88b64f","SCH23390",FALSE,0,50,"Mean","%",8.5,"SEM"
"543","be004a09-1836-4176-9a5e-8b2e4e724817","Orbital frontal cortex D1 dopamine receptor modulate glutamate and NMDA receptor in depression induced by chronic unpredictable mild stress","Wu, Shuai and An, Shucheng and Chen, Huibin and Li, Fei","Acta Psychologica Sinica",NA,"Stressors play a pivotal role in the occurrence of depressive illnesses. Disorders of monoamine neurotransmitters and their receptors may be the fundamental causes of depression. Additionally, abnormal expression of glutamic acid (Glu) and its receptor may be a major reason for depression. Consequently, the study of the relationship between monoamine and glutamic acid neurotransmitter in stress-induced depression has significances to reveal the profound mechanism of depression. NR2B subunits which are highly expressed in the cortex, hippocampus and olfactory bulb, are one of the key subunits of NMDA receptors. Orbital frontal cortex (orbital frontal cortex, OFC), which plays a significant role in higher brain function, such as emotional and complex behavior, is one of the major sub-regions of prefrontal. This study was to investigate the effect of orbital frontal cortex D1 dopamine receptor on Glu and its receptors, especially on NR2B subunits of N-methyl-D-aspartic acid (NMDA) receptors in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intra-orbital frontal cortex microinjections of D1 dopamine receptor agonist SKF38393 and its antagonist SCH23390 were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of sucrose preference test, open-field test and tail suspension test. The concentration of Glu and the expression of NR2B subunits in orbital frontal cortex were detected by high-performance liquid chromatography (HPLC) and Western blot (WB) respectively. In comparison to control groups, depression-like behavioral changes were observed in CUMS rats, the concentration of dopamine and its D1 receptor were decreased: conversely, the increase of Glu and NR2B subunits of its NMDA receptors were observed in orbital frontal cortex. Depression-like behavioral of CUMS rats was obviously improved after pretreatment with injection of SKF38393, the expression of Glu and NR2B subunits of its NMDA receptors were also decreased. Normal rats showed depression-like behavioral which similar to the CUMS rats after pretreatment with injection of D1 dopamine receptor antagonist SCH23390, meanwhile, in orbital frontal cortex the expression of Glu and NR2B subunits of its NMDA receptors were significantly increased. These results suggest that the lowered dopamine release may be caused by chronic unpredictable mild stress, as the result of insufficient dopamine, orbital frontal cortex releases extra amounts of glutamic acid and its NMDA receptors are over activated. All those above then may lead to depression. Antidepressant effect of dopamine may be functioned by inhibiting the expression of Glu and NR2B subunits of its NMDA receptors. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"An, Shucheng: College of Life Science, Shaanxi Normal University, Xi'an, China, 710062, shuchengan@snnu.edu.cn and An, Shucheng: shuchengan@snnu.edu.cn","2014",NA,"JOUR","*Dopamine and *Neural Receptors and *Prefrontal Cortex and *Stress and Rats",NA,"PsychINFO-0439-755X-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,NA,NA,NA,"Days","At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 11:23:15,"38dbb3e0-7eb2-45d5-b76c-c90b8c057116","EXP","sucrose consumption %","bd5d4fe4-1353-45fc-ab57-0a9a03186a92","489de7bb-e707-4b62-aade-02659e65fb86","CUMS",6,"False","ccf1b7e4-d7b0-41c0-9084-9afd27bc75d3","CUMS",NA,NA,NA,FALSE,0,46,"Mean","%",10.6,"SEM"
"544","be004a09-1836-4176-9a5e-8b2e4e724817","Orbital frontal cortex D1 dopamine receptor modulate glutamate and NMDA receptor in depression induced by chronic unpredictable mild stress","Wu, Shuai and An, Shucheng and Chen, Huibin and Li, Fei","Acta Psychologica Sinica",NA,"Stressors play a pivotal role in the occurrence of depressive illnesses. Disorders of monoamine neurotransmitters and their receptors may be the fundamental causes of depression. Additionally, abnormal expression of glutamic acid (Glu) and its receptor may be a major reason for depression. Consequently, the study of the relationship between monoamine and glutamic acid neurotransmitter in stress-induced depression has significances to reveal the profound mechanism of depression. NR2B subunits which are highly expressed in the cortex, hippocampus and olfactory bulb, are one of the key subunits of NMDA receptors. Orbital frontal cortex (orbital frontal cortex, OFC), which plays a significant role in higher brain function, such as emotional and complex behavior, is one of the major sub-regions of prefrontal. This study was to investigate the effect of orbital frontal cortex D1 dopamine receptor on Glu and its receptors, especially on NR2B subunits of N-methyl-D-aspartic acid (NMDA) receptors in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intra-orbital frontal cortex microinjections of D1 dopamine receptor agonist SKF38393 and its antagonist SCH23390 were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of sucrose preference test, open-field test and tail suspension test. The concentration of Glu and the expression of NR2B subunits in orbital frontal cortex were detected by high-performance liquid chromatography (HPLC) and Western blot (WB) respectively. In comparison to control groups, depression-like behavioral changes were observed in CUMS rats, the concentration of dopamine and its D1 receptor were decreased: conversely, the increase of Glu and NR2B subunits of its NMDA receptors were observed in orbital frontal cortex. Depression-like behavioral of CUMS rats was obviously improved after pretreatment with injection of SKF38393, the expression of Glu and NR2B subunits of its NMDA receptors were also decreased. Normal rats showed depression-like behavioral which similar to the CUMS rats after pretreatment with injection of D1 dopamine receptor antagonist SCH23390, meanwhile, in orbital frontal cortex the expression of Glu and NR2B subunits of its NMDA receptors were significantly increased. These results suggest that the lowered dopamine release may be caused by chronic unpredictable mild stress, as the result of insufficient dopamine, orbital frontal cortex releases extra amounts of glutamic acid and its NMDA receptors are over activated. All those above then may lead to depression. Antidepressant effect of dopamine may be functioned by inhibiting the expression of Glu and NR2B subunits of its NMDA receptors. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"An, Shucheng: College of Life Science, Shaanxi Normal University, Xi'an, China, 710062, shuchengan@snnu.edu.cn and An, Shucheng: shuchengan@snnu.edu.cn","2014",NA,"JOUR","*Dopamine and *Neural Receptors and *Prefrontal Cortex and *Stress and Rats",NA,"PsychINFO-0439-755X-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",10,90,NA,NA,NA,"Days","At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 11:23:15,"38dbb3e0-7eb2-45d5-b76c-c90b8c057116","EXP","sucrose consumption %","bd5d4fe4-1353-45fc-ab57-0a9a03186a92","7f7b599c-1fee-4d81-b447-5e0ea8623b3f","CONTROL",6,NA,NA,NA,NA,NA,NA,FALSE,0,88,"Mean","%",1.4,"SEM"
"545","be004a09-1836-4176-9a5e-8b2e4e724817","Orbital frontal cortex D1 dopamine receptor modulate glutamate and NMDA receptor in depression induced by chronic unpredictable mild stress","Wu, Shuai and An, Shucheng and Chen, Huibin and Li, Fei","Acta Psychologica Sinica",NA,"Stressors play a pivotal role in the occurrence of depressive illnesses. Disorders of monoamine neurotransmitters and their receptors may be the fundamental causes of depression. Additionally, abnormal expression of glutamic acid (Glu) and its receptor may be a major reason for depression. Consequently, the study of the relationship between monoamine and glutamic acid neurotransmitter in stress-induced depression has significances to reveal the profound mechanism of depression. NR2B subunits which are highly expressed in the cortex, hippocampus and olfactory bulb, are one of the key subunits of NMDA receptors. Orbital frontal cortex (orbital frontal cortex, OFC), which plays a significant role in higher brain function, such as emotional and complex behavior, is one of the major sub-regions of prefrontal. This study was to investigate the effect of orbital frontal cortex D1 dopamine receptor on Glu and its receptors, especially on NR2B subunits of N-methyl-D-aspartic acid (NMDA) receptors in depression induced by chronic unpredictable mild stress (CUMS). CUMS-induced depression model was established in Sprague-Dawley rats, and intra-orbital frontal cortex microinjections of D1 dopamine receptor agonist SKF38393 and its antagonist SCH23390 were respectively adopted by rat brain stereotaxic coordinates. The behavioral observations were conducted by measurement of sucrose preference test, open-field test and tail suspension test. The concentration of Glu and the expression of NR2B subunits in orbital frontal cortex were detected by high-performance liquid chromatography (HPLC) and Western blot (WB) respectively. In comparison to control groups, depression-like behavioral changes were observed in CUMS rats, the concentration of dopamine and its D1 receptor were decreased: conversely, the increase of Glu and NR2B subunits of its NMDA receptors were observed in orbital frontal cortex. Depression-like behavioral of CUMS rats was obviously improved after pretreatment with injection of SKF38393, the expression of Glu and NR2B subunits of its NMDA receptors were also decreased. Normal rats showed depression-like behavioral which similar to the CUMS rats after pretreatment with injection of D1 dopamine receptor antagonist SCH23390, meanwhile, in orbital frontal cortex the expression of Glu and NR2B subunits of its NMDA receptors were significantly increased. These results suggest that the lowered dopamine release may be caused by chronic unpredictable mild stress, as the result of insufficient dopamine, orbital frontal cortex releases extra amounts of glutamic acid and its NMDA receptors are over activated. All those above then may lead to depression. Antidepressant effect of dopamine may be functioned by inhibiting the expression of Glu and NR2B subunits of its NMDA receptors. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"An, Shucheng: College of Life Science, Shaanxi Normal University, Xi'an, China, 710062, shuchengan@snnu.edu.cn and An, Shucheng: shuchengan@snnu.edu.cn","2014",NA,"JOUR","*Dopamine and *Neural Receptors and *Prefrontal Cortex and *Stress and Rats",NA,"PsychINFO-0439-755X-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","No","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","SKF38393","Dopamine agonist (e.g. apomorphine, rotigotine)","1.12","micrograms (ug)","At disease model induction","21","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",21,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Sprague-dawley (rat)","Exact number",999,90,NA,NA,NA,"Days","At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-14 11:23:15,"38dbb3e0-7eb2-45d5-b76c-c90b8c057116","EXP","sucrose consumption %","bd5d4fe4-1353-45fc-ab57-0a9a03186a92","c6198dfe-e656-4727-ad56-0d2eb8715739","CUMS +SK",6,"False","ccf1b7e4-d7b0-41c0-9084-9afd27bc75d3","CUMS","False","0c34edef-bcfa-4cf3-80bd-a1c802167a09","SKF38393",FALSE,0,86.7,"Mean","%",1.6,"SEM"
"546","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,0,5.97,"Mean","g",0.68,"SEM"
"547","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,1,9.05,"Mean","g",1.56,"SEM"
"548","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,2,9.96,"Mean","g",0.96,"SEM"
"549","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,3,11.85,"Mean","g",1,"SEM"
"550","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,4,13.6,"Mean","g",0.92,"SEM"
"551","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","40","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","2732b372-10d1-499c-95e3-ada82bd13d9f","CMS + piribedil (40 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","2ab7639a-c139-467a-b68f-2b7184867ea6","Piribedil 40 mg/kg",FALSE,5,12.88,"Mean","g",0.6,"SEM"
"552","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,6.53,"Mean","g",0.5,"SEM"
"553","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,6.56,"Mean","g",1.54,"SEM"
"554","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,7.66,"Mean","g",1.67,"SEM"
"555","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,8.33,"Mean","g",1.04,"SEM"
"556","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,7.46,"Mean","g",1.14,"SEM"
"557","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","5978174b-693e-4647-b1ea-b9fab3291977","CMS + vehicle (4d)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,8.38,"Mean","g",1.65,"SEM"
"558","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,13.75,"Mean","g",1.44,"SEM"
"559","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,14.03,"Mean","g",1.89,"SEM"
"560","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,14.95,"Mean","g",1.84,"SEM"
"561","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,14.43,"Mean","g",1.54,"SEM"
"562","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,14.09,"Mean","g",2.8,"SEM"
"563","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"2454c305-9928-4d6a-a07c-3a5425d00702","Sucrose intake 4d","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","d96b22a0-4fd9-41df-bad7-04a8744f9389","Control + vehicle (4d)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,13.95,"Mean","g",1.75,"SEM"
"564","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,0,6.32,"Mean","g",0.9,"SEM"
"565","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,1,10.43,"Mean","g",1.44,"SEM"
"566","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,2,13.57,"Mean","g",1.48,"SEM"
"567","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,3,14.7,"Mean","g",0.9,"SEM"
"568","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,4,12.59,"Mean","g",0.96,"SEM"
"569","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","10","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","15fef698-f50b-4f4c-8bc5-3b239effac06","CMS + piribedil (10 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","8b00b6e6-2ce7-4a51-bcce-1bcae8816ea5","Piribedil 10mg/kg",FALSE,5,13.22,"Mean","g",0.92,"SEM"
"570","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,13.65,"Mean","g",1.49,"SEM"
"571","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,13.97,"Mean","g",1.9,"SEM"
"572","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,14.88,"Mean","g",1.6,"SEM"
"573","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,14.41,"Mean","g",1.76,"SEM"
"574","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,14.11,"Mean","g",7.56,"SEM"
"575","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","821e91fb-0fc2-4f33-ab90-3017d9c6c216","Control + vehicle (4c)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,14.58,"Mean","g",1.09,"SEM"
"576","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,6.6,"Mean","g",0.96,"SEM"
"577","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,6.6,"Mean","g",1.53,"SEM"
"578","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,7.63,"Mean","g",1.61,"SEM"
"579","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,8.37,"Mean","g",1.06,"SEM"
"580","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,7.43,"Mean","g",1.01,"SEM"
"581","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"5e3a199e-a695-402b-be73-84014db38dde","Sucrose intake 4c","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","9a3f0d79-b82f-46f9-ba7e-fdf9f1f4b519","CMS + vehicle (4c)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,8.36,"Mean","g",1.58,"SEM"
"582","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,0,6.7,"Mean","g",1.33,"SEM"
"583","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,1,6.76,"Mean","g",1.33,"SEM"
"584","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,2,6.51,"Mean","g",1.48,"SEM"
"585","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,3,9.52,"Mean","g",1.46,"SEM"
"586","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,4,8.8,"Mean","g",1.19,"SEM"
"587","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","PIRIBEDIL","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","After disease model induction","5","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","58cd2e84-6416-48c3-b0a3-72a3a39e55aa","CMS + piribedil (2.5 mg/kg)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","False","9a4ff48a-c448-41e4-a244-0a4be09f314e","Piribedil 2.5mg/kg",FALSE,5,13.02,"Mean","g",1.63,"SEM"
"588","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,6.58,"Mean","g",1.09,"SEM"
"589","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,6.58,"Mean","g",1.31,"SEM"
"590","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,7.62,"Mean","g",1.64,"SEM"
"591","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,8.33,"Mean","g",1.01,"SEM"
"592","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,7.5,"Mean","g",1.11,"SEM"
"593","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","72b331e6-8609-4b6a-b830-c4996004ae24","CMS + vehicle (4b)",8,"False","9a382595-df56-48d0-b0fa-10857a0f3d03","CMS","True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,8.38,"Mean","g",1.6,"SEM"
"594","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,0,13.68,"Mean","g",1.5,"SEM"
"595","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,1,14.01,"Mean","g",1.84,"SEM"
"596","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,2,14.85,"Mean","g",1.9,"SEM"
"597","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,3,14.35,"Mean","g",2.19,"SEM"
"598","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,4,14.11,"Mean","g",2.15,"SEM"
"599","c5f599a4-839a-4c7a-80c9-f40ba1d46969","Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","Brocco, Mauricette and Dekeyne, Anne and Papp, Mariusz and Millan, Mark J","Behavioural Pharmacology",NA,"The dopamine D2/D3 receptor agonist and alpha2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5-10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63-10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5-40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63-10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63-10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Brocco, Mauricette: Psychopharmacology Department, Institut de Recherches Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde, 78290 Croissy/Seine, Paris, France, mauricette.brocco@fr.netgrs.com and Brocco, Mauricette: mauricette.brocco@fr.netgrs.com","2006","https://dx.doi.org/10.1097/01.fbp.0000236267.41806.5b","JOUR","*Adrenergic Receptors and *Antidepressant Drugs and *Antitremor Drugs and *Rodents and Dopamine and Fluvoxamine and Imipramine and Parkinsonism and Quinpirole",NA,"PsychINFO-0955-8810-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",24,"Hours","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",999,999,999,999,999,"Days","At recruitment to study",999,996,220,250,"Grams (g)","No",2024-01-26 13:21:38,"e792484a-1f29-43a7-b360-db438ddf240d","Sucrose intake 4b","Sucrose intake","3484eb5a-32a4-45be-9d1b-c98e1a9d2c0f","ebc93ce5-b0ff-46a9-9afd-4dd9e94ab07e","Control + vehicle (4b)",8,NA,NA,NA,"True","fa1beeeb-6cad-40e1-9c7b-2937ef3ea6aa","Vehicle",FALSE,5,14.56,"Mean","g",2.16,"SEM"
"600","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","244e8225-95d9-405b-924a-8f14983caabe","CMS",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS",NA,NA,NA,FALSE,0,19.31,"Mean","ml/kg",7.07,"SD"
"601","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","244e8225-95d9-405b-924a-8f14983caabe","CMS",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS",NA,NA,NA,FALSE,1,19.14,"Mean","ml/kg",7.62,"SD"
"602","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","244e8225-95d9-405b-924a-8f14983caabe","CMS",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS",NA,NA,NA,FALSE,2,14.58,"Mean","ml/kg",7.07,"SD"
"603","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","244e8225-95d9-405b-924a-8f14983caabe","CMS",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS",NA,NA,NA,FALSE,3,9.01,"Mean","ml/kg",4.01,"SD"
"604","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","244e8225-95d9-405b-924a-8f14983caabe","CMS",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS",NA,NA,NA,FALSE,4,9.37,"Mean","ml/kg",4.36,"SD"
"605","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","65625264-1abd-42cd-b5ff-6479e4bcee43","Control",8,NA,NA,NA,NA,NA,NA,FALSE,0,20.38,"Mean","ml/kg",9.98,"SD"
"606","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","65625264-1abd-42cd-b5ff-6479e4bcee43","Control",8,NA,NA,NA,NA,NA,NA,FALSE,1,24.96,"Mean","ml/kg",8.6,"SD"
"607","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","65625264-1abd-42cd-b5ff-6479e4bcee43","Control",8,NA,NA,NA,NA,NA,NA,FALSE,2,29.91,"Mean","ml/kg",12.33,"SD"
"608","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","65625264-1abd-42cd-b5ff-6479e4bcee43","Control",8,NA,NA,NA,NA,NA,NA,FALSE,3,27.24,"Mean","ml/kg",19.06,"SD"
"609","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","65625264-1abd-42cd-b5ff-6479e4bcee43","Control",8,NA,NA,NA,NA,NA,NA,FALSE,4,25.9,"Mean","ml/kg",16.44,"SD"
"610","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","77399098-4bb5-44ea-8489-70fb69530b89","CMS + aripiprazole",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS","False","bb39280c-27b4-4819-aba8-89f38a031b36","Aripiprazole",FALSE,0,18.67,"Mean","ml/kg",6.87,"SD"
"611","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","77399098-4bb5-44ea-8489-70fb69530b89","CMS + aripiprazole",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS","False","bb39280c-27b4-4819-aba8-89f38a031b36","Aripiprazole",FALSE,1,33.8,"Mean","ml/kg",22.08,"SD"
"612","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","77399098-4bb5-44ea-8489-70fb69530b89","CMS + aripiprazole",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS","False","bb39280c-27b4-4819-aba8-89f38a031b36","Aripiprazole",FALSE,2,21.84,"Mean","ml/kg",19.08,"SD"
"613","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","77399098-4bb5-44ea-8489-70fb69530b89","CMS + aripiprazole",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS","False","bb39280c-27b4-4819-aba8-89f38a031b36","Aripiprazole",FALSE,3,29.43,"Mean","ml/kg",13.56,"SD"
"614","c7bcbb44-e2eb-4410-a70b-781a444c0195","Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain","Eren, I and Naziroglu, M and Demirdas, A","NEUROCHEMICAL RESEARCH",NA,"We investigated the effects of lamotrigine, aripiprazole and escitalopram administration and experimental depression on lipid peroxidation (LP) and antioxidant levels in cortex of the brain in rats. Forty male wistar rats were randomly divided into five groups. First group was used as control although second group was depression-induced group. Aripiprazole, lamotrigine and escitalopram per day were orally supplemented to chronic mild stress (CMS) depression-induced rats constituting the third, fourth and fifth groups for 28 days, respectively. Depression resulted in significant decrease in the glutathione peroxidase (GSH-Px) activity, reduced glutathione and vitamin C of cortex of the brain although their levels and beta-carotene concentrations were increased by the three drugs administrations to the animals of CMS induced depression group. The LP levels in the cortex of the brain and plasma of depression group were elevated although their levels were decreased by the administrations. The increases of antioxidant values in lamotrigine group were higher according to aripiprazole and escitalopram supplemented groups. Vitamin A level did not change in the five groups. In conclusion, the experimental depression is associated with elevated oxidative stress although treatment with lamotrigine has most protective effects on the oxidative stress within three medicines.",NA,"Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey and Suleyman Demirel Univ, Fac Med, Dept Psychiat, Isparta, Turkey","2007","10.1007/s11064-007-9289-x","JOUR","lamotrigine and depression and antioxidant and oxidative stress and selective-serotonin reuptake inhibitors and LIPID-PEROXIDATION and MAJOR DEPRESSION and VITAMIN-C and INHIBITORS and BLOOD and SUPPRESSION and CYTOKINES and SELENIUM and REAGENT and PROTEIN",NA,"WOS:000246768100011",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Not specified/unclear","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","4","Weeks",NA,"Oral administration/gavage","Multiple doses (enter details in comments)","0","Hours","Sucrose/saccharin intake or preference test",4,"Weeks","Exact value (in table or text)","Endpoint measurement","Continuous",FALSE,"Male","WT","Rat","Wistar (rat)","Exact number",8,999,999,999,999,"Days","At recruitment to study",200,20,999,999,"Grams (g)","Yes",2024-01-26 15:06:49,"be39cad9-95c1-4f2f-bb7c-d966625fab06","sucrose intake","Sucrose preference test","1fcb75eb-7add-4a01-9ffd-b1b00ba0a75e","77399098-4bb5-44ea-8489-70fb69530b89","CMS + aripiprazole",8,"False","d0ec40a9-4b86-4280-b948-bb5d2db4d209","CMS","False","bb39280c-27b4-4819-aba8-89f38a031b36","Aripiprazole",FALSE,4,32.12,"Mean","ml/kg",14.44,"SD"
"615","cc6534a5-d880-45a2-ab36-544a2e30d3c1","Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity","Russo, Emilio and Citraro, Rita and Davoli, Alessandro and Gallelli, Luca and Donato Di Paola, Eugenio and De Sarro, Giovambattista","Neuropharmacology",NA,"Aripiprazole (APZ) is regarded as a first-line atypical antipsychotic used for the treatment of first and multiple episodes of schizophrenia to improve positive- and negative-symptoms. Its therapeutic indications were extended to acute manic and mixed episodes associated with bipolar disorder. In addition, APZ was approved as an adjunct therapy for major depressive disorder in 2007. Compared to other antipsychotic drugs, APZ has a unique pharmacological profile. It is a partial agonist at D2 dopamine receptors and serotonin 5-HT1A and 5-HT7 receptors, whereas it is an antagonist at serotonin 5-HT2A and 5-HT6 receptors. Since epilepsy is often accompanied with neurological comorbidities such as depression, anxiety and cognitive deficits caused by both the disease and/or drug treatment, we wished to examine the effects of a sub-chronic treatment (>14 consecutive days) with APZ (0.3, 1 and 3 mg/kg: i.p.) on both absence seizures and WAG/Rij rat's behavior using different standard paradigms: Open field (OF) test, elevated plus maze (EPM) test, forced swimming (FS) test, sucrose consumption (SC) test and Morris water maze (MWM). WAG/Rij rats represent a validated genetic animal model of absence epilepsy with mild-depression comorbidity, also including other behavioral alterations. APZ treatment showed some anti-absence properties and regarding the behavioral comorbidity in this rat strain, we observed that APZ possesses clear antidepressant effects in the FS and SC tests also increasing memory/learning function in the Morris water maze test. In the two anxiety models used, APZ showed only minor effects. In conclusion, our results indicate that APZ might actually have a potential in treating absence seizures or as add-on therapy but more interestingly, these effect might be accompanied by positive modulatory actions on depression, anxiety and memory which might be also beneficial in other epileptic syndromes. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Russo, Emilio: Science of Health Department, School of Medicine, University ""Magna Graecia"" of Catanzaro, Via T. Campanella, 115, Catanzaro, Italy, 88100, erusso@unicz.it and Russo, Emilio: erusso@unicz.it","2013","https://dx.doi.org/10.1016/j.neuropharm.2012.06.039","JOUR","*Cognitive Processes and *Comorbidity and *Epilepsy and *Major Depression and *Aripiprazole and Animal Models and Rats",NA,"PsychINFO-0028-3908-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Genetic model of depression (e.g. transgenic models, Flinder's Sensitive Line (FSL))",NA,"Other (specify in comments)","Prenatal/gestational","Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Not reported","10","Rat","Other","Exact number",10,6,999,999,999,"Months","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 17:50:54,"c4cd75cc-7874-4211-9585-d99ec238e92a","sucrose intake (fig1)","sucrose intake","dee5cffe-1a14-49e9-b032-499155d048ee","0b96c462-a094-4558-a30f-24fe185e0d63","WAG/Rij: Aripiprazole 1mg/kg",10,"False","293fbce9-37b1-474b-aaf3-49623f903bdb","WAG/Rij rat","False","bfb9a624-897a-4ec6-b03d-9d3033b686f8","Aripiprazole (1mg/kg)",FALSE,0,7.66,"Mean","g/15 minutes",0.46,"SEM"
"616","cc6534a5-d880-45a2-ab36-544a2e30d3c1","Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity","Russo, Emilio and Citraro, Rita and Davoli, Alessandro and Gallelli, Luca and Donato Di Paola, Eugenio and De Sarro, Giovambattista","Neuropharmacology",NA,"Aripiprazole (APZ) is regarded as a first-line atypical antipsychotic used for the treatment of first and multiple episodes of schizophrenia to improve positive- and negative-symptoms. Its therapeutic indications were extended to acute manic and mixed episodes associated with bipolar disorder. In addition, APZ was approved as an adjunct therapy for major depressive disorder in 2007. Compared to other antipsychotic drugs, APZ has a unique pharmacological profile. It is a partial agonist at D2 dopamine receptors and serotonin 5-HT1A and 5-HT7 receptors, whereas it is an antagonist at serotonin 5-HT2A and 5-HT6 receptors. Since epilepsy is often accompanied with neurological comorbidities such as depression, anxiety and cognitive deficits caused by both the disease and/or drug treatment, we wished to examine the effects of a sub-chronic treatment (>14 consecutive days) with APZ (0.3, 1 and 3 mg/kg: i.p.) on both absence seizures and WAG/Rij rat's behavior using different standard paradigms: Open field (OF) test, elevated plus maze (EPM) test, forced swimming (FS) test, sucrose consumption (SC) test and Morris water maze (MWM). WAG/Rij rats represent a validated genetic animal model of absence epilepsy with mild-depression comorbidity, also including other behavioral alterations. APZ treatment showed some anti-absence properties and regarding the behavioral comorbidity in this rat strain, we observed that APZ possesses clear antidepressant effects in the FS and SC tests also increasing memory/learning function in the Morris water maze test. In the two anxiety models used, APZ showed only minor effects. In conclusion, our results indicate that APZ might actually have a potential in treating absence seizures or as add-on therapy but more interestingly, these effect might be accompanied by positive modulatory actions on depression, anxiety and memory which might be also beneficial in other epileptic syndromes. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Russo, Emilio: Science of Health Department, School of Medicine, University ""Magna Graecia"" of Catanzaro, Via T. Campanella, 115, Catanzaro, Italy, 88100, erusso@unicz.it and Russo, Emilio: erusso@unicz.it","2013","https://dx.doi.org/10.1016/j.neuropharm.2012.06.039","JOUR","*Cognitive Processes and *Comorbidity and *Epilepsy and *Major Depression and *Aripiprazole and Animal Models and Rats",NA,"PsychINFO-0028-3908-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Genetic model of depression (e.g. transgenic models, Flinder's Sensitive Line (FSL))",NA,"Other (specify in comments)","Prenatal/gestational","Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","0.3","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Not reported","10","Rat","Other","Exact number",10,6,999,999,999,"Months","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 17:50:54,"c4cd75cc-7874-4211-9585-d99ec238e92a","sucrose intake (fig1)","sucrose intake","dee5cffe-1a14-49e9-b032-499155d048ee","30f318a1-96c3-47a6-8430-e46d0cfeb132","WAG/Rij: Aripiprazole 0.3mg/kg",10,"False","293fbce9-37b1-474b-aaf3-49623f903bdb","WAG/Rij rat","False","11d96e0b-ff36-4d39-b54e-b53325a62ba0","Aripiprazole (0.3mg/kg)",FALSE,0,6.1,"Mean","g/15 minutes",0.48,"SEM"
"617","cc6534a5-d880-45a2-ab36-544a2e30d3c1","Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity","Russo, Emilio and Citraro, Rita and Davoli, Alessandro and Gallelli, Luca and Donato Di Paola, Eugenio and De Sarro, Giovambattista","Neuropharmacology",NA,"Aripiprazole (APZ) is regarded as a first-line atypical antipsychotic used for the treatment of first and multiple episodes of schizophrenia to improve positive- and negative-symptoms. Its therapeutic indications were extended to acute manic and mixed episodes associated with bipolar disorder. In addition, APZ was approved as an adjunct therapy for major depressive disorder in 2007. Compared to other antipsychotic drugs, APZ has a unique pharmacological profile. It is a partial agonist at D2 dopamine receptors and serotonin 5-HT1A and 5-HT7 receptors, whereas it is an antagonist at serotonin 5-HT2A and 5-HT6 receptors. Since epilepsy is often accompanied with neurological comorbidities such as depression, anxiety and cognitive deficits caused by both the disease and/or drug treatment, we wished to examine the effects of a sub-chronic treatment (>14 consecutive days) with APZ (0.3, 1 and 3 mg/kg: i.p.) on both absence seizures and WAG/Rij rat's behavior using different standard paradigms: Open field (OF) test, elevated plus maze (EPM) test, forced swimming (FS) test, sucrose consumption (SC) test and Morris water maze (MWM). WAG/Rij rats represent a validated genetic animal model of absence epilepsy with mild-depression comorbidity, also including other behavioral alterations. APZ treatment showed some anti-absence properties and regarding the behavioral comorbidity in this rat strain, we observed that APZ possesses clear antidepressant effects in the FS and SC tests also increasing memory/learning function in the Morris water maze test. In the two anxiety models used, APZ showed only minor effects. In conclusion, our results indicate that APZ might actually have a potential in treating absence seizures or as add-on therapy but more interestingly, these effect might be accompanied by positive modulatory actions on depression, anxiety and memory which might be also beneficial in other epileptic syndromes. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Russo, Emilio: Science of Health Department, School of Medicine, University ""Magna Graecia"" of Catanzaro, Via T. Campanella, 115, Catanzaro, Italy, 88100, erusso@unicz.it and Russo, Emilio: erusso@unicz.it","2013","https://dx.doi.org/10.1016/j.neuropharm.2012.06.039","JOUR","*Cognitive Processes and *Comorbidity and *Epilepsy and *Major Depression and *Aripiprazole and Animal Models and Rats",NA,"PsychINFO-0028-3908-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Genetic model of depression (e.g. transgenic models, Flinder's Sensitive Line (FSL))",NA,"Other (specify in comments)","Prenatal/gestational","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Not reported","10","Rat","Other","Exact number",10,6,999,999,999,"Months","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 17:50:54,"c4cd75cc-7874-4211-9585-d99ec238e92a","sucrose intake (fig1)","sucrose intake","dee5cffe-1a14-49e9-b032-499155d048ee","b79a37fc-d70c-40db-aa45-d0bb43c2ae0b","WAG/Rij: control",10,"False","293fbce9-37b1-474b-aaf3-49623f903bdb","WAG/Rij rat","True","34f0d0f8-11a6-4838-8a5f-0271708d3c18","vehicle",FALSE,0,4.4,"Mean","g/15 minutes",0.2,"SEM"
"618","cc6534a5-d880-45a2-ab36-544a2e30d3c1","Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity","Russo, Emilio and Citraro, Rita and Davoli, Alessandro and Gallelli, Luca and Donato Di Paola, Eugenio and De Sarro, Giovambattista","Neuropharmacology",NA,"Aripiprazole (APZ) is regarded as a first-line atypical antipsychotic used for the treatment of first and multiple episodes of schizophrenia to improve positive- and negative-symptoms. Its therapeutic indications were extended to acute manic and mixed episodes associated with bipolar disorder. In addition, APZ was approved as an adjunct therapy for major depressive disorder in 2007. Compared to other antipsychotic drugs, APZ has a unique pharmacological profile. It is a partial agonist at D2 dopamine receptors and serotonin 5-HT1A and 5-HT7 receptors, whereas it is an antagonist at serotonin 5-HT2A and 5-HT6 receptors. Since epilepsy is often accompanied with neurological comorbidities such as depression, anxiety and cognitive deficits caused by both the disease and/or drug treatment, we wished to examine the effects of a sub-chronic treatment (>14 consecutive days) with APZ (0.3, 1 and 3 mg/kg: i.p.) on both absence seizures and WAG/Rij rat's behavior using different standard paradigms: Open field (OF) test, elevated plus maze (EPM) test, forced swimming (FS) test, sucrose consumption (SC) test and Morris water maze (MWM). WAG/Rij rats represent a validated genetic animal model of absence epilepsy with mild-depression comorbidity, also including other behavioral alterations. APZ treatment showed some anti-absence properties and regarding the behavioral comorbidity in this rat strain, we observed that APZ possesses clear antidepressant effects in the FS and SC tests also increasing memory/learning function in the Morris water maze test. In the two anxiety models used, APZ showed only minor effects. In conclusion, our results indicate that APZ might actually have a potential in treating absence seizures or as add-on therapy but more interestingly, these effect might be accompanied by positive modulatory actions on depression, anxiety and memory which might be also beneficial in other epileptic syndromes. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Russo, Emilio: Science of Health Department, School of Medicine, University ""Magna Graecia"" of Catanzaro, Via T. Campanella, 115, Catanzaro, Italy, 88100, erusso@unicz.it and Russo, Emilio: erusso@unicz.it","2013","https://dx.doi.org/10.1016/j.neuropharm.2012.06.039","JOUR","*Cognitive Processes and *Comorbidity and *Epilepsy and *Major Depression and *Aripiprazole and Animal Models and Rats",NA,"PsychINFO-0028-3908-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","No","No",FALSE,TRUE,"Genetic model of depression (e.g. transgenic models, Flinder's Sensitive Line (FSL))",NA,"Other (specify in comments)","Prenatal/gestational","Other","ARIPIPRAZOLE","Dopamine agonist (e.g. apomorphine, rotigotine)","3","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Not reported","10","Rat","Other","Exact number",10,6,999,999,999,"Months","Weight not reported",999,999,999,999,"Grams (g)","Yes",2023-12-18 17:50:54,"c4cd75cc-7874-4211-9585-d99ec238e92a","sucrose intake (fig1)","sucrose intake","dee5cffe-1a14-49e9-b032-499155d048ee","e9892d24-0758-4247-b957-1ea94702c5fb","WAG/Rij: Aripiprazole 3mg/kg",10,"False","293fbce9-37b1-474b-aaf3-49623f903bdb","WAG/Rij rat","False","3a664ffb-7b4a-4f63-bf1e-dd47bc4bb4aa","Aripiprazole (3mg/kg)",FALSE,0,5.4,"Mean","g/15 minutes",0.5,"SEM"
"619","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","0d012f07-3f42-4077-b9c2-7b8ef8d18fc8","TBZ + vehicle (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.09,"Mean","mL",0.03,"SEM"
"620","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","0d012f07-3f42-4077-b9c2-7b8ef8d18fc8","TBZ + vehicle (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.78,"Mean","index",0.08,"SEM"
"621","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","0d012f07-3f42-4077-b9c2-7b8ef8d18fc8","TBZ + vehicle (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.99,"Mean","mL",0.32,"SEM"
"622","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","a58b2f08-24fa-47b2-b585-815e7014a13a","Control + vehicle (male)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.24,"Mean","mL",0.07,"SEM"
"623","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","a58b2f08-24fa-47b2-b585-815e7014a13a","Control + vehicle (male)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.84,"Mean","index",0.04,"SEM"
"624","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","a58b2f08-24fa-47b2-b585-815e7014a13a","Control + vehicle (male)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,1.53,"Mean","mL",0.27,"SEM"
"625","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","b47943f2-ae53-4a86-867e-f2fbab77662a","TBZ + Bupropion (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,0.11,"Mean","mL",0.05,"SEM"
"626","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","b47943f2-ae53-4a86-867e-f2fbab77662a","TBZ + Bupropion (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,0.91,"Mean","index",0.02,"SEM"
"627","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Male","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"222b8f5a-d2fb-4a9d-a9b9-73f13a799787","Sucrose consumption (male)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","b47943f2-ae53-4a86-867e-f2fbab77662a","TBZ + Bupropion (male)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,1.7,"Mean","mL",0.34,"SEM"
"628","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","2c80bea2-205a-440f-b017-d2fb463f8c84","TBZ + Bupropion (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,0.15,"Mean","mL",0.05,"SEM"
"629","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","2c80bea2-205a-440f-b017-d2fb463f8c84","TBZ + Bupropion (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,0.67,"Mean","index",0.1,"SEM"
"630","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other","BUPROPION","DAT inhibitor (Methylphenidate, Bupropion)","10","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Intraperitoneal (IP) injection","Single dose","1.5","Hours","Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","2c80bea2-205a-440f-b017-d2fb463f8c84","TBZ + Bupropion (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","False","0434a7b5-2f92-49f3-96e6-20d2e5af6613","bupropion",FALSE,0,0.77,"Mean","mL",0.19,"SEM"
"631","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","428447c9-420b-4525-b519-04bf95767248","TBZ + vehicle (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.15,"Mean","mL",0.04,"SEM"
"632","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","428447c9-420b-4525-b519-04bf95767248","TBZ + vehicle (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.85,"Mean","index",0.02,"SEM"
"633","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Pharmacological post-weaning (e.g. cytokine or cortisol injection)",NA,"Single acute stressor","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","428447c9-420b-4525-b519-04bf95767248","TBZ + vehicle (female)",11,"False","6422b38e-ab81-4f5e-aa0f-8266b46d0cc9","Tetrabenzine","True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.93,"Mean","mL",0.14,"SEM"
"634","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 5% solution (mL)","4b9f296b-485c-4e77-8287-5069e0fcbc19","a9240e44-9c82-4680-9221-8f5218e66ae3","Control + vehicle (female)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.1,"Mean","mL",0.045,"SEM"
"635","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose preference index","829164dd-b4a9-49cf-a18b-8c30a71d6422","a9240e44-9c82-4680-9221-8f5218e66ae3","Control + vehicle (female)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.81,"Mean","index",0.08,"SEM"
"636","ce8caea9-c7e8-4742-9111-e12e7abbed44","Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles.","Carratal<c3><a1>-Ros C and Mart<c3><ad>nez-Verd<c3><ba> A and Olivares-Garc<c3><ad>a R and Salamone JD and Correa M","Psychopharmacology",NA,"BACKGROUND: Depression is a disorder twice as common in women than in men. There are sex differences in the symptomatology and treatment response to this disorder. Impairments in behavioral activation (i.e. anergia, fatigue) are often seen in people with depression and are highly resistant to treatment. The role of mesolimbic dopamine (DA) in regulating behavioral activation has been extensively studied in male rodents, but little is known in female rodents. OBJECTIVE: The present studies assessed potential sex differences in rodent paradigms used to study different components of depressive-like behavior, and in the treatment response to antidepressants with different mechanisms of action. METHODS: Male and female CD1 mice received Tetrabenazine (TBZ), a VMAT-2 blocker that depletes DA and induces depressive symptoms in humans. Mice were tested on the Forced Swim Test, (FST), the Dark-Light box (DL), the elevated plus maze (EPM), Social Interaction (SI) test, and sucrose preference and consumption using the two bottles test. In addition, bupropion (a DA reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor) were used to reverse TBZ-induced anergia. RESULTS: In the FST, bupropion reversed TBZ effects in both sexes but fluoxetine was only effective in female mice. DA depletion did not affect other aspects of depression such as anxiety, sociability or sucrose consumption, and there was no interaction with bupropion on these parameters. In TBZ treated-females SERT-blockers may be effective at reversing anergia in aversive contexts (FST), and potentiating avoidance of anxiogenic stimuli. CONCLUSIONS: Pro-dopaminergic antidepressants seem more efficacious at improving anergia in both sexes than SERT-blockers.",NA,"rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. and rea de Psicobiologia, Universitat Jaume I, Campus de Riu Sec, 12071, Castell, and Spain. correa@uji.es. and Behavioral Neuroscience Div, University of Connecticut, Storrs, CT, 06269-1020, and USA. correa@uji.es.","2023","10.1007/s00213-023-06412-9","Journal Article","Anergia and Bupropion and Depression and Fatigue and Fluoxetine and Rodent models and Sex differences",NA,"pubmed-37407727",2023-10-10 14:14:07,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",30,"Minutes","Measured from figures","Endpoint measurement","Ratio",FALSE,"Female","WT","Mouse","CD-1 (mouse)","Lower bound of range (put range in comments)",999,999,999,7,9,"Weeks","At recruitment to study",999,999,25,50,"Grams (g)","No",2024-01-29 14:15:55,"291edf56-a101-4a70-ac9b-87ee03b7e122","Sucrose consumption (female)","Sucrose intake 10% solution (mL)","dba54be3-5a2f-40af-9251-e3b8c4569776","a9240e44-9c82-4680-9221-8f5218e66ae3","Control + vehicle (female)",11,NA,NA,NA,"True","db4ceb83-932f-4a55-ad8a-ff16ef8b4af2","vehicle",FALSE,0,0.97,"Mean","mL",0.24,"SEM"
"637","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,4,10.8,"Mean","g",0,"SEM"
"638","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,5,11,"Mean","g",0,"SEM"
"639","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,6,10.57,"Mean","g",0,"SEM"
"640","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,7,11.7,"Mean","g",0,"SEM"
"641","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,8,11,"Mean","g",0,"SEM"
"642","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,9,11.6,"Mean","g",0,"SEM"
"643","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,10,11.44,"Mean","g",0,"SEM"
"644","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,11,11.4,"Mean","g",0,"SEM"
"645","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","0536171f-2764-4831-bbfa-2f441d497857","quinpirole 0,1",10,NA,NA,NA,"False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,12,12.4,"Mean","g",0,"SEM"
"646","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,4,7,"Mean","g",0,"SEM"
"647","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,5,6.6,"Mean","g",0,"SEM"
"648","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,6,5.62,"Mean","g",0,"SEM"
"649","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,7,5.68,"Mean","g",0,"SEM"
"650","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,8,6.44,"Mean","g",0,"SEM"
"651","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,9,6.83,"Mean","g",0,"SEM"
"652","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,10,5.74,"Mean","g",0,"SEM"
"653","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,11,5.68,"Mean","g",0,"SEM"
"654","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6342245c-2ea9-48e5-91f6-2c30da59eb8e","veh + Stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,12,6.26,"Mean","g",0,"SEM"
"655","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,4,10.88,"Mean","g",0,"SEM"
"656","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,5,10.45,"Mean","g",0,"SEM"
"657","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,6,10.12,"Mean","g",0,"SEM"
"658","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,7,10.57,"Mean","g",0,"SEM"
"659","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,8,10.68,"Mean","g",0,"SEM"
"660","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,9,10.2,"Mean","g",0,"SEM"
"661","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,10,11.2,"Mean","g",0,"SEM"
"662","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,11,11.3,"Mean","g",0,"SEM"
"663","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","7e28ac9a-40d9-42c7-8b41-1d65c2468f0a","control + vehicle",10,NA,NA,NA,NA,NA,NA,FALSE,12,11.8,"Mean","g",0,"SEM"
"664","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,4,10.9,"Mean","g",0.2,"SEM"
"665","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,5,10.1,"Mean","g",0,"SEM"
"666","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,6,10.45,"Mean","g",0,"SEM"
"667","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,7,10.6,"Mean","g",0,"SEM"
"668","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,8,10.4,"Mean","g",0,"SEM"
"669","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,9,11.1,"Mean","g",0,"SEM"
"670","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,10,10.9,"Mean","g",0,"SEM"
"671","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,11,11.4,"Mean","g",0,"SEM"
"672","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","89312f3a-5fa9-40dc-98c1-7c3d3a4d15b0","quinpirole 0,2",10,NA,NA,NA,"False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,12,11.6,"Mean","g",0,"SEM"
"673","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,4,6.9,"Mean","g",0,"SEM"
"674","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,5,4.8,"Mean","g",0,"SEM"
"675","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,6,5.5,"Mean","g",0,"SEM"
"676","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,7,6.7,"Mean","g",0,"SEM"
"677","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,8,7.9,"Mean","g",0,"SEM"
"678","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,9,7,"Mean","g",0,"SEM"
"679","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,10,5.6,"Mean","g",0,"SEM"
"680","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,11,6.5,"Mean","g",0,"SEM"
"681","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","100","Other (enter in comments box)","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","cf660599-5863-4e9f-9844-7fea4f65e420","quinpirole 0,1 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","7619832f-f761-41f2-a036-caf1d9738e7d","quinpirole 100",FALSE,12,6.5,"Mean","g",0,"SEM"
"682","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,4,6.7,"Mean","g",0,"SEM"
"683","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,5,6.1,"Mean","g",0,"SEM"
"684","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,6,6.7,"Mean","g",0,"SEM"
"685","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,7,7.9,"Mean","g",0,"SEM"
"686","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,8,9.1,"Mean","g",0,"SEM"
"687","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,9,8.5,"Mean","g",0,"SEM"
"688","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,10,6.8,"Mean","g",0,"SEM"
"689","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,11,8,"Mean","g",0,"SEM"
"690","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","micrograms (ug) per kg","At disease model induction","7","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-4","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"9048579f-7e3b-491e-9c49-0c471eaaae6e","exp 1","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","e3758def-fa2a-4d98-bba2-b289d882a46c","quinpirole 0,2 + stress",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","f5b5427d-84d1-4b48-90aa-76bc84b8ea58","quinpirole 200",FALSE,12,8.3,"Mean","g",0,"SEM"
"691","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6b0eea3f-20b1-4c57-abab-d988dc60bdad","control veh exp3",10,NA,NA,NA,NA,NA,NA,FALSE,5.5,10.1,"Mean","g",0.33,"SEM"
"692","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","6b0eea3f-20b1-4c57-abab-d988dc60bdad","control veh exp3",10,NA,NA,NA,NA,NA,NA,FALSE,6.5,11,"Mean","g",0.44,"SEM"
"693","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","8f1f18f2-d829-457f-8994-91e65f4d72f1","quin control exp3",10,NA,NA,NA,"False","edd3379f-28bd-44d3-a2b9-06738e599bfb","quinpirole 200 exp3",FALSE,5.5,10.95,"Mean","g",0.58,"SEM"
"694","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","8f1f18f2-d829-457f-8994-91e65f4d72f1","quin control exp3",10,NA,NA,NA,"False","edd3379f-28bd-44d3-a2b9-06738e599bfb","quinpirole 200 exp3",FALSE,6.5,12,"Mean","g",0.53,"SEM"
"695","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","d2aac9bd-75eb-43f1-881f-73771f460264","quin stress exp3",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","edd3379f-28bd-44d3-a2b9-06738e599bfb","quinpirole 200 exp3",FALSE,5.5,9.7,"Mean","g",0.6,"SEM"
"696","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","4","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","999","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","d2aac9bd-75eb-43f1-881f-73771f460264","quin stress exp3",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","edd3379f-28bd-44d3-a2b9-06738e599bfb","quinpirole 200 exp3",FALSE,6.5,11.38,"Mean","g",0.5,"SEM"
"697","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","fe1f8dfc-c44d-4f6e-8b13-ee5f525591b6","stress veh exp3",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,5.5,6.2,"Mean","g",0.36,"SEM"
"698","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"a02dd01b-f401-453b-8e00-e1c89508a369","exp 3","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","fe1f8dfc-c44d-4f6e-8b13-ee5f525591b6","stress veh exp3",10,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,6.5,7.1,"Mean","g",0.33,"SEM"
"699","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,3,13.8,"Mean","g",0,"SEM"
"700","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,4,13,"Mean","g",0,"SEM"
"701","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,5,12.6,"Mean","g",0,"SEM"
"702","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,6,14.4,"Mean","g",0,"SEM"
"703","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,7,15,"Mean","g",0,"SEM"
"704","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,8,15.1,"Mean","g",0,"SEM"
"705","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","160317b3-514a-44f0-a1a3-abe06ee51fd6","Brom 2,5",8,NA,NA,NA,"False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,9,15.9,"Mean","g",0,"SEM"
"706","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,3,8,"Mean","g",0,"SEM"
"707","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,4,7.5,"Mean","g",0,"SEM"
"708","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,5,11.5,"Mean","g",0,"SEM"
"709","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,6,11.5,"Mean","g",0,"SEM"
"710","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,7,11.4,"Mean","g",0,"SEM"
"711","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,8,10.8,"Mean","g",0,"SEM"
"712","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","4ad5b0fa-1161-488a-8bc8-67cf3500852d","Quin + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,9,7.6,"Mean","g",0,"SEM"
"713","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,3,13.5,"Mean","g",0,"SEM"
"714","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,4,13,"Mean","g",0,"SEM"
"715","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,5,12,"Mean","g",0,"SEM"
"716","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,6,14.5,"Mean","g",0,"SEM"
"717","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,7,13.46,"Mean","g",0,"SEM"
"718","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,8,13.7,"Mean","g",0,"SEM"
"719","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","61a28aea-8626-48bc-a307-2cd50cb1be77","Brom 1,25 control",8,NA,NA,NA,"False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,9,13.9,"Mean","g",0,"SEM"
"720","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,3,8,"Mean","g",0,"SEM"
"721","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,4,8.2,"Mean","g",0,"SEM"
"722","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,5,11.8,"Mean","g",0,"SEM"
"723","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,6,7.9,"Mean","g",0,"SEM"
"724","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,7,11.7,"Mean","g",0,"SEM"
"725","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,8,10.7,"Mean","g",0,"SEM"
"726","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","2.5","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","a246a676-39ad-4515-babb-8b24efea69b4","Brom 2,5 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","76544cb9-59d7-4180-adc4-3433423ca46f","bromocriptine 2,5",FALSE,9,10.3,"Mean","g",0,"SEM"
"727","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,3,13.3,"Mean","g",0,"SEM"
"728","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,4,13.9,"Mean","g",0,"SEM"
"729","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,5,12.5,"Mean","g",0,"SEM"
"730","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,6,17,"Mean","g",0,"SEM"
"731","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,7,16.6,"Mean","g",0,"SEM"
"732","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,8,15,"Mean","g",0,"SEM"
"733","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"quinpirole","Dopamine agonist (e.g. apomorphine, rotigotine)","200","Other (enter in comments box)","At disease model induction","2","Weeks",NA,"Subcutaneous (SC) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","b68e65ba-c05a-4063-b102-5ab83b10d474","Quin + control 2b",8,NA,NA,NA,"False","9a81ae6c-b25a-41ab-9565-6ed643991344","quinpirole 200 2b",FALSE,9,15.1,"Mean","g",0,"SEM"
"734","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,3,8.1,"Mean","g",0,"SEM"
"735","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,4,6,"Mean","g",0,"SEM"
"736","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,5,7.46,"Mean","g",0,"SEM"
"737","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,6,8.48,"Mean","g",0,"SEM"
"738","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,7,8.66,"Mean","g",0,"SEM"
"739","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,8,8.3,"Mean","g",0,"SEM"
"740","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","bromocriptine","Dopamine agonist (e.g. apomorphine, rotigotine)","1.25","miligrams (mg) per kg","At disease model induction","1","Weeks",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","-3","Weeks","Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","baddb134-9962-400a-bb37-b7a860b1e672","Brom 1,25 + stress",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress","False","1a8315cc-f6c0-4f03-a5d9-95302a1188f1","bromocriptine 1,25 fig2",FALSE,9,7.2,"Mean","g",0,"SEM"
"741","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,3,8.1,"Mean","g",0,"SEM"
"742","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,4,7.7,"Mean","g",0,"SEM"
"743","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,5,8.6,"Mean","g",0,"SEM"
"744","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,6,8.4,"Mean","g",0,"SEM"
"745","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,7,7.5,"Mean","g",0,"SEM"
"746","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,8,8,"Mean","g",0,"SEM"
"747","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","bdf18fa4-31e0-4b5d-9786-8f849ccbb0b4","vehicle + stress 2b",8,"False","a0af1c02-939c-43eb-b3bd-36f09b1092ec","stress",NA,NA,NA,FALSE,9,9.7,"Mean","g",0,"SEM"
"748","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,3,13.58,"Mean","g",0,"SEM"
"749","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,4,14.35,"Mean","g",0,"SEM"
"750","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,5,11,"Mean","g",0,"SEM"
"751","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,6,14.5,"Mean","g",0,"SEM"
"752","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,7,15.2,"Mean","g",0,"SEM"
"753","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,8,13.3,"Mean","g",0,"SEM"
"754","d51b4559-f349-4c76-a5db-e63698b10f46","Antidepressant-like effects of dopamine agonists in an animal model of depression","Muscat, Richard and Papp, Mariusz and Willner, Paul","Biological Psychiatry",NA,"Examined whether treatment known to increase the functional responsiveness of dopamine (DA) systems, intermittent administration of DA agonists, would have antidepressant-like effects in 3 experiments with male rats. Chronic mild stress (CMS)-induced decreases in sucrose consumption were reversed by 3-4 twice-weekly injections of quinpirole (QN) or bromocriptine. The effects lasted for several weeks, and when they wanned, could be reinstated by a single injection of QN. Results suggest that intermittent administration of DA agonists merits study as a strategy for the treatment of depression. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"CITY LONDON POLYTECH,DEPT PSYCHOL,OLD CASTLE ST,LONDON E1 7NT,ENGLAND","1992","https://dx.doi.org/10.1016/0006-3223%2892%2990119-K","JOUR","*Animal Models and *Bromocriptine and *Dopamine Agonists and *Major Depression and *Stress and Antidepressant Drugs and Food Intake and Rats and Sugars",NA,"PsychINFO-0006-3223-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","Other (use comments box)","Unclear","Yes","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","Yes","NA (ethical approval declared)","No","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",0,"Hours","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Rat","Lister hooded (rat)","Exact number",10,NA,NA,NA,NA,NA,"At recruitment to study",275,NA,250,300,"Grams (g)","Yes",2023-12-19 13:15:06,"f2ad154b-aca9-422d-b7ab-4d507687fad5","exp 2","sucrose intake","6986dc05-4f78-463c-ade8-a127a5b70467","c1e2a350-655e-4654-8cf9-ff2adbe5f0a1","control vehicle 2b",8,NA,NA,NA,NA,NA,NA,FALSE,9,12.9,"Mean","g",0,"SEM"
"755","e3a49205-7b42-46ff-bc13-4b34597d7e94","Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice","Wang, KX and Zhai, QL and Wang, SW and Li, QY and Liu, J and Meng, FT and Wang, WT and Zhang, JJ and Wang, D and Zhao, D and Liu, CL and Dai, JJ and Li, C and Cui, MH and Chen, JB","TRANSLATIONAL NEUROSCIENCE",NA,"Objectives Cryptotanshinone (CPT), a natural quinoid diterpene, isolated from Salvia miltiorrhiza, has shown various pharmacological properties. However, its effect on chronic unpredictable stress (CUS)-induced depression phenotypes and the underlying mechanism remain unclear. Therefore, the aim of this study was to investigate whether CPT could exert an antidepressant effect. Methods We investigated the effects of CPT in a CUSinduced depression model and explored whether these effects were related to the anti-inflammatory and neurogenesis promoting properties by investigating the expression levels of various signaling molecules at the mRNA and protein levels. Results Administration of CPT improved depression like behaviors in CUS-induced mice. CPT administration increased the levels of doublecortin-positive cells and reversed the decrease in the expression levels of brain derived neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) signaling transduction, as well as the downstream functional proteins, phosphorylated extracellular regulated protein kinases (p-ERK), and cyclic adenosine monophosphate (cAMP)-response element-binding protein levels (pCREB) in hippocampus. CPT treatment also inhibited the activation of microglia and suppressed M1 microglial polarization, while promoting M2 microglial polarization by monitoring the expression levels of arginase 1 (Arg-1) and inducible nitric oxide synthase (iNOS), and further inhibited the expression of proinflammatory cytokines, including interleukin (IL)-1, IL 6, and tumor necrosis factor-alpha (TNF-alpha), and increased the expression of the anti-inflammatory cytokine IL-10 by regulating nuclear factor-KB (NF-KB) activation. Conclusions CPT relieves the depressive-like state in CUS-induced mice by enhancing neurogenesis and inhibiting inflammation through the BDNF/TrkB and NF-KB pathways and could therefore serve as a promising candidate for the treatment of depression.",NA,"Binzhou Med Univ Hosp, Dept Psychol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Neurol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Med Res Ctr, Binzhou, Shandong, Peoples R China and Binzhou Med Univ Hosp, Inst Metab & Neuropsychiat Disorders, Binzhou, Shandong, Peoples R China and Jinan Hosp, Dept Internal Med, Jinan, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Gastroenterol, Binzhou, Shandong, Peoples R China","2021","10.1515/tnsci-2020-0198","JOUR","cryptotanshinone and depression and neuroinflam-mation and microglial polarization and neurogenesis and BDNF and NEUROTROPHIC FACTOR and EPIGENETIC MECHANISMS and BDNF and BRAIN and PROMOTERS and NEURONS and NEUROGENESIS and INFLAMMATION and ACTIVATION and EXPRESSION",NA,"WOS:000725194200001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",8,8,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2023-12-19 11:01:57,"c54c3e5f-52e7-4afd-aa0a-4a9bb08b4e24","sucrose preference","sucrose preference","0908f37c-5dc4-4fe1-87e2-bc39f3b2d205","7f305452-51e2-4164-81ad-90a4976094d9","control: vehicle",8,NA,NA,NA,"True","0ce6c21a-c69f-4878-a261-832dbba157d4","vehicle",FALSE,0,80.2,"Mean","%",4.1,"SEM"
"756","e3a49205-7b42-46ff-bc13-4b34597d7e94","Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice","Wang, KX and Zhai, QL and Wang, SW and Li, QY and Liu, J and Meng, FT and Wang, WT and Zhang, JJ and Wang, D and Zhao, D and Liu, CL and Dai, JJ and Li, C and Cui, MH and Chen, JB","TRANSLATIONAL NEUROSCIENCE",NA,"Objectives Cryptotanshinone (CPT), a natural quinoid diterpene, isolated from Salvia miltiorrhiza, has shown various pharmacological properties. However, its effect on chronic unpredictable stress (CUS)-induced depression phenotypes and the underlying mechanism remain unclear. Therefore, the aim of this study was to investigate whether CPT could exert an antidepressant effect. Methods We investigated the effects of CPT in a CUSinduced depression model and explored whether these effects were related to the anti-inflammatory and neurogenesis promoting properties by investigating the expression levels of various signaling molecules at the mRNA and protein levels. Results Administration of CPT improved depression like behaviors in CUS-induced mice. CPT administration increased the levels of doublecortin-positive cells and reversed the decrease in the expression levels of brain derived neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) signaling transduction, as well as the downstream functional proteins, phosphorylated extracellular regulated protein kinases (p-ERK), and cyclic adenosine monophosphate (cAMP)-response element-binding protein levels (pCREB) in hippocampus. CPT treatment also inhibited the activation of microglia and suppressed M1 microglial polarization, while promoting M2 microglial polarization by monitoring the expression levels of arginase 1 (Arg-1) and inducible nitric oxide synthase (iNOS), and further inhibited the expression of proinflammatory cytokines, including interleukin (IL)-1, IL 6, and tumor necrosis factor-alpha (TNF-alpha), and increased the expression of the anti-inflammatory cytokine IL-10 by regulating nuclear factor-KB (NF-KB) activation. Conclusions CPT relieves the depressive-like state in CUS-induced mice by enhancing neurogenesis and inhibiting inflammation through the BDNF/TrkB and NF-KB pathways and could therefore serve as a promising candidate for the treatment of depression.",NA,"Binzhou Med Univ Hosp, Dept Psychol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Neurol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Med Res Ctr, Binzhou, Shandong, Peoples R China and Binzhou Med Univ Hosp, Inst Metab & Neuropsychiat Disorders, Binzhou, Shandong, Peoples R China and Jinan Hosp, Dept Internal Med, Jinan, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Gastroenterol, Binzhou, Shandong, Peoples R China","2021","10.1515/tnsci-2020-0198","JOUR","cryptotanshinone and depression and neuroinflam-mation and microglial polarization and neurogenesis and BDNF and NEUROTROPHIC FACTOR and EPIGENETIC MECHANISMS and BDNF and BRAIN and PROMOTERS and NEURONS and NEUROGENESIS and INFLAMMATION and ACTIVATION and EXPRESSION",NA,"WOS:000725194200001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other","CRYPTOTANSHINONE","MAO inhibitor (Selegiline, Rasagiline)","20","miligrams (mg) per kg","At disease model induction","14","Days",NA,"Other (enter in comments)","Multiple doses (enter details in comments)","999","Hours","Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",8,8,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2023-12-19 11:01:57,"c54c3e5f-52e7-4afd-aa0a-4a9bb08b4e24","sucrose preference","sucrose preference","0908f37c-5dc4-4fe1-87e2-bc39f3b2d205","abe946c3-2c58-4e3b-b977-6ef41f8f947c","CMS: CPT",8,"False","944169ce-3245-4579-83e2-857756232753","CUS","False","90ecd9f1-f6fe-43ef-bd8c-496fbad02af0","CPT",FALSE,0,77.2,"Mean","%",3.3,"SEM"
"757","e3a49205-7b42-46ff-bc13-4b34597d7e94","Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice","Wang, KX and Zhai, QL and Wang, SW and Li, QY and Liu, J and Meng, FT and Wang, WT and Zhang, JJ and Wang, D and Zhao, D and Liu, CL and Dai, JJ and Li, C and Cui, MH and Chen, JB","TRANSLATIONAL NEUROSCIENCE",NA,"Objectives Cryptotanshinone (CPT), a natural quinoid diterpene, isolated from Salvia miltiorrhiza, has shown various pharmacological properties. However, its effect on chronic unpredictable stress (CUS)-induced depression phenotypes and the underlying mechanism remain unclear. Therefore, the aim of this study was to investigate whether CPT could exert an antidepressant effect. Methods We investigated the effects of CPT in a CUSinduced depression model and explored whether these effects were related to the anti-inflammatory and neurogenesis promoting properties by investigating the expression levels of various signaling molecules at the mRNA and protein levels. Results Administration of CPT improved depression like behaviors in CUS-induced mice. CPT administration increased the levels of doublecortin-positive cells and reversed the decrease in the expression levels of brain derived neurotrophic factor (BDNF)/tyrosine kinase receptor B (TrkB) signaling transduction, as well as the downstream functional proteins, phosphorylated extracellular regulated protein kinases (p-ERK), and cyclic adenosine monophosphate (cAMP)-response element-binding protein levels (pCREB) in hippocampus. CPT treatment also inhibited the activation of microglia and suppressed M1 microglial polarization, while promoting M2 microglial polarization by monitoring the expression levels of arginase 1 (Arg-1) and inducible nitric oxide synthase (iNOS), and further inhibited the expression of proinflammatory cytokines, including interleukin (IL)-1, IL 6, and tumor necrosis factor-alpha (TNF-alpha), and increased the expression of the anti-inflammatory cytokine IL-10 by regulating nuclear factor-KB (NF-KB) activation. Conclusions CPT relieves the depressive-like state in CUS-induced mice by enhancing neurogenesis and inhibiting inflammation through the BDNF/TrkB and NF-KB pathways and could therefore serve as a promising candidate for the treatment of depression.",NA,"Binzhou Med Univ Hosp, Dept Psychol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Neurol, 661 Huanghe 2nd Rd, Binzhou 256603, Shandong, Peoples R China and Binzhou Med Univ Hosp, Med Res Ctr, Binzhou, Shandong, Peoples R China and Binzhou Med Univ Hosp, Inst Metab & Neuropsychiat Disorders, Binzhou, Shandong, Peoples R China and Jinan Hosp, Dept Internal Med, Jinan, Shandong, Peoples R China and Binzhou Med Univ Hosp, Dept Gastroenterol, Binzhou, Shandong, Peoples R China","2021","10.1515/tnsci-2020-0198","JOUR","cryptotanshinone and depression and neuroinflam-mation and microglial polarization and neurogenesis and BDNF and NEUROTROPHIC FACTOR and EPIGENETIC MECHANISMS and BDNF and BRAIN and PROMOTERS and NEURONS and NEUROGENESIS and INFLAMMATION and ACTIVATION and EXPRESSION",NA,"WOS:000725194200001",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"3eed8e8f-ea6f-48ba-a768-a5578c431862","Francesca Tinsdeall","Animal","Complete randomisation","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Chronic unpredictable mild stress (CMS) or restraint stress",NA,"Multiple acute stressors","Post-weaning","Other",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",999,"Minutes","Measured from figures","Endpoint measurement","Interval",FALSE,"Male","WT","Mouse","C57BL/6 (mouse)","Exact number",8,8,999,999,999,"Weeks","At recruitment to study",999,999,20,25,"Grams (g)","Yes",2023-12-19 11:01:57,"c54c3e5f-52e7-4afd-aa0a-4a9bb08b4e24","sucrose preference","sucrose preference","0908f37c-5dc4-4fe1-87e2-bc39f3b2d205","cde6744b-d623-4aa4-8a1c-a7119884558b","CMS: vehicle",8,"False","944169ce-3245-4579-83e2-857756232753","CUS","True","0ce6c21a-c69f-4878-a261-832dbba157d4","vehicle",FALSE,0,63.1,"Mean","%",5.2,"SEM"
"758","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"dd6a4101-1b29-4e03-9005-f482b7814a44","exp 3c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","3069bbb7-ff55-40f8-8d83-11489c530b2d","MS 3c",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation",NA,NA,NA,FALSE,0,49.4,"Mean","%",4.3,"SEM"
"759","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"dd6a4101-1b29-4e03-9005-f482b7814a44","exp 3c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","4f1b4797-33d6-42b6-8ae1-8ee1bc112c0f","control 3c",6,NA,NA,NA,NA,NA,NA,FALSE,0,74.2,"Mean","%",8.4,"SEM"
"760","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)","selegiline","MAO inhibitor (Selegiline, Rasagiline)","3","miligrams (mg) per kg","After disease model induction","999","Single dose",NA,"Subcutaneous (SC) injection","Single dose","-48","Days","Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"dd6a4101-1b29-4e03-9005-f482b7814a44","exp 3c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","bb705bbe-3257-46f1-b62b-08396e575812","selegiline + MS 3c",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation","False","d9435a95-efe0-4d74-a544-47022a1a59c2","selegiline 3",FALSE,0,61.1,"Mean","%",3,"SEM"
"761","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,"selegiline","MAO inhibitor (Selegiline, Rasagiline)","3","miligrams (mg) per kg","After disease model induction","999","Single dose",NA,"Subcutaneous (SC) injection","Single dose","-48","Days","Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"dd6a4101-1b29-4e03-9005-f482b7814a44","exp 3c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","e67b441b-8134-4ecd-b3be-57cd03ab5ea2","selegiline 3c",6,NA,NA,NA,"False","d9435a95-efe0-4d74-a544-47022a1a59c2","selegiline 3",FALSE,0,76.5,"Mean","%",5.3,"SEM"
"762","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)","selegiline","MAO inhibitor (Selegiline, Rasagiline)","5","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Subcutaneous (SC) injection","Single dose","-48","Days","Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"fd362d6f-204a-460b-a986-cc9564b80ef4","EXP 2c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","2e245fb6-9197-4bed-985c-fdae12e70508","MS + SELEGILINE 5",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation","False","3a6af069-9044-474d-a731-1f2d1cbbaab6","selegiline 5",FALSE,0,65.8,"Mean","%",3.6,"SEM"
"763","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"fd362d6f-204a-460b-a986-cc9564b80ef4","EXP 2c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","403fc69b-1553-4bae-b60b-8d309a17ae07","control",6,NA,NA,NA,NA,NA,NA,FALSE,0,75.6,"Mean","%",8,"SEM"
"764","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)","selegiline","MAO inhibitor (Selegiline, Rasagiline)","1","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Subcutaneous (SC) injection","Single dose","-48","Days","Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"fd362d6f-204a-460b-a986-cc9564b80ef4","EXP 2c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","7b8190e9-ee60-456d-9add-c75b340a8a11","MS + SELEGILINE 1",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation","False","053cbc32-dd5b-4ee1-a20d-a7a9c399a63f","selegiline 1",FALSE,0,53,"Mean","%",4.8,"SEM"
"765","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)","selegiline","MAO inhibitor (Selegiline, Rasagiline)","3","miligrams (mg) per kg","After disease model induction","1","Single dose",NA,"Subcutaneous (SC) injection","Single dose","-48","Days","Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"fd362d6f-204a-460b-a986-cc9564b80ef4","EXP 2c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","7e542de5-47a1-4408-9fef-d4dd0e623691","MS + SELEGILINE 3",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation","False","62ec58fa-d2ed-4638-9ad7-77425dde5546","selegiline 3",FALSE,0,61.5,"Mean","%",2.5,"SEM"
"766","f4f81624-4f5f-401f-a2b5-62a690fbd6d1","Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse","Amiri, Shayan and Amini-Khoei, Hossein and Mohammadi-Asl, Ali and Alijanpour, Sakineh and Haj-Mirzaian, Arya and Rahimi-Balaei, Maryam and Razmi, Ali and Olson, Carl O and Rastegar, Mojgan and Mehdizadeh, Mehdi and Zarrindast, Mohammad- Reza","Physiology & Behavior",NA,"Mother-infant interactions are known to be associated with the psychological well-being of an individual in adulthood. It is well accepted that emotional stress in early life, such as maternal separation (MS), leads to alterations in the neurotransmission systems of various brain regions, especially the mesolimbic dopaminergic system, and subsequently can increase the risk for development of psychiatric disorders including depression in adulthood. Selegiline is an irreversible monoamine oxidase (MAO) type B inhibitor which increases striatal dopamine levels and exerts an antidepressant effect. In this study, 180min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests for determining depressive-like behaviors, such as forced swimming test (FST), splash test and sucrose preference test (SPT) in adult mice (PND 50). The open field test (OFT) also was applied to validate FST results. We used SCH23390 (D1 antagonist) and sulpiride (D2 antagonist) in order to determine the role of D1 and D2 dopamine receptors in antidepressant-like effects of selegiline. Our results revealed that MS provoked depressive-like behaviors in adult male mice, and the administration of selegiline attenuated depressive-like behaviors in MS mice. Our findings showed that D1 dopamine receptors facilitate the positive effects of selegiline on the passive behavior in the FST. Furthermore, antidepressant effects of selegiline on hedonic difficulties are mediated via D2 receptor in the SPT. The results of the splash test revealed that both D1 and D2 receptors mediate the protective effect of selegiline against motivational and self-care problems. Based on our results, we conclude that both D1 and D2 dopamine receptors are involved in mediating the antidepressant-like effect of selegiline. We found that D1 receptors mediate an effect on despair behavior, D2 receptors mediate an effect on anhedonia, and both D1 and D2 receptors contribute to the protective effects of selegiline on motivational complications. (PsycInfo Database Record (c) 2021 APA, all rights reserved)",NA,"Zarrindast, Mohammad- Reza: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran, zarinmr@ams.ac.ir and Zarrindast, Mohammad- Reza: zarinmr@ams.ac.ir","2016","https://dx.doi.org/10.1016/j.physbeh.2016.04.052","JOUR","*Animal Models and *Dopamine and *Separation Anxiety and Mice",NA,"PsychINFO-0031-9384-ISSN",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"dc46ca91-f68a-4a61-b4f4-e26c16a2d1a1","Olena Maksym","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","Yes","No","Yes","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","No","No","No","Yes","No","No",FALSE,TRUE,"Behavioural early life stress (e.g. maternal separation)",NA,"Multiple acute stressors","Perinatal/before weaning","MAO inhibitor (Selegiline, Rasagiline)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",60,"Minutes","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","wt","Mouse","Other","Lower bound of range (put range in comments)",999,50,NA,NA,NA,"Days","Weight not reported",NA,NA,NA,NA,NA,"Yes",2023-12-14 11:05:48,"fd362d6f-204a-460b-a986-cc9564b80ef4","EXP 2c","sucrose intake","c1e393ba-e0ca-4097-a7a6-a1959b3b7fd8","e8fe0cbd-e6bd-46ca-b6ef-e57e6c515dcb","MS",6,"False","c29fdee5-40ce-48c0-9237-b457d04c1851","maternal separation",NA,NA,NA,FALSE,0,50,"Mean","%",4.1,"SEM"
"767","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"146f5938-9654-443a-b771-06f3f9751365","1B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","02b43673-656c-472f-bac0-25a278fa34ce","SDS + SFK 1.0",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","a2c85c77-8139-47c3-8fcd-9d96c29201ff","SKF83959 1.0",FALSE,0,63.55,"Mean","% over H2O",5.1,"SEM"
"768","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","0.5","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"146f5938-9654-443a-b771-06f3f9751365","1B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","15744644-a29d-41d4-9a00-aee69e8f065f","SDS + SKF 0.5",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","45dfa7b7-253c-4a18-addc-ee0ade35c76d","SKF83959 0.5",FALSE,0,56.05,"Mean","% over H2O",10,"SEM"
"769","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"146f5938-9654-443a-b771-06f3f9751365","1B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","4d62f839-3357-4fba-ac84-8b6c24da71d7","Control",10,NA,NA,NA,"True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,70.35,"Mean","% over H2O",10.9,"SEM"
"770","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"146f5938-9654-443a-b771-06f3f9751365","1B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","aea36c51-387c-49ba-8d70-252640a51e75","SDS",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,13.62,"Mean","% over H2O",5.55,"SEM"
"771","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4912d753-6e18-4bdc-945d-9850540128bf","6B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","ddd966e7-de94-4d98-99e1-40ca29ebe4a3","SDS + SKF 1.0 (6B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","a2c85c77-8139-47c3-8fcd-9d96c29201ff","SKF83959 1.0",FALSE,0,65.18,"Mean","% over H2O",6.6,"SEM"
"772","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4912d753-6e18-4bdc-945d-9850540128bf","6B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","ed920834-5600-4a75-9226-27f266fb6851","SDS (6B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,38.38,"Mean","% over H2O",7.35,"SEM"
"773","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4912d753-6e18-4bdc-945d-9850540128bf","6B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","ef50a971-763b-435d-9548-19479490644a","Control (6B)",10,NA,NA,NA,"True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,72.9,"Mean","% over H2O",9.3,"SEM"
"774","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4cc4885c-ff70-440c-bc6c-2d5bf8360249","4B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","526caadd-4801-4485-8c8d-c2a11ee9b0be","SDS + SKF 1.0 (4B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","a2c85c77-8139-47c3-8fcd-9d96c29201ff","SKF83959 1.0",FALSE,0,66.35,"Mean","% over H2O",6.4,"SEM"
"775","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4cc4885c-ff70-440c-bc6c-2d5bf8360249","4B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","58256972-b793-4405-9370-9f5187d27b2c","SDS (4B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,43.46,"Mean","% over H2O",3.95,"SEM"
"776","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"4cc4885c-ff70-440c-bc6c-2d5bf8360249","4B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","a1a701cf-6df1-433f-8247-533712ed5b6f","Control (4B)",10,NA,NA,NA,"True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,81.35,"Mean","% over H2O",7.3,"SEM"
"777","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"6d719c48-6022-4493-a539-be436feddcc8","S3","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","11f0dd5d-04ac-49d5-bbb3-200dfa6ed322","SDS + SKF 1.0 (S3)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","a2c85c77-8139-47c3-8fcd-9d96c29201ff","SKF83959 1.0",FALSE,0,65.8,"Mean","% over H2O",7.58,"SEM"
"778","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"6d719c48-6022-4493-a539-be436feddcc8","S3","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","49168f31-1bb8-41c4-9bc7-9ff94c8d4442","Control (S3)",10,NA,NA,NA,"True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,76.31,"Mean","% over H2O",8.73,"SEM"
"779","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"6d719c48-6022-4493-a539-be436feddcc8","S3","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","dda0d720-a1ec-4f0a-bf0b-af2fa85c9ae2","SDS (S3)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,30.29,"Mean","% over H2O",4.07,"SEM"
"780","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear","SKF83959","Dopamine agonist (e.g. apomorphine, rotigotine)","1","miligrams (mg) per kg","After disease model induction","14","Days",NA,"Intraperitoneal (IP) injection","Multiple doses (enter details in comments)","10","Days","Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"842dabd4-81c5-4c8b-9ee8-cd09e10db115","7B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","06c01a63-f970-40f7-bc64-97c616ad6045","SDS + SKF 1.0 (7B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","False","a2c85c77-8139-47c3-8fcd-9d96c29201ff","SKF83959 1.0",FALSE,0,59.17,"Mean","% over H2O",11.15,"SEM"
"781","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"842dabd4-81c5-4c8b-9ee8-cd09e10db115","7B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","37c5cf4d-0f73-4e8f-9215-6057ecaca2ff","Control (7B)",10,NA,NA,NA,"True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,61.66,"Mean","% over H2O",11,"SEM"
"782","ff9a635f-d905-4601-b6dd-8702371e3d76","SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.","Jiang B and Wang F and Yang S and Fang P and Deng ZF and Xiao JL and Hu ZL and Chen JG","The international journal of neuropsychopharmacology",NA,"BACKGROUND: SKF83959 stimulates the phospholipase C/inositol phosphate 3 pathway, resulting in the activation of Ca(2+)/calmodulin-dependent kinase II, which affects the synthesis of brain-derived neurotrophic factor, a neurotrophic factor critical for the pathophysiology of depression. Previous reports showed that SKF83959 elicited antidepressant activity in the forced swim test and tail suspension test as a novel triple reuptake inhibitor. However, there are no studies showing the effects of SKF83959 in a chronic stress model of depression and the role of phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway in SKF83959-mediated antidepressant effects. METHODS: In this study, SKF83959 was firstly investigated in the chronic social defeat stress model of depression. The changes in hippocampal neurogenesis, dendrite spine density, and brain-derived neurotrophic factor signaling pathway after chronic social defeat stress and SKF83959 treatment were then investigated. Pharmacological inhibitors and small interfering RNA/short hairpin RNA methods were further used to explore the antidepressive mechanisms of SKF83959. RESULTS: We found that SKF83959 produced antidepressant effects in the chronic social defeat stress model and also restored the chronic social defeat stress-induced decrease in hippocampal brain-derived neurotrophic factor signaling pathway, dendritic spine density, and neurogenesis. By using various inhibitors and siRNA/shRNA methods, we further demonstrated that the hippocampal dopamine D5 receptor, phospholipase C/inositol phosphate 3/ calmodulin-dependent kinase II pathway, and brain-derived neurotrophic factor system are all necessary for the SKF83959 effects. CONCLUSION: These results suggest that SKF83959 can be developed as a novel antidepressant and produces antidepressant effects via the hippocampal D5/ phospholipase C/inositol phosphate 3/calmodulin-dependent kinase II/brain-derived neurotrophic factor pathway.",NA,"Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). and Department of Pharmacology, School of Basic Medicine, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China (Drs Jiang, Wang, and Yang, Fang, Deng, Xiao, and Chen): Key Laboratory of Neurological Diseases and (HUST), Ministry of Education of China, Wuhan, Hubei, China (Drs Wang, Hu, and and Chen): The Key Laboratory for Drug Target Researches and Pharmacodynamic and Evaluation of Hubei Province, Wuhan, China (Drs Wang, Hu, and Chen): The and Institute of Brain Research, Huazhong University of Science and Technology, and Wuhan, China (Drs Wang and Chen). chenj@mails.tjmu.edu.cn.","2014","10.1093/ijnp/pyu096","Journal Article and Research Support, Non-U.S. Gov't","SKF83959 and brain-derived neurotrophic factor and chronic social defeat stress and depression",NA,"pubmed-25522427",2023-10-10 14:14:08,"4f0df68a-cad3-4a3a-8c46-91f93b86e91f","screening_decisions_GALENOSLSR1project",FALSE,"87890e5c-5da6-4669-9742-891aa2e43a82","Fiona Ramage","Animal","None specified","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Unclear","Yes","No","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","NA (ethical approval declared)","Yes","Yes","No",FALSE,TRUE,"Social stress or social defeat stress (SDS)",NA,"Chronic stressor","Post-weaning","Not specified/unclear",NA,NA,NA,NA,NA,NA,NA,"Vehicle",NA,NA,NA,NA,"Sucrose/saccharin intake or preference test",15,"Days","Measured from figures","Endpoint measurement","Continuous",FALSE,"Male","WT","Mouse","C57BL/6J (mouse)","Exact number",999,999,999,10.5,12.5,"Weeks","Weight not reported",999,999,999,999,"Grams (g)","Yes",2024-01-27 19:01:58,"842dabd4-81c5-4c8b-9ee8-cd09e10db115","7B","Sucrose preference","88e24fc8-1b85-41a1-b3a6-d72dd0bb7c2c","c9fb58a3-708a-4e0a-939f-d9662d8c5b8d","SDS (7B)",10,"False","91f21c36-fa01-4030-abbc-29e2d0154199","Defeat","True","27f91615-6551-42bc-b811-c3b76381390b","Vehicle",FALSE,0,34.64,"Mean","% over H2O",11.01,"SEM"
